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Abstract 
TCR gene transfer can generate tumour antigen-specific T cells for adoptive 
immunotherapy. Following TCR gene transfer, transduced T cells usually display the 
same functional avidity as the parental clone from which the TCR was isolated. 
However, tumour-antigen specific T cells typically recognize over-expressed self-
antigen and are often of low/moderate avidity. It is known that optimal recognition of 
target cells by CTL requires binding of the cognate peptide MHC class I complex 
(MHCI) by both TCR and the CD8 co-receptor. Some CD8β chain mutations have 
been shown to increase CD8 binding affinity with peptide/MHCI and enhance T cell 
effector function.  
Murine CD8β chain mutants were generated affecting MHC binding sites (L58R, S53L, 
S54V and L58R/I25A) or glycosylation sites (T120A, T121A, T124A, and 
T120A/T121A/T124A). The mutated CD8β molecules were introduced into murine 
splenocytes using retroviral vectors together with tumour antigen-specific TCRs. 
The CD8β mutants or control CD8β wild type (WT) chains were first introduced into 
CD8αα T cells obtained from CD8β knockout mice. All T cells were co-transduced to 
express the murine F5-TCR which recognizes the model tumour antigen, influenza A 
nucleoprotein (NP366) presented by H2-Db. The L58R MHC binding CD8 co-receptor 
mutant (L58R) demonstrated better IFN-γ and IL-2 production in response to 
relevant peptide while the CD8 glycosylation mutant (T120A/T121A/T124A) mutant 
demonstrated the opposite effect. 
The in vitro function of CD4+ T cells transduced with F5-TCR showed that IL-2 and 
IFN-γ production was enhanced with CD8 co-receptor. In addition, introducing a 
L58R mutation in the CD8 co-receptor could further increase this effect. The effects 
of the human CD8 co-receptor with a homologous mutation (I59R) was also 
investigated in human CD4+ T-cells with a CMV-specific TCR.  
In vivo studies showed that introducing the F5-TCR alone did not endow CD4+ T cells 
with significant protection against injected lymphoma cells expressing NP366. 
However adding CD8 co-receptor to the CD4+ T cells enhanced tumour protection. 
The genetically modified CD4+ T cells persisted for greater than three months in 
surviving mice and when re-challenged with antigen the CD4+ T cells with both F5-
TCR and CD8 co-receptor had greater proliferative capacity and had more central 
memory phenotype cells. 
  
  Table of contents 
3 
 
Table of contents 
DECLARATION 1 
ABSTRACT 2 
TABLE OF CONTENTS 3 
LIST OF FIGURES AND TABLES 7 
ABBREVIATIONS 13 
CHAPTER 1 17 
CHAPTER 1. INTRODUCTION 18 
1.1 Adaptive immunity: T vs B lymphocytes 18 
1.2 T lymphocyte development 19 
1.3 T cell receptor structure and signal transduction 21 
1.4 The CD8 co-receptor 24 
1.4.1 CD8 co-receptor: from structure to function 24 
1.4.1.1 Comparisons between two naturally existing forms of CD8 co-receptor 24 
1.4.1.2 Structural and molecular aspects of the CD8 co-receptor 26 
1.4.1.3 Role of CD8 co-receptor in TCR proximal signalling 28 
1.4.2 Role of the CD8 co-receptor in the thymus 30 
1.4.3 Role of the CD8 co-receptor in peripheral T cells 32 
1.5 Immune surveillance and the immune response to tumours 33 
1.5.1 The role of CD8+ T cells in tumour immunity 35 
1.5.2 The role of CD4+ T cells in tumour immunity 36 
1.6 Cancer immunotherapy using adoptive T cell transfer 37 
1.6.1 Non-modified T cells 37 
1.6.2 Genetically modified T cells 38 
1.6.2.1 Chimeric Antigen Receptor (CAR) gene transfer 43 
1.7 Project background 44 
1.8 Aim of the project 47 
CHAPTER 2 49 
CHAPTER 2. MATERIALS AND METHODS 50 
2.1 Molecular techniques 50 
2.1.1 Retroviral vector backbones 50 
2.1.2 Bacterial culture 50 
2.1.2.1 Preparation of LB broth and agar 50 
2.1.2.2 Transformation of competent bacterial cells 50 
2.1.3 Large scale preparation of plasmids 51 
  Table of contents 
4 
 
2.1.4 PCR amplification 51 
2.1.5 PCR mutagenesis 51 
2.1.6 Restriction digestion and gel extraction 52 
2.1.7 Ligation 52 
2.1.8 Sequencing of DNA 52 
2.2 Cells, Cell lines, and culturing conditions 52 
2.2.1 Media 52 
2.2.2 Antigen presenting cells and tumour cell lines 53 
2.2.3 Retroviral packaging cell lines 53 
2.2.4 T cell lines 54 
2.3 Generation of TCR-transduced T cells 54 
2.3.1 Transfection and production of recombinant retroviral particles 54 
2.3.2 Preparation of T cells before and after transduction 55 
2.3.2.1 Murine CD8+ T cell purification 55 
2.3.2.2 Murine CD4+ T cell purification 55 
2.3.2.3 Human CD4+ T cell purification 56 
2.3.3 Transduction of T cells 56 
2.3.3.1 Murine T cells 56 
2.3.3.2 Human T- cells 56 
2.4 Flow cytometry 57 
2.5 In-vitro functional assays 57 
2.5.1 Peptides 57 
2.5.2 Peptide loading of RMAS and T2 target cells 58 
2.5.3 IFN-γ and IL-2 ELISA assay 58 
2.5.4 IFN-γ and IL-2 intracellular cytokine assay 59 
2.5.5 Cytotoxicity assay 59 
2.6 In-vivo studies 59 
2.6.1 Mouse lines 59 
2.6.2 Bioilluminescence 60 
2.6.3 Tumour protection experiment 60 
2.6.3.1 Tumour challenge and T cell transfer 60 
2.6.3.2 Monitoring tumour growth 60 
2.6.3.3 Monitoring of transferred CD4+ T cells 61 
2.6.4 Antigen re-challenge 62 
CHAPTER 3 63 
CHAPTER 3. MOLECULAR BIOLOGY 64 
3.1 TCR vectors 64 
3.2 CD8 vectors 65 
3.2.1 Cloning the CD8β gene into the pMP71 retroviral vector 65 
3.2.2 CD8β gene mutagenesis 66 
3.3 Generation of retroviral vectors encoding both the TCR and CD8 co-receptor 73 
3.3.1 Construction of the F5-TCR-CD8 pMP71 retroviral vector 73 
3.3.2 Construction of the F5-TCR-CD8α and F5-TCR-CD8β pMP71 vectors 75 
3.3.3 In vitro analysis of murine CD4+ T cells transduced with the F5-TCR-CD8 pMP71 vector 76 
3.3.4 Further development of the of F5-TCR-CD8 pMP71 vector 78 
3.3.5 Transduction of murine CD4+ T cells with the revised F5-TCR-CD8 pMP71 retroviral vector 79 
  Table of contents 
5 
 
3.4 Summary 82 
CHAPTER 4 83 
CHAPTER 4. IN-VITRO ANALYSIS IN CD8Β-/- T CELLS 84 
4.1 Introduction 84 
4.2 Co-transduction of CD8β mutants and the MDM-TCR into CD8β-/- CD8+ T cells 85 
4.2.1 Successful cell surface expression of the MDM-TCR and CD8β mutants following transduction 
of CD8β-/- CD8+ T cells 85 
4.2.2 Antigen-specific IFN-γ production of MDM-TCR-td CD8β-/- T cells 87 
4.3 In-vitro functional analysis of CD8β-/- CD8+ T cells following co-transduction with F5-TCR and 
CD8β  90 
4.3.1 Cell surface expression of CD8β-/- CD8+ T cells following transduction with F5-TCR and CD8β90 
4.3.2 Antigen specific IFN-γ production of F5-TCR transduced CD8β-/- CD8+ T cells 94 
4.4 Summary 99 
CHAPTER 5 101 
CHAPTER 5. IN-VITRO ANALYSIS IN CD4+ AND CD8+ T CELLS 102 
5.1 Introduction 102 
5.2 In-vitro characterisation of F5-TCR and CD8 co-receptor transduced CD8+ T cells 102 
5.2.1 Transduction of CD8+ T cells with the F5-TCR-CD8β vector 102 
5.2.2 Cell surface expression of F5-TCR and CD8β on transduced CD8+ T cells 103 
5.2.3 In vitro Ag-specific cytokine production of transduced CD8+ T cells 104 
5.3 In-vitro characterisation of F5-TCR and CD8 co-receptor transduced CD4+ T cells 108 
5.3.1 Cell surface expression of F5-TCR and CD8 co-receptor on transduced CD4+ T cells 108 
5.3.2 In vitro Ag-specific cytokine secretion of transduced CD4+ T cells 110 
5.3.3 In-vitro cytotoxicity of F5-TCR and CD8 co-receptor transduced CD4+ T cells 115 
5.4 In-vitro characterisation of human CD4+ T cells following transduction of CMV-TCR and CD8 co-
receptor 116 
5.4.1 Cell surface expression of human CD4+ T cells following transduction with CMV-TCR and CD8 
co-receptor 116 
5.4.2 In-vitro Ag-specific cytokine secretion of transduced human CD4+ T cells 118 
5.5 Summary 121 
CHAPTER 6 123 
CHAPTER 6. IN-VIVO WORK 124 
6.1 Introduction 124 
6.2 Tumour protection with CD4+ T cells transduced with F5-TCR and CD8 co-receptor. 124 
6.2.1 Characterization of transferred transduced CD4+ T cells 125 
6.2.2 Identification of adoptively transferred CD4+ T cells 126 
6.2.3 Tumour protection and survival 128 
6.2.4 Persistence of transferred CD4+ T cells in surviving mice 129 
  Table of contents 
6 
 
6.3 In vivo tumour protection following adoptive transfer of transduced CD4+ T cells 135 
6.3.1 Characterization of transferred transduced CD4+ T cells 136 
6.3.2 Identification of transferred cells 137 
6.3.3 Effect of adoptively transferred transduced CD4+ T cells on tumour protection and survival 140 
6.3.4 In vivo Ag-specific re-call responses of adoptively transferred transduced CD4+ T cells 145 
6.3.5 Summary 150 
CHAPTER 7 151 
CHAPTER 7. DISCUSSION 152 
REFERENCES 163 
APPENDICES 190 
I. Base sequence of F5-TCR used in F5-TCR pMP71 vector 190 
II. Base sequence of Cβ-CD8αβ construct 191 
III. Base sequence of revised CD8α construct 192 
 
  
  List of figures and tables 
7 
 
List of figures and tables 
Figure 1-1 Schematic diagram showing components of the TCR/CD3 signalling complex. .......................... 20 
Figure 1-2 CD8 co-receptor can exist in two forms. ...................................................................................... 25 
Figure 1-3 CD8 co-receptor engages with the α-3 domain of MHCI The CD8 heterodimer (left) and CD8 
homodimer (right) have similar elongated stalks with immunoglobulin domain in the distal most 
portion which engages the α3 domain of MHCI (shown in blue outline). ........................................... 26 
Figure 1-4 The TCR and CD8 co-receptor engage pMHCI at two distinct points. .......................................... 27 
Figure 1-5 The CD8 co-receptor zipper model. ............................................................................................. 28 
Figure 1-6 Schematic diagram showing the different stages of TCR gene transfer. ..................................... 40 
Figure 1-7 Molecular engineering of TCR signalling complex can improve T cell avidity. ............................. 42 
Figure 1-8 Schematic diagram showing the structure of chimeric antigen receptor (CAR). ......................... 43 
Table 1-1 Results taken from three studies co-transducing CD8 co-receptor with MHCI restricted TCR into 
CD4+ T cells. ......................................................................................................................................... 46 
Table 2-1 Distress scoring system used to determine end point. Mice is culled if total score >8, or scoring a 
3 in any category, or any losing >20% of body weight, or tumour >14mm. ........................................ 61 
Table 3-1 Summary of characteristics of modified TCR constructs used. ..................................................... 65 
Figure 3-1 Derivation of CD8β-pMP71 vector. .............................................................................................. 66 
Figure 3-2 Mutagenesis of the murine CD8β gene. ....................................................................................... 67 
Figure 3-3 Graphic representation of the CD8 co-receptor showing the position of mutations known to 
enhance MHC-binding. ........................................................................................................................ 67 
Table 3-2 PAGE purified oligonucleotide primers. ........................................................................................ 69 
Figure 3-4 Introduction of CD8β MHC-binding site mutations by PCR mutagenesis. ................................... 69 
Figure 3-5 The introduction of CD8β- glycosylation site mutations by PCR mutagenesis. ........................... 70 
Figure 3-6 Agarose gel showing Not1 and BsrG1 digestion of all mini-prep DNA of E Coli colonies 
transformed using CD8β-pMP71 products .......................................................................................... 70 
Figure 3-7 Sequence chromatograms confirming CD8β transgene base mutations. .................................... 71 
Figure 3-8 Sequence chromatograms confirming CD8β transgene base mutations. .................................... 72 
Figure 3-9 Schematic representation of the generation of the pMP71 vector containing F5-TCR, CD8α and 
CD8β coding sequences. ...................................................................................................................... 74 
Figure 3-10 Summary of the molecular cloning required to derive the F5-TCR-CD8αβ pMP71 vector. The 
combination of F5-TCR (red block) and CD8 transgene (blue block) was performed through 
  List of figures and tables 
8 
 
overlapping of the TCR constant β chain (Cβ) present in both vectors and restriction sites XhoI and 
EcoRI in the pGA4 vector (purple ring). ............................................................................................... 74 
Figure 3-11 Schematic representation of the generation of the pMP71 vector encoding F5-TCR and CD8α 
coding sequences. Digestion using restriction site RSRII removed the CD8β gene and the remaining 
vector ligated to form the F5-TCR and CD8α transgene. ..................................................................... 75 
Figure 3-12 Schematic representation of the generation of the pMP71 vector containing F5-TCR and CD8β 
coding sequences. Digestion using restriction site BstZ17I removed the CD8α gene and the 
remaining vector ligated to form the F5-TCR and CD8β transgene..................................................... 76 
Figure 3-13 FACS plots showing transduction of CD4+ T cells using F5-TCR, F5-TCR-CD8α and F5-TCR-
CD8αβ vectors...................................................................................................................................... 77 
Figure 3-14 FACS plots showing transduction of CD8β-/- CD8+ T cells using pMP71 vectors containing the 
F5-TCR or F5-TCR-CD8β vectors. .......................................................................................................... 77 
Figure 3-15 Enhanced Ag-specific IFN-γ secretion of CD8β-/- T cells transduced with the F5-TCR-CD8β 
(green line) retroviral vector compared to the F5-TCR vector (black line). ......................................... 78 
Figure 3-16 Schematic representation of the generation of the revised F5-TCR-CD8αβ pMP71 retroviral 
vector. The original F5-CD8 transgene (yellow) was revised through removal of the F2A-CD8α 
transgene (cyan) using restriction sites BstZ17I and EcoRI and ligating with T2A-CD8α using the same 
restriction sites to produce the revised F5-CD8 transgene (green). .................................................... 79 
Figure 3-17 FACS plots showing transduction of CD4+ T cells using F5-TCR, F5-TCR-CD8α and F5-TCR-
CD8αβ vectors...................................................................................................................................... 81 
Figure 3-18 IL-2 ELISA assay comparing function of transduced CD4+ T cells. .............................................. 81 
Figure 3-19 FACS plots showing transduction of BW cells using F5-TCR, F5-TCR-CD8αβ (original) or F5-TCR-
CD8 (revised) vectors. .......................................................................................................................... 82 
Figure 4-1 FACS analysis of CD8β-/- T cells transduced with retroviral vectors encoding the MDM-TCR and 
CD8β (WT) in separate vectors. ........................................................................................................... 86 
Figure 4-2 FACS analysis of CD8β-/- T cells transduced with the MDM-TCR and CD8β MHC-binding site 
mutants (S53L, S54V, L58R and L58R/I25A) in separate vectors. ........................................................ 86 
Figure 4-3 FACS analysis of CD8β-/- T cells transduced with the MDM-TCR and CD8β glycosylation mutants 
in separate vectors. ............................................................................................................................. 87 
Figure 4-4 Recognition of RMAS cells loaded with saturating concentrations of peptide induces IFN-γ 
production by TCR transduced CD8α+ T cells. ..................................................................................... 88 
Figure 4-5 Recognition of RMAS cells loaded with saturating concentrations of peptide induces IL-2 
production by TCR transduced CD8α+ T cells. ..................................................................................... 88 
  List of figures and tables 
9 
 
Figure 4-6 Recognition of RMAS cells loaded with saturating concentrations of peptide induces IFN-γ 
production by TCR transduced CD8+ T cells. ....................................................................................... 89 
Figure 4-7 FACS analysis following F5-TCR and CD8β (WT) transduction of CD8β-/- CD8+ T cells. .............. 91 
Figure 4-8 FACS analysis following transduction of CD8β-/- CD8+ T cells with the F5-TCR vector and CD8β 
vector containing MHC-binding site mutations (S53L, S54V, L58R or L58R/I25A). ............................. 91 
Figure 4-9 FACS analysis following transduction of CD8β-/- CD8+ T cells with the  F5-TCR vector and CD8β 
vector containing glycosylation site mutations (T120A, T121A, T124A, and TglyM). .......................... 92 
Figure 4-10 Enrichment of F5-TCR and CD8β (WT) transduced CD8β-/- CD8+ T cells................................... 93 
Figure 4-11 Enrichment of the F5-TCR and CD8β transduced CD8β-/- CD8+ T cells containing CD8β MHC-
binding site mutations (S53L, S54V, L58R and L58R/I25A). ................................................................. 93 
Figure 4-12 Enrichment of F5-TCR and CD8β transduced CD8β-/- CD8+ T cells containing CD8β 
glycosylation site mutations (T120A, T121A or T124A and TglyM). .................................................... 94 
Figure 4-13 In vitro functional avidity of F5-TCR CD8β-/- CD8+ T cells is augmented by CD8β L58R and 
L58R/I25A mutations compared to CD8β wild-type (WT). .................................................................. 96 
Figure 4-14  In vitro functional avidity of F5-TCR CD8β-/- CD8+ T cells is not augmented by CD8β 
glycosylation site mutations (T120A, T121A, T124A or TglyM) compared to CD8β wild-type (WT). .. 97 
Figure 4-15 Higher Ag-specific IFN-γ production by CD8β L58R and L58R/I25A compared to CD8β wild-type 
(WT) co-transduced F5-TCR CD8α+ T cells to EL4NP tumour cells which express endogenously 
processed NP peptide. ......................................................................................................................... 99 
Figure 5-1 FACS analysis of transduced CD8β-/- CD8+ T cells using F5-TCR-CD8β vector containing CD8β 
(WT), CD8β L58R or CD8β TglyM. ...................................................................................................... 103 
Figure 5-2 FACS analysis of transduced CD8+ T cells using F5-TCR-CD8β vector containing CD8β (WT or 
L58R or TglyM). .................................................................................................................................. 104 
Figure 5-3 In vitro Ag-specific IFN-γ production of transduced CD8+ T cells showed no difference between 
CD8β wild-type or mutants (L58R and TglyM). .................................................................................. 105 
Figure 5-4 In vitro Ag-specific IL2 production of transduced CD8+ T cells showed no difference between 
CD8β wild-type or mutants (L58R and TglyM). .................................................................................. 105 
Figure 5-5 Recognition of EL4NP tumour cells expressing endogenously processed NP peptide induces IFN-
γ production by F5-TCR transduced CD8+ T cells  that was inferior in CD8β TglyM compared to CD8β 
wild-type or L58R. .............................................................................................................................. 106 
Figure 5-6 Recognition of EL4NP tumour cells expressing endogenously processed NP peptide induces IL-2 
production by F5-TCR transduced CD8+ T cells  that was inferior in CD8β TglyM compared to CD8β 
wild-type or L58R. .............................................................................................................................. 106 
  List of figures and tables 
10 
 
Figure 5-7 In vitro Ag-specific intracellular IFN-γ and IL-2 production to EL4NP tumour cells by transduced 
CD8+ T cells was inferior in CD8β TglyM compared to CD8β WT or L58R . ....................................... 107 
Figure 5-8 F5-TCR and CD8 co-receptor expression of transduced CD4+ T cells. ....................................... 109 
Figure 5-9 F5-TCR and CD8 co-receptor expression of transduced CD4+ T cell populations was similar 
between CD8 wild-type and mutants. ............................................................................................... 109 
Figure 5-10 In vitro IFN-γ functional avidity of F5-TCR and CD8 transduced CD4+ T cells was higher in CD8 
L58R compared to CD8 WT and TglyM. ............................................................................................. 111 
Figure 5-11 In vitro IL-2 functional avidity of F5-TCR and CD8 co-receptor T cells was similar between CD8 
wildtype and mutants. ....................................................................................................................... 111 
Figure 5-12 Ag-specific IL-2 production by F5-TCR transduced CD4+ T cells was highest in CD8 L58R 
compared to CD8 wild-type and TglyM against EL4NP tumour cells expressing endogenously 
processed NP peptide. ....................................................................................................................... 112 
Figure 5-13 Ag-specific IL-2 production by F5-TCR transduced CD4+ T cells was highest in CD8 L58R 
compared to CD8 wild-type and TglyM against EL4NP tumour cells expressing endogenously 
processed NP peptide. ....................................................................................................................... 112 
Figure 5-14 In vitro Ag-specific intracellular IFN-γ and IL-2 production by F5-TCR transduced CD4+ T cells 
production was highest in CD8 L58R compared to CD8 wild-type and TglyM against EL4NP tumour 
cells expressing endogenously processed NP peptide. ..................................................................... 114 
Figure 5-15 In vitro cytotoxicity of F5-TCR and CD8 transduced CD4+ T cells was similar between CD8 WT 
and L58R or TglyM mutants. .............................................................................................................. 115 
Figure 5-16 TCR and CD8 expression of human CD4+ T cells following transduction with the CMV-TCR-CD8 
vector containing CD8β wild-type or I59R mutation. ........................................................................ 117 
Figure 5-17 FACS analysis of CMV-TCR and CD8 transduced human CD4+ T cells after one re-stimulation 
show enrichment of TCR expressing cells. ......................................................................................... 117 
Figure 5-18 FACS analysis of CMV-TCR and CD8 transduced human CD4+ T cells after two re-stimulations 
show further enrichment of TCR expressing cells. ............................................................................ 118 
Figure 5-19 In vitro functional avidity of CMV-TCR and CD8 transduced human CD4+ T cells was similar 
between CD8 wild-type and I59R mutant.......................................................................................... 119 
Figure 5-20 In vitro functional avidity of CMV-TCR and CD8 transduced human CD4+ T cells was similar 
between CD8 wild-type and I59R mutant.......................................................................................... 119 
Figure 5-21 Recognition of KA2pp65 tumour cells expressing endogenously processed pp65 peptide induce 
IL-2 production by transduced CD4+ T cells was similar between CD8 wild-type and I59R mutant. 120 
  List of figures and tables 
11 
 
Figure 5-22 Recognition of KA2pp65 tumour cells expressing endogenously processed pp65 peptide induce 
IFN-γ production by transduced CD4+ T cells was similar between CD8 wild-type and I59R mutant.
 ........................................................................................................................................................... 120 
Figure 5-23 Recognition of KA2pp65 tumour cells induce IL-2 and IFN-γ production by transduced CD4+ T-
cells was similar between CD8 wild-type and I59R mutant. .............................................................. 121 
Figure 6-1 Schematic representation of the in-vivo model used to assess the ability of different doses of 
CD4+ T cells transduced with both F5-TCR and CD8 co-receptor to eradicate EL4NP tumour and 
persist. ............................................................................................................................................... 125 
Figure 6-2 FACS analysis of CD8α sorted thy1.1+ CD4+ T cells transduced with F5-TCR and CD8 co-receptor.
 ........................................................................................................................................................... 126 
Figure 6-3 FACS analysis of peripheral bloood at D14 post transfer confirming the presence of transduced 
CD4+ T cells . ...................................................................................................................................... 127 
Figure 6-4 Titration experiment showing in vivo tumour protection is achieved by transferring as few as 
5x10
4
 transduced CD4+ T cells into tumour bearing mice. ................................................................ 128 
Figure 6-5 Survival curve showing in vivo tumour protection is achieved by transferring as few as 5x10
4
 
transduced CD4+ T cells into tumour bearing mice. .......................................................................... 129 
Figure 6-6 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken from spleen 120 days after 
adoptive transfer. .............................................................................................................................. 130 
Figure 6-7 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken from lymph nodes 120 
days after transfer. ............................................................................................................................ 131 
Figure 6-8 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken from bone marrow 120 
days after transfer. ............................................................................................................................ 132 
Figure 6-9 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken from spleen 120 days 
after transfer. ..................................................................................................................................... 133 
Figure 6-10 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken from lymph nodes 120 
days after transfer. ............................................................................................................................ 134 
Figure 6-11 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken from bone marrow 
120 days after transfer. ..................................................................................................................... 135 
Figure 6-12 Schematic representation of the experimental model used to compare the ability of F5-TCR 
transduced CD4+ T cells with or without CD8 co-receptor to eradicate EL4NP tumour, persist and 
respond to Ag re-challenge. ............................................................................................................... 136 
Figure 6-13 FACS analysis of CD8α sorted thy1.1+ CD4+ T cells transduced with F5-TCR alone or with CD8 
co-receptor containing CD8β WT or CD8β L58R. ............................................................................... 137 
  List of figures and tables 
12 
 
Figure 6-14 FACS analysis of peripheral bloood at D14 post transfer confirming the presence of mock 
transduced CD4+ T cells in all three mice. ......................................................................................... 138 
Figure 6-15 FACS analysis of peripheral bloood at D14 post transfer confirming the presence of F5-TCR 
transduced CD4+ T cells in all five mice. ............................................................................................ 138 
Figure 6-16 FACS analysis of peripheral bloood at D14 post transfer confirming the presence of F5-TCR and 
CD8 co-transduced CD4+ T cells in all five mice. ............................................................................... 139 
Figure 6-17 FACS analysis of peripheral bloood at D14 post transfer confirming the presence of mock 
transduced CD4+ T cells in all three mice. ......................................................................................... 140 
Figure 6-18 In vivo tumour protection was superior when F5-TCR/CD8 CD4+ T cells compared to F5-TCR 
CD4+T cells was transferred into tumour bearing mice. ................................................................... 142 
Figure 6-19 Control of tumour growth after transfer of F5-TCR transduced CD4+ T cells show superior early 
tumour control when CD8 coreceptor is co-transduced. .................................................................. 143 
Figure 6-20 CD4+ T cells transduced with F5-TCR and CD8 co-receptor reduce tumour burden visualised 
using bioluminescence. ...................................................................................................................... 143 
Figure 6-21 CD4+ T cells co-transduced with F5-TCR and CD8 co-receptor reduces tumour burden based on 
objective measures using bioluminescence. ..................................................................................... 144 
Figure 6-22 CD4+ T cells transduced with F5-TCR and CD8 co-receptor improve survival of tumour bearing 
mice. .................................................................................................................................................. 145 
Figure 6-23 Ex vivo phenotypic analysis of lymphoid cells taken from draining (TDLN) with non-draining 
(NDLN) lymph nodes after Ag re-challenge in mice previously treated with thy1.1+ CD4+ CD8(WT) 
F5-TCR transduced T cells. ................................................................................................................. 146 
Figure 6-24 Ex vivo phenotypic analysis of lymphoid cells taken from draining (TDLN) with non-draining 
(NDLN) lymph nodes after Ag re-challenge in mice previously treated with thy1.1+ CD4+ CD8 L58R 
F5-TCR transduced T cells. ................................................................................................................. 147 
Figure 6-25 In vivo expansion of transferred thy1.1+ CD4+ T cells in tumour draining (TDLN) compared to 
non-draining (NDLN). ......................................................................................................................... 148 
Figure 6-26 Preferential in vivo expansion of CD8+ CD4+ T cells after tumour re-challenge. .................... 148 
Figure 6-27 In vivo Ag re-challenge affected the proportion of central memory phenotype CD8+ CD4+ T 
cells isolated from tumour draining lymph nodes (TDLN). ................................................................ 149 
Figure 6-28 In vivo Ag re-challenge affected the proportion of effector memory phenotype CD8+ CD4+ T 
cells in the tumour draining lymph nodes (TDLN). ............................................................................ 149 
Appendix I Base sequence of F5-TCR used in the F5-TCR pMP71 vector. ................................................... 190 
Appendix II Base sequence of Cβ-CD8αβ construct made by Geneart. ...................................................... 191 
Appendix III Base sequence of revised CD8α construct made by Geneart. ................................................ 192  
  Abbreviations 
13 
 
Abbreviations 
2D  two-dimensions 
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APC  antigen presenting cells 
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Cα  constant domain of the TCR-α chain 
Cβ  constant domain of the TCR-β chain 
CDR  complementarity determining region 
CTL  cytotoxic T lymphocyte 
dH2O  distilled water 
DN  double negative 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonucleotide triphosphate 
DLN  draining lymph nodes 
DP  double positive 
EBV  Epstein-Barr virus 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
E:T  effector:target ratio 
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FACS  fluorescence-activated cell sorter 
FCS  foetal calf serum 
FITC  fluorescein isothiocyanate 
FRET  fluorescent resonance energy transfer 
GVL  graft-versus-leukaemia 
GVHD  graft-versus-host disease 
Gy  Gray 
HSCT  haemopoietic stem cell transplantation 
ICS  intracellular cytokine staining 
IFN-  interferon- 
IL-  interleukin- 
IRES  internal ribosomal entry site 
IS  immunological synapse 
ITAM  immunoreceptor tyrosine based activation motif 
kb  kilobases 
Lck  p56lck tyrosine kinase 
LCTE  low concentration tris-EDTA buffer 
LFA-1  lymphocyte function-associated antigen-1 
LN  lymph node 
LTR  long terminal repeat 
M  molar 
m  milli (10-3) 
μ  micro (10-6) 
MDM2  murine double minute-2 protein 
MFI  mean fluorescence intensity 
MHCI  Major Histocompatibility Complex Class I 
MHCII  Major Histocompatibility Complex Class I 
MPSV  myeloproliferative sarcoma virus 
MSCV  moloney sarcoma cell virus 
mRNA  messenger ribonucleic acid 
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n  nano (10-9) 
NDLN  non-draining lymph nodes 
NK  natural killer 
OD  optical density 
p  pico (10-12) 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PD1  programme cell death protein 1 
PE  phycoerhthrin 
PhAmpho Phoenix-Amphotrophic packaging cells 
PhEco  Phoenix-Ecotrophic packaging cells 
PMA  phorbol myristate acetate 
pMHCI  peptide loaded Major Histocompatibility Complex Class I 
PTLD  post-transplant lympho-proliferative disease 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RPMI  Roswell Park Memorial Institute medium 
RT  room temperature 
sc  subcutaneous 
siRNA  small interfering ribonucleic acid 
SP  single positive 
SPL  spleen 
SPR  surface plasma resonance 
TAA  tumour associated antigen 
TAP  transporter associated with antigen processing 
Tcm  central memory T cells 
Tem  effector memory T cells 
TCR  T cell receptor 
TCR-td  T cell receptor transduced 
TGF-β  transforming growth factor-β 
  Abbreviations 
16 
 
Th  T-helper CD4+ T cells 
TIL  tumour infiltrating lymphocytes 
TNF  tumour necrosis factor 
Treg  T-regulatory CD4+ T cells 
U  units 
Vα  variable domain of TCR-α chain 
Vβ   variable domain of TCR-β chain 
WT  wild-type 
WT1  Wilms tumour antigen 1 
ZAP70  ζ-chain-associated protein  
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Chapter 1. Introduction 
This project investigates the potential of exploiting the CD8 co-receptor for T cell 
receptor (TCR) gene therapy of cancer. TCR gene therapy typically transfers TCR 
genes isolated from a single clone of antigen (Ag)-specific T cells. Retroviral transfer 
of cloned T cell receptor (TCR) genes has been shown to reliably re-direct the Ag 
specificity of T cells. This chapter provides background information on T cells, TCR 
structure, T cell signalling and the use of T cells for cancer immunotherapy. 
1.1 Adaptive immunity: T vs B lymphocytes 
The central function of the immune system is defence against infection. The adaptive 
immune system has evolved to distinguish small differences in molecular structure 
between foreign organisms (non-self) and native cells (self) through Ag-specific 
receptors on B and T lymphocytes (Nemazee 2000; Stritesky et al. 2012). The 
presence of additional danger signals from the innate system is often required for the 
adaptive system to target and eradicate pathogens (Banchereau & Steinman 1998; 
Pasare & Medzhitov 2005). Ag-specific receptors on B and T cells are generated by a 
process involving somatic gene recombination in the bone marrow and thymus. This 
allows the potential for a large number (>1013) of Ag-specific receptors with different 
specificities (Nemazee 2000). The strength by which an Ag specific receptor binds to 
its ligand (antigen) is usually measured by its dissociation constant (Kd) and is known 
as receptor affinity. High affinity receptors (with low Kd) do not always have 
increased sensitivity to antigen (see Section 1.3). The antigen sensitivity of 
lymphocytes is often measured by detection of cytokines, proliferation or cytotoxicity 
in antigen titration experiments which is defined here as functional avidity. High 
avidity T cells are able to respond to low levels of antigen.    
B cells and T cells are dissimilar in many aspects. B cell receptors (BCRs) bind to 
complex three-dimensional conformational determinants with high affinity, in 
contrast (Pierce & Liu 2010), T cell receptors (TCRs) bind short linear peptide 
fragments presented on major histocompatibility complex (MHC) molecules with 
lower affinity (Smith-Garvin et al. 2009). BCR secreted from B cells are called 
antibodies, which bind to surface Ag present on pathogens to trigger effector immune 
responses (Mikolajczyk et al. 2004; Corti & Lanzavecchia 2013). Unlike BCR, TCR are 
cell surface bound and target intracellularly processed peptide presented by MHC 
initiating T cell responses (Chaplin 2010). After encountering cognate Ag in the 
periphery, both B and T cells undergo expansion followed by a contraction phase 
(Krammer et al. 2007). Some cells may persist in the periphery as memory B or T 
cells (Mueller et al. 2012; Sanz et al. 2008). These cells which survive Ag-induced 
cell death (AICD) have augmented responses upon encountering the same Ag 
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(Williams et al. 2008).  As the main focus of this thesis is T cells, there will be no 
further mention of B cells or BCR. 
1.2 T lymphocyte development 
Distinct stages in the development of thymocytes are marked by changes in cell 
surface molecules (Pear et al. 2004). Immature T lymphocytes, originating from the 
bone marrow, begin development in the thymus as double-negative (DN) T 
lymphocytes as there is no CD4 or CD8 expression. The DN3 thymocytes undergo 
gene rearrangement of the TCR-β chain and express an early form of TCR known as 
the pre-TCR (Fehling et al. 1995). These thymocytes later acquire both CD4 and CD8 
expression and are known as double-positive (DP) thymocytes (Teh et al. 1988; 
Kisielow et al. 1988). The DP thymocytes undergo gene rearrangement for the TCR-α 
chain and express the complete TCR at low levels (Sebzda et al. 1999). DP 
thymocytes undergo positive selection in the cortex of the thymus following 
recognition of self-peptide/MHC and those that are not positively selected are 
deleted. During the process of positive selection DP thymocytes cease to express 
either the CD4 or the CD8 molecules and become single positive (SP) thymocytes. 
The role of CD4 and CD8 molecules in lineage selection is elaborated below in Section 
1.4.2. The SP thymocytes migrate into the medulla and undergo negative selection 
(Morris & Allen 2012). During this process, T cells exhibiting strong interactions with 
self-Ag are deleted.  One study showed that the negative selection for MHCI 
restricted TCR occur when the dissociation constant, Kd  is <6μM (Naeher et al. 
2007). During thymic development, only 2% of DP thymocytes survive the selection 
process and migrate into the periphery as SP CD4+ or CD8+ T lymphocytes. This 
process is responsible for central tolerance. 
Peripheral T lymphocytes are identified by the presence of TCR and the CD3 complex 
(see Fig 1.1). The majority of T lymphocytes utilise the α- and β-TCR chains (as 
opposed to the γ- and δ-TCR chains) and as mentioned above express either the CD4 
or the CD8 molecules. The TCR expressed by CD8+ T lymphocytes bind optimally to 
cognate peptide presented by MHC Class I (MHCI) and are described as MHCI 
restricted TCR, while the TCR expressed by CD4+ T cells bind to cognate peptide 
presented by MHC Class II (MHCII) and are likewise described as MHCII restricted 
TCR. 
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Figure 1-1 Schematic diagram showing components of the TCR/CD3 signalling 
complex.  
TCR consists of variable (V)α or Vβ domains and constant (C)α or Cβ domains. The CD3 chains 
consist of ε, γ, δ, ζ which are closely associated with TCR. Immune tyrosine-based activating 
motifs (ITAMs) are found on the cytoplasmic tail of CD3 molecules which are below the cell 
membrane (grey line). 
 
CD8+ and CD4+ T cells have different effector functions. CD8+ T cells mature into 
cytotoxic T cells (CTL) and release granzyme and perforin to directly kill target cells. 
CD8+ T cells can produce cytokines, mainly IFN-γ but also small amounts of IL-2 
upon recognition of cognate Ag. Conversely, CD4+ T cells, also known as T-helper 
(Th) cells, are primarily cytokine producing cells. CD4+ T cells secrete a large 
number of cytokines to orchestrate the immune system. The sub-populations of 
mature CD4+ T cells are classified according to their cytokine signature: Th-1 cells 
produce IL-12, IFN-γ; Th-2 cells produce IL-4 and IL-5, T regulatory (Treg) cells 
produce TGF-β and IL-10; and Th17 cells produce IL-17, IL-21. 
Both CD8+ and CD4+ T cells proliferate upon activation, following which a proportion 
of cells undergo AICD. The T cells surviving AICD can persist for long periods of time 
and become memory T cells. Memory phenotype T cells have the ability to respond 
rapidly on re-encounter with specific Ag without priming. CD8+ memory T cells are 
better characterised in the literature than CD4+ memory T cells (Marshall et al. 
2011). Two distinct subtypes of memory exist; central memory T cells (Tcm) which 
express CD62L and CCR7 and home to lymph nodes and effector memory T cells 
(Tem), which circulate in the periphery without CD62L and CCR7 expression. 
γ ε
Cα Cβ
Vα Vβ
ε δ
ζ ζ
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Of interest to this project is the influence CD4+ T cells have on the development of 
memory CD8+ T cells, particularly in the context of the non-infectious setting of 
cancer. The presence of Ag-specific CD4+ T cells, from the initial priming event, 
facilitates the induction and maintenance of memory CD8+ T cells and affects the 
quality of secondary responses. Research studies have shown that T cell help can 
occur either directly through an intermediary ‘third cell’ such as an Ag-presenting cell 
(APC) or through direct contact with the CD8+ T cell (de Goër de Herve et al. 2010). 
In many experimental settings, licensing through ligation of CD40 (on either APC or 
CD8+ T cell) by CD40L expressed on CD4+ T cells is thought to be a crucial factor.  A 
second key mediator of T cell help is paracrine  secretion of IL-2 from CD4+ T cells 
(de Goër de Herve et al. 2010), although a one recent paper suggests that  autocrine 
IL-2 from the CD8+ T cell may be sufficient (Feau et al. 2011).  
1.3 T cell receptor structure and signal transduction 
The TCR propagates Ag-specific stimuli internally into the T cell thus initiating the 
effector response.  The TCR is a hetero-dimer consisting of α- and β- chains linked by 
disulphide bonds (Fig 1-1). Each chain is formed of a variable region containing the 
Ag binding site and a constant region. The variable (V) regions, Vα and Vβ 
respectively, each contain sites known as complementary determining regions 
(CDRs) which are hyper-variable for amino-acid (aa) sequences and account for the 
large diversity of TCR specificities. The constant (C) regions have conserved aa 
sequences and function as a scaffold for the variable regions. The constant region 
contains trans-membrane and cytosolic domains which are important for transduction 
of TCR signalling to downstream molecules.  
Following thymic deletion of T cells expressing TCR with high affinity to endogenous-
peptide/MHC, most peripheral T cells express TCR of low to moderate affinity. Cognate 
peptide may be derived from endogenous (self) or proteins from a foreign source e.g. 
pathogens (non-self). Low affinity interaction with self-peptide/MHC is required for 
survival of naive T cells in the periphery and  was shown to enhance recognition of 
foreign antigen especially when the foreign-peptide (agonistic)/MHC surface density is 
low (Irvine et al. 2002; Krogsgaard et al. 2005). An explanation for this process is that 
self-peptide/MHC can form pseudo-dimers with agonistic-peptide/MHC resulting in 
aggregates and clustering (Krogsgaard et al. 2007). 
Structural studies show that the Ag-binding site of the TCR is orientated diagonally to 
the long axis of the peptide/MHC (pMHC)-binding groove (Garcia et al. 1996; Garboczi 
et al. 1996). The CDR1 and CDR2 regions of the TCR form conserved contacts with MHC 
while the CDR3 region forms contacts with aa residues of the presented peptide 
situated in the MHC groove (Rudolph et al. 2006). As TCR have to screen a large 
number of pMHC complexes, it is postulated that a two-step process may occur where 
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CDR1 and CDR2 initiate contact with MHC and then allow CDR3 to ‘sample’ the peptide 
groove (Wu et al. 2002).   The angle of the diagonal is variable for different TCRs and 
may determine the CD8 dependency of the TCR; four TCRs with Vα chains that 
approximated with the N-terminal end of the bound peptide were found to be CD8 
dependent whereas in a different four TCRs where the Vα chain approximated to the C-
terminal end of the bound peptide were found to be CD8 independent (Buslepp et al. 
2003). Structural studies of the TCR-pMHC interaction suggest that most of the TCR 
binding energy is focused on the peptide which allows discrimination between self and 
non-self (Lee et al. 2000; Simpson et al. 2011). The role of co-receptors in this process 
is discussed separately below (Section 1.4).  
As introduced in Section 1.1, the strength or degree by which TCR binds to pMHC is 
known as TCR affinity (kd). The affinity of most naturally selected TCR, measured 
using surface plasmon resonance (SPR), are typically between 1-100 μM. These are 
relatively low affinity interactions compared to antibody binding affinities (pM-nM 
range). To measure TCR affinity using SPR, MHC molecules coated on a metallic 
surface are allowed to interact with monoclonal TCRs in a liquid solution. When 
interaction between TCR and MHC occurs the aggregation of TCR/MHC complexes 
increase the surface ‘roughness’  and interrupts an electromagnetic wave 
propagating on the metal surface (surface plasmons) causing light to be emitted and 
detected with a photo-detector. Recently, a new method using red blood cell coated 
with MHC is thought to be more physiologically relevant as the molecules of interest 
are on a membrane which allows two-dimensional (2D)-interaction to be measured. 
The experimental data using the 2D method suggested that TCR first binds to MHC 
followed by enhancement of binding by CD8 co-receptor in a two-stage process. 
Within the TCR-α constant membrane proximal region is a conserved motif known as 
the connecting peptide motif (CPM) which when mutated reduces CD3δ association 
(Bäckström et al. 1998) and diminishes antigen responsiveness (Bäckström et al. 
1996). The reason for CPM deficient TCR inability to utilize CD8 co-receptor (Naeher 
et al. 2002) was attributed to the failure of co-receptor approximation (Mallaun et al. 
2008).   
In order for the TCR to be expressed on the cell surface it has to form a stable 
heteromeric complex with the CD3 molecules (γ, δ, ε, ζ) on the T cell membrane (Fig 
1-1). The different CD3 chains contain immune tyrosine-based activating motifs 
(ITAMs) in the cytoplasmic domain which when phosphorylated recruit downstream 
signalling molecules. The exact molecular structure for the TCR/CD3 complex has not 
yet been elucidated but molecular studies have revealed that CD3 molecules are 
heterodimers with the CD3ε chain pairing with either CD3δ (Sun et al. 2004; Arnett 
et al. 2004) or CD3γ (Sun et al. 2001; Kjer-Nielsen et al. 2004). Recent studies have 
suggested that the CD3δ and γ chains associate with the TCRα and β chains 
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respectively (Kuhns et al. 2010; Kim et al. 2010; Kuhns & Davis 2007). The CD3ε 
chains contain a proline-rich sequence, which undergoes conformational change after 
TCR ligation, and is involved in the recruitment of adaptor Nck (Gil et al. 2002; Gil et 
al. 2005). The importance of this region for TCR signalling is unclear as Nck was 
shown to be dispensable for T cell development (Szymczak et al. 2005) and its role 
may be limited to low avidity TCR interactions (Tailor et al. 2008) or related to 
regulating TCR/CD3 expression (Mingueneau et al. 2008; Wang et al. 2010).  The 
CD3ζ chains, unlike the other CD3 molecules, are mostly cytosolic and form 
homodimers with six ITAM motifs (Call et al. 2002).  The ITAMS of CD3ζ may be 
buried in the negatively charged lipid membrane as a result of basic residue rich 
domains (Aivazian & Stern 2000) and released when TCR conformational change 
occurs (Gagnon et al. 2010). Currently, there is still uncertainty of how TCR ligation 
induces conformational change within the TCR/CD3 complex resulting in 
phosphorylation of ITAMs by serine kinases Lck or Fyn. 
The aggregation of TCRs at the T cell/APC interface due to presence of MHC 
complexes may trigger T cell signalling and increase the concentration of signalling 
complexes.  The exclusion of large signalling inhibitive molecules such as CD45 
phosphatases and the aggregation of pro-signalling molecules such as TCR, CD3, Lck 
has been observed by confocal microscopy. This ordered structure is known as the 
immunological synapse (IS). The mature IS consists of distinct zones with the 
TCR/CD3 clustered in the centre and adhesion molecules such as LFA-1 in the 
periphery. However, as the IS can take up to 30 minutes to form, it was argued by 
some that TCR triggering does not require the formation of the IS and that the IS 
has a regulatory role in TCR signalling (Lee et al. 2002). Subsequently the initiation 
of TCR triggering was found to occur on microclusters of TCR/CD3, which form within 
seconds of T cell/APC interaction (Bunnell et al. 2002; Yokosuka et al. 2005). Using 
advance microscopy techniques, Varma et al (Varma et al. 2006) discovered that 
TCR/CD3 microclusters have as little as 11-17 TCR molecules. Several microclusters 
may coalesce to form larger clusters before migrating towards the central zone of the 
IS where they are degraded. The microclusters do not contain CD45 phophatases 
suggesting that tyrosine kinases within the microcluster are in an active state. 
Inhibition of microclusters using MHC blocking antibodies abrogates formation of new 
microclusters and T cell calcium flux. 
Recent studies of real time in-vivo data of T cell/APC interaction have shown that 
high affinity TCR/pMHC interactions lead to the formation of stable synapses and 
strong TCR signalling, whereas low affinity TCR/pMHC interactions lead to short-lived 
synapses and weaker TCR signalling (Henrickson et al. 2008; Moreau et al. 2012). 
Related to this, another group found that only high affinity interactions result in a 
prolonged expansion phase (Zehn et al. 2009). 
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Down-stream signalling after phosphorylation of ITAMs is complex and involves a 
multitude of tyrosine kinases, adaptor molecules, secondary messengers and 
transcription factors. As this is beyond the scope of this thesis, the intricacies are not 
discussed here. Three divergent downstream pathways lead to activation of 
transcription factors NFAT (calcium flux), NF-κB and AP1 which result in proliferation, 
production of cytokines, cytoskeletal changes and degranulation.  
1.4 The CD8 co-receptor 
The CD8 and CD4 co-receptors are surface markers for MHCI and MHCII restricted T 
cells respectively. Both co-receptors play an important role facilitating proximal TCR 
signalling and have elongated glycoprotein structures allowing engagement with their 
respective MHC molecules. The cytoplasmic tails of both receptors contain motifs 
which allow binding of Lck a crucial tyrosine kinase involved in TCR proximal 
signalling. As the thesis relates to the use of a MHCI restricted TCR and the use of 
mutated CD8 co-receptor molecules, this section will focus on the CD8 co-receptor.   
1.4.1 CD8 co-receptor: from structure to function 
1.4.1.1 Comparisons between two naturally existing forms of CD8 co-
receptor 
The CD8 co-receptor is a glycoprotein dimer with each dimer containing an 
immunoglobulin like domain (Fig 1-2). The most prevalent CD8 co-receptor on 
thymocytes and conventional T cells is in the form of a heterodimer consisting of α- 
and β- chains. The CD8 co-receptor can also exist as α-chain homodimer in a wide 
range of immune cells including T, natural killer and dendritic cells. Despite the large 
differences between the sequence of the CD8α and CD8β chains, predictions based 
on molecular structure suggest that both have a similar topology which is confirmed 
when the crystal structure of CD8αβ co-receptor is finally made available (Wang et 
al. 2009). 
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Figure 1-2 CD8 co-receptor can exist in two forms.  
The CD8 co-receptor on conventional T cells is a heterodimer (left) consisting of 
immunoglobulin like α (light green) and β chain (green), whereas it can also exist as a CD8αα 
homodimer (right) in T and non-T cells. The α chain contain a motif which allow engagement 
with LCK (yellow) The β chain is palmitoylated (orange), which allows partition onto the lipid 
raft which was thought to improve TCR signalling.  
 
Affinity studies have shown that CD8αα and CD8αβ have similar binding strengths to 
MHCI molecules (Sun & Kavathas 1997; Kern et al. 1999). Even though the CD8αα 
has been shown to be able to induce proximal signalling in hybridomas, it is generally 
acknowledged that CD8αβ is the functional homologue of the TCR signalling 
apparatus (Gangadharan & Cheroutre 2004). However without the CD8β chain, most 
CD8+ T cells do not survive thymic selection and CD8β-/- mice have few peripheral 
CD8+ T cells (Fung-Leung et al. 1994; Crooks & Littman 1994). When tested the 
CD8β-/- CD8 T cells have decreased sensitivity to antigen in functional assays (Witte 
et al. 1999; Bosselut et al. 2000; Potter et al. 2001; Arcaro et al. 2001). Although 
one study showed that the CD8αα homodimer does not co-localise with TCR 
(Cawthon & Alexander-Miller 2002), a recent fluorescent resonance energy transfer 
(FRET) based imaging study performed by Rybakin showed there was no difference in 
recruitment of either forms of CD8 to the immunological synapse (Rybakin et al. 
2011).  
The CD8αα molecule has a higher affinity (kd=10μM) for the non-classical MHC 
molecule thymic leukaemia antigen (TL antigen) than MHCI (Liu et al. 2003). TL 
antigen expression on intestinal epithelial was shown to mediate cell death of 
CD8αβ+ T cells that do not express CD8αα molecule. It was discovered that strong T 
cell activation up-regulates the CD8αα homodimer which sequesters TL away from 
CD8αβ and protects these cells from FAS induced cell death. Such a mechanism may 
result in affinity maturation within the gut, as surviving T cells are typically high 
avidity memory T cells (Huang et al. 2011). 
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1.4.1.2 Structural and molecular aspects of the CD8 co-receptor 
The CD8 co-receptor is a transmembrane glycoprotein consisting of two 
immunoglobulin-like domains suspended from the cell membrane by an elongated 
stalk, which extends through the cell membrane into the cytoplasm (Fig 1-3). The 
apex of the CD8 co-receptor consisting of two globulin domains associates with the 
conserved regions of MHC-I through non-convalent bonds in a bidentate manner. The 
earlier structural studies of the CD8 co-receptor using crystallography of CD8αα co-
receptor ligating with TL antigen or human and murine MHC molecules (Gao et al. 
1997; Kern et al. 1998; Liu et al. 2003) showed that the globular domains are 
situated on either side of the α3-domain, which is distant from the TCR binding site 
(Connolly et al. 1990), in a clamp like fashion. 
  
Figure 1-3 CD8 co-receptor engages with the α-3 domain of MHCI 
The CD8 heterodimer (left) and CD8 homodimer (right) have similar elongated stalks with 
immunoglobulin domain in the distal most portion which engages the α3 domain of MHCI 
(shown in blue outline). 
The long axis of the globular domains is perpendicular to the long axis of the MHCI 
molecule (Fig 1-3) with slight asymmetry: one globular domain in the T cell proximal 
position is assigned as CD8α1 and the other domain in the T cell distal position is 
assigned as CD8α2. The CD8α1 globulin domain accounts for about 70% of the 
binding site and also makes some contact with the MHC-I α2 and β2-microglobulin 
domains. There have been conflicting predictions on whether the CD8β chain in the 
CD8αβ molecule occupies the upper CD8α1 or lower CD8α2 positions: predictions 
based on stalk length suggest the former (Kern et al. 1999), predictions based on 
surface electrostatic charge (Devine et al. 1999) suggest the latter and 
extrapolations based on mutagenesis data suggest that both positions are possible 
(Chang et al. 2006; Devine et al. 2006). This uncertainty was only resolved when the 
crystal structure of the CD8αβ molecule with H2-Dd-MHC molecule was finally solved 
showing that CD8β occupies the T cell proximal CD8α1 position and only contacts the 
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α3-domain of the MHC-I (Fig 1-4), contributing about 50% of the total binding 
energy (Wang et al. 2009). 
  
Figure 1-4 The TCR and CD8 co-receptor engage pMHCI at two distinct points. 
When cognate interaction between TCR/CD3 complex (central structure annotated in Fig 1-1) 
and pMHCI (yellow pentagon with blue outline above) occurs, the CD8 coreceptor (elongated 
heterodimer on the left of TCR) also engages MHCI and becomes closely associated with 
TCR/CD3 complex. As the LCK is attached to the tail of CD8α chain, this also engages the 
ITAMs in the cytoplasmic portion of the CD3 chains forming a second point of contact. 
 
The CD8α and CD8β stalk regions are rich in proline, serine and threonine residues 
and both contain N and O-glycosylation sites which allow post-translational 
modification. The chemistry of the stalks allow an extended rigid conformation but 
with some flexibility (Fig 1-2 and 1-3). The CD8β stalk is shorter than the CD8α stalk 
and contains one N-glycosylation and three O-glycosylation sites which are highly 
conserved between different species. Removing the CD8β stalk and replacing it with 
the CD8α stalk results in failure of CD8+ SP T cell selection in the thymus (Rettig et 
al. 2009). Performing the reverse and removing the CD8α stalk and replacing it with 
the CD8β stalk improves the sensitivity of T cells to antigen (Wong et al. 2003). 
These results emphasise the important contribution of the CD8β chain to the function 
of the CD8 co-receptor (Renard et al. 1996). The high level of conservation of the 
CD8β stalk region between different species adds further weight to this 
interpretation. The role that the CD8β plays in optimizing TCR signalling was thought 
to be related to the intramembrane portion of CD8β containing sequences for 
palmitoylation which is regarded as important for lipid raft partitioning. However, this 
has been disputed because CD8β with mutated palmitoylation sequences were still 
functional and CD8α also contains sequences for palmitoylation (Pascale et al. 1992; 
Fragoso et al. 2003). As mentioned above, the CD8β stalk region is essential to the 
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co-receptor function and was shown to enable CD8 association with CD3δ and the 
CPM motif of the TCR-α chain (Wheeler et al. 1998; Doucey et al. 2003; Mallaun et 
al. 2008; Naeher et al. 2002). It is postulated that the CD8β stalk forms the centre 
portion of a TCR co-receptor zipper model and allows optimal orientation with the 
TCR/CD3 complex to facilitate signalling (Palmer & Naeher 2009) (Fig 1-5). 
 
Figure 1-5 The CD8 co-receptor zipper model. 
Naher and Palmer proposed that the CD8 co-receptor forms a tight association, like a zip, with 
the TCR after antigen ligation. Using the TCR/pMHCI/CD8 structure shown in Fig 1.4 to 
illustrate this, a further third point of engagement is postulated to occur between the CD8β 
stalk (pink line) with the CPM motif within the Cα (dark blue) chain of TCR. 
 
Lastly, the cytoplasmic portion of the CD8α chain contains a CxC motif that allows 
association with Lck (Zamoyska et al. 1989; Turner et al. 1990). This is similar to the 
CD4 co-receptor although the CD4 co-receptor contains two extra CxC motifs, which 
potentially allow for increased Lck binding (Wiest et al. 1993; Shaw et al. 1989; 
Erman et al. 2006).  
1.4.1.3 Role of CD8 co-receptor in TCR proximal signalling 
The close physical association of the CD8 co-receptor and TCR on lipid rafts has been 
well documented in many studies (Takada & Engleman 1987; Beyers et al. 1992; 
Suzuki et al. 1992; Gallagher et al. 1989). Structural studies have also shown that in 
the tri-molecular assembly of TCR/pMHCI/CD8 the TCR and CD8 engage the same 
pMHCI molecule at distinct positions. Therefore, it is envisaged that biologically, TCR 
and CD8 on the T cell (in cis) will interact with pMHC on an APC (in trans). However, 
as the TCR and CD8 co-receptor have different binding affinities to the pMHCI (Wyer 
et al. 1999), simultaneous engagement is unlikely. Evidence that the CD8 co-
receptor is the first to engage MHCI was based on experiments using fluorescence 
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correlation spectroscopy of T cells stained with multimer. It was found that the early 
association rates (κon) were not related to pMHCI structure and could be blocked 
using anti-CD8 antibodies (Gakamsky et al. 2005). Furthermore, the early 
association rates determined in this study were similar to the association rate of CD8 
co-receptor and MHCI using SPR (Wyer et al. 1999) but not between TCR and MHC 
(Gakamsky et al. 2004). The authors suggested that CD8 co-receptor enhanced the 
TCR-pMHCI interaction by increasing the number of TCR/MHC complexes (Pecht & 
Gakamsky 2005). Others have postulated that the fast CD8 co-receptor engagement 
can re-orientate MHC from a supine position (Mitra et al. 2004) into a more 
convenient position for TCR engagement. 
Other studies have suggested that the TCR first engages MHCI, in keeping with the 
function of TCR as an Ag-specific receptor triggering positive signalling only when 
cognate pMHCI is encountered (Irvine et al. 2002). Zal and Gascoigne found that the 
FRET between CD8 co-receptor and TCR only occurred during cognate interactions. 
Experiments using RBC coated with pMHCI molecules to measure the TCR and CD8 
interaction, demonstrated a biphasic association with the early phase involving the 
TCR and the second phase involving the CD8 co-receptor (Jiang et al. 2011). 
Consequently, current opinion favours the hypothesis that TCR binds to pMHCI first 
followed by recruitment of CD8 co-receptor and Lck by association (van der Merwe & 
Dushek 2011; Laugel et al. 2011; Edwards et al. 2012). Surprisingly, the cooperative 
effects of CD8 co-receptor in cell-cell adhesion requires phosphorylation of ITAMs by 
free Lck (Jiang et al. 2011).  The role of free Lck in proximal signalling was first 
mentioned in a study examining alloreactive and anti-viral T cell responses in CD8 
and CD4 co-receptor deficient mice (Schilham et al. 1993). The same mechanism 
may explain how high affinity MHCI restricted TCR generated through affinity 
maturation can function in CD4+ T cells (Robbins et al. 2008). However, in the 
context of weak TCR/pMHC interactions, TCR ligation may still allow recruitment of 
free Lck to partially phosphorylate CD3 associated ITAMs. Jiang et al showed that the 
initial step involving free Lck is required for cooperative effects mediated by the CD8 
co-receptor. It has been postulated that CD8 co-receptor recruitment to the TCR 
activation site depends on intracellular attributes such as complementarity between 
the much stronger Lck/LAT interaction (Gibbings & Befus 2009); this is known as the 
‘inverted model’ as it is independent of MHC binding by the extracellular portion of 
CD8 co-receptor. Experimetal data from a number of groups supports this model (Xu 
& Littman 1993; Thome et al. 1996; Purbhoo et al. 2004). 
There can be two possible explanations for the cooperative effect of CD8 co-receptor 
on TCR function; firstly it enhances stabilization of TCR/pMHCI interactions (Luescher 
et al. 1995; Garcia, Scott, et al. 1996; Cebecauer et al. 2005) and secondly it 
facilitates transport of Lck to the vicinity of the TCR signalling complex. The 
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importance of the first effect has been disputed as CD8 co-receptor affinity for MHCI 
is several logs lower than the affinity of TCR for pMHCI, CD8 aggregation is 
independent of MHC molecules (Wooldridge et al. 2003; Buslepp, Kerry, et al. 2003) 
and site-directed mutagenesis of MHCI reducing affinity of TCR binding have been 
shown to have little effect on T cell signalling. However mathematical modelling 
suggests that the extracellular portion of the CD8 molecule increase ligand 
interaction 30-fold  with respect to recruitment of Lck (van den Berg et al. 2007) 
rather than stabilisation of TCR/pMHCI (Artyomov et al. 2010).  
The transportation of Lck to the TCR signalling complex is critical for CD8 co-receptor 
function. It has been demonstrated that Lck mutagenesis abrogates recruitment of 
CD8 (Xu & Littman 1993) and mutagenesis of the Lck binding site on the CD8 co-
receptor impairs T cell activation (Arcaro et al. 2001). CD8-associated LCK optimizes 
the phosphorylation of ITAMS allowing TCR signal transduction (Purbhoo et al. 2001). 
The palmitoylation of the CD8β chain facilitates partitioning of the CD8 with the TCR 
on the same lipid raft thus enhancing this effect. 
1.4.2 Role of the CD8 co-receptor in the thymus 
Immature CD8+ CD4+ DP thymocytes have to be able to recognise MHC molecules 
and discriminate them from non-MHC molecules in order to undergo positive and 
negative selection. During this early stage in T cell development, Lck levels are low 
and are mostly co-receptor associated (Wiest et al. 1996). This restricted distribution 
of Lck is instrumental in imposing MHC specificity as the remaining Lck is 
sequestered by CD8 or CD4 co-receptor.  Murine immature thymocytes deficient in 
CD8 and CD4 co-receptors have higher levels of free Lck and can be activated more 
easily with anti-TCR antibodies compared to wild-type immature thymocytes. In an 
MHC-deficient environment, these thymocytes can mature and cause autoimmune 
disease in the periphery via the targeting of non-MHC targets in vitro (Park et al. 
2007). 
TCR triggering requirements of positive and negative selection are different; for 
positive selection a high number of low affinity interactions are necessary (Hogquist 
et al. 1994) whilst during negative selection a low number of high affinity interactions 
are sufficient (Ebert et al. 2008; Alam et al. 1996; Williams et al. 1999). The CD8 co-
receptor has been shown to play a role in modulating the strength of TCR signalling 
through post-translational glycosylation during T cell development (Daniels et al. 
2001; Baum 2002; Gascoigne 2002). Immature DP thymocytes were found to bind 
non-cognate MHCI multimers better than mature CD8+ SP thymocytes (Daniels et al. 
2001). These changes occurred through the addition or removal of sialic acid 
moieties on O-linked glycans on conserved threonine residues on the CD8β chain 
under the influence of ST3-Gal-1 enzyme (Moody et al. 2001). On immature 
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thymocytes the CD8 co-receptor was found to exhibit lower levels of cell surface 
sialylation. Ex vivo mature thymocytes when desialylated artificially by 
neuraminidase were found to bind more strongly to MHC multimers, suggesting that 
desialylated CD8 co-receptor could improve TCR signalling and increase positive 
selection (Daniels et al. 2001).  
After positive selection in the thymus, it is possible that the sialylation of O-linked 
glycans of the CD8 co-receptor may help mature thymocytes avoid negative 
selection. Subsequently it was found that the post-translational sialylation changes 
occur on the three threonine residues (T120, T121 and T124) that are conserved 
between all species studied to date (Moody et al. 2003). It was suggested that the 
presence of sialic acid in the stalk region gives rise to electrostatic repulsion effects 
between CD8 and pMHCI (Moody et al. 2003; Rudd et al. 1999), however 
thermodynamic considerations make this mechanism unlikely (Shore et al. 2005). A 
more plausible explanation is that the O-glycans, which are on the membrane distal 
region of the CD8 stalk, may influence the stalk conformation such that it 
reorientates the CD8 immunoglobulin domain and affects engagement with the MHCI 
molecule (Shore et al. 2005). 
One of the significant stages of thymocyte development is lineage selection. This 
lineage divergence is largely determined by the MHC restriction of the TCR (Singer et 
al. 2008); TCR that have greater affinity for MHCI lose CD4 expression and become 
CD8+ SP T cells, TCR that have greater affinity for MHCII lose CD8 expression and 
become CD4+ SP T cells. The process involves an intermediate stage where upon 
engagement of TCR by MHC thymocytes down-regulate CD8 and become CD4+ 
CD8lo thymocytes (Brugnera et al. 2000). The CD8 downregulation was also 
observed with T cells are engaged only by MHCI (Bosselut et al. 2003).  Therefore 
downregulation of CD8 gene transcription is considered to be a reliable indicator of 
the intermediate stage phenotype between DP and SP thymocytes (Singer 2002). 
During CD8 co-receptor downregulation, the persistence of a positive signal results in 
CD4+ differentiation (Liu & Bosselut 2004). In the opposite situation when a positive 
signal diminishes, the cell receives survival signals from IL-7 in a process known as 
‘co-receptor reversal’ where CD4 gene transcription is silenced and CD8 gene 
transcription is re-initiated (Yu et al. 2003) through the activation of E8I enhancer 
elements (Park et al. 2007). Silencing of the CD4 gene in experimental conditions 
also results in intermediate thymocytes differentiating into CD8+ T cells (Sarafova et 
al. 2005). Intermediate thymocyte CD8 and CD4 genes are regulated in a co-
ordinated fashion by the transcription factors Th-POK (T-helper-inducingPOX/Kruppel 
factor) and Runx, which have reciprocal actions on CD8 and CD4 genes. Th-POK 
induces CD4 expression and silences CD8 gene expression (He et al. 2005; Sun et al. 
2005), Runx silences CD4 expression by binding to Th-POK while promoting CD8 
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enhancers (Taniuchi et al. 2002). Recently, it was found that Runx mediates the 
physical association of CD8 and CD4 genes, which are separated by 53.3 megabases, 
to enable coordinate gene regulation (Collins et al. 2011). 
1.4.3 Role of the CD8 co-receptor in peripheral T cells 
The CD8 co-receptor is important for tuning TCR responses in peripheral CD8+ T 
cells.  In the periphery, expression levels of the CD8 co-receptor are lower than in 
thymocytes  and modulated through gene transcription (Zamoyska & Parnes 1988). 
Even before Ag encounter, naïve CD8+ T cells require interaction with MHCI 
molecules for survival and may be able to up-regulate CD8 co-receptor expression in 
order to enhance sensitivity to low affinity antigens (Takada & Jameson 2009). In 
vitro experiments which show that the CD8 co-receptor contributes significantly to 
the function of peripheral MHCI restricted T cells (Holler & Kranz 2003). In the rare 
event that a strong interaction with self-Ag occurs, the CD8 co-receptor can be down 
regulated to prevent autoimmunity (Teh et al. 1989; Zhang et al. 1995). As 
mentioned in Section 1.3, self-Ag can enhance low density agonist-pMHCI interaction 
and this was shown in a viral Ag model to be a CD8 dependent process (Anikeeva et 
al. 2006). 
Modulation of CD8 expression can be influenced by γ-chain cytokines (IL-2, IL-4, IL-7 
and IL-15) through the JAK-STAT pathway, this was found to be independent of cell 
metabolism which is driven by phosphatidylinositol-3OH kinase (Park et al. 2007).  It 
is thought that during homeostatic conditions, weak interactions between TCR and 
self-pMHC allow IL-7 to mediate γ-chain signalling through IL-7R to up-regulate CD8 
expression. This dynamic feedback loop is known as ‘CD8 tuning’. However, there are 
other studies that have shown that IL-2 and IL-4 exposure results in downregulation 
of CD8 expression (Erard et al. 1993; Kienzle et al. 2002; Maile et al. 2005; 
Kambayashi et al. 2001). The interaction between cytokines and CD8 expression can 
be complex, for example the effects of IL-4 mediated down-regulation of the CD8 co-
receptor can be ameliorated by the presence of IFN-γ (Apte et al. 2008). CD8 
downregulation has been seen in chronic infections including human immune-
deficiency virus infection (Schmitz et al. 1998), Trypanosoma cruzi infection in mice 
(Grisotto et al. 2001) and Echinococcus locularis infection in mice (Kizaki et al. 
1991). During acute infections to Listeria monocytogenes and Vaccinia virus there is 
transient downregulation of the CD8 co-receptor, mediated by IFN-γ, which results in 
loss of pMHCI binding and reduction of T cell response to antigen (Xiao et al. 2007). 
Downregulation of CD8 co-receptor occurs between four to eight days after 
Lymphocytic choriomeningitis infection (LCMV) (Slifka & Whitton 2000). However, the 
Ag experienced memory T cells have ten-fold higher functional responses despite 
CD8 co-receptor down-regulation, which may be related to higher levels of Lck (Slifka 
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& Whitton 2001). However, Jameson et al demonstrated that the Ag experienced 
CD8+ T cells did not have increased functional responses and remained dependent 
on the CD8 co-receptor for antigen recognition. This discrepancy may be related to 
the different MHCI alleles used by Jameson (Kb) vs Slifka (Db) (Xiao et al. 2007). 
Desialylation of the O-linked sugars of the CD8β chain occurred after cognate antigen 
recognition following the vaccination of F5-TCR transgenic mice with relevant peptide 
(Casabó et al. 1994). Although there is no direct evidence that desialylation of CD8β 
enhances T cell function in the periphery, two studies using neuraminidase enzyme to 
reduce total cell surface sialic acid on naïve and activated T cells resulted in 
enhanced T cell function (Pappu & Shrikant 2004; Kao et al. 2005).  
The CD8 co-receptor is part of a negative feedback signalling network that modulates 
responses within a narrow physiological range even when there are large differences 
in signalling molecule expression (Feinerman et al. 2008). Recently the fine-tuning 
effects of CD8 co-receptor were also demonstrated for TCR interaction with 
endogenous peptides; using a panel of self-peptides with agonistic or antagonistic 
properties, presence or absence of CD8 co-receptor had different effects on the T cell 
responses. For example, an antagonistic peptide in the absence of CD8 co-receptor 
became a co-agonist in CD8+ T cells (Stone et al. 2011). It is possible that the CD8 
co-receptor allows the T cell to have active control over which antigen to ‘focus on’ to 
counter the effects of TCR degeneracy thus discriminating recognition of self or non-
self (Laugel et al. 2011).  
1.5 Immune surveillance and the immune response to tumours 
It was postulated as early as the 1900s that the immune system has an important 
role in preventing cancer in long-lived organisms (Ehrlich 1909).  The evidence for 
the theory of immune surveillance is in part the increase incidence of cancers 
observed in immune-compromised individuals (Vajdic & van Leeuwen 2009; Chua et 
al. 2008) together with the association of tumour infiltrating CD8+ T cells and NK 
cells with better prognosis (Hayakawa et al. 2011; Nelson 2008). The early research 
that led to the breakthrough findings that immune cells can detect tumour associated 
antigen (TAA) and differentiate cancer cells from normal cells (Old & Boyse 1964) 
have provided the basis for Burnet to propose the cancer immune surveillance 
hypothesis, which predicted that the immune cells were responsible for inhibiting 
cancer growth in healthy hosts. This can occur through the elimination of viral 
infections which can induce tumours; the prevention of a tumourigenic inflammatory 
environment; and the elimination of spontaneous tumours expressing ligands for 
activating receptors of  innate and adaptive immunity (Schreiber et al. 2011).  
The identification and characterisation of tumour antigens followed the use of 
carcinogens, viruses or ultraviolet irradiation to induce tumour in animal models. The 
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tumour antigens were found to be products of mutated cellular genes, abnormally 
expressed normal genes or non-human viral genes. Human tumour antigens can be 
divided into two main categories- tumour specific antigens (TSA) and tumour 
associated antigens (TAA). Tumour specific antigens include differentiation antigens 
(melanoma), mutated oncogenes (p53, RAS), viral antigens (human papilloma virus 
proteins) and germline antigens (NY-ESO-1) whilst tumour associated antigens are 
typically overexpressed cellular antigens (Wilms tumour antigen-1 and murine 
double-minute [MDM] antigen), which are also expressed at lower levels in normal 
tissue. TSA are often presented poorly on the cell surface due to competition with the 
large number of peptides derived from normal cellular proteins for MHC and may not 
be amenable for immune targeting. 
Animal models have allowed the immune elements important for cancer surveillance 
to be dissected; cellular elements including CD8+ cytotoxic T lymphocytes (CTLs), 
CD4+ Th1 helper T cells and natural killer (NK) cells were crucial in limiting the 
formation of carcinogen induced tumours (Teng et al. 2008; Kim et al. 2007). 
Animals without T and NK cells such as RAG2-/- mice had an even more profound 
susceptibility to tumour (Kaplan et al. 1998; Shankaran et al. 2001). Among the 
cellular products, the cytokine IFN-γ was especially important in mediating rejection 
of transplanted tumour cells (Dighe et al. 1994). Immuno-editing is a more recent 
model describing the dynamic process between the immune system and the 
immunogenic phenotype of tumours (Schreiber et al. 2011). In this model, 
immunogenic cancer cells are eliminated but less immunogenic cancer cells are left 
behind with the potential to escape. The less immunogenic cancer cells do not 
immediately proliferate to generate large tumours but may go through an equilibrium 
phase where outgrowth is inhibited by the immune system. This is also known as the 
dormant phase where latent tumour cells may lie quiescent for years before 
progression (Aguirre-Ghiso 2007). Both innate and adaptive immunity are involved in 
the elimination phase via type 1 interferon which activate dendritic cells and promote 
induction of adaptive anti-tumour responses (Schreiber et al. 2011). An elegant 
study showed that adaptive immunity involving CD8+ and CD4+ T cells and the 
cytokines IL-12 and IFN-γ were accountable for tumour latency (Koebel et al. 2007). 
Others have long supported a mouse model of spontaneous tumour development and 
have suggested instead that tumour escape occurs because of induction of tumour 
tolerance rather than loss of intrinsic immunogenicity (Willimsky & Blankenstein 
2005). This process was found to occur at a premalignant stage and is associated 
with non-responsive CD8+ T cells. Hence although tumour immunogenicity exists, 
the elicited immune response is non-destructive (Willimsky et al. 2008). To reconcile 
these alternate models, Pradeu and Carosella suggested that tumour immunogenicity 
does not only depend on the presence of a sufficient density of novel antigens but 
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that these antigens have to undergo repeated modifications (Pradeu & Carosella 
2006). This concept has been appropriately paraphrased by Blankenstein as ‘antigen 
discontinuum’ (Blankenstein et al. 2012). 
There are several immune-modulatory mechanisms by which tumour cells escape 
immune-surveillance. The most common cause is MHCI down-regulation, which 
frequently occurs in human tumours (Garrido et al. 2010). Defects in antigen 
processing also cause a similar form of resistance (Dunn et al. 2002). Prominent 
tumour associated immunosuppressive effects include expression of programme cell 
death protein 1 (PD1) ligands; production of indoleamine-pyrrole-2, 3-dioxygenase 
(IDO) (Uyttenhove et al. 2003) or tryptophan-2,3 dioxygenase (TDO) which depletes 
tryptophan (Opitz et al. 2011; Pilotte et al. 2012); production of galectin-3 which 
reversibly impairs T cell activation (Demotte et al. 2010); and lastly production of 
lactic acid, prostaglandins and transforming growth factor β (TGF-β). The tumour 
milieu is not only low in oxygen and difficult to penetrate (Trédan et al. 2007), but 
there are non-tumour cells, which have direct immunosuppressive effects including 
Tregs (Curiel et al. 2004; Getnet et al. 2009) and myeloid suppressive cells 
(Gabrilovich & Nagaraj 2009). Here, tumour infiltrating lymphocytes (TILs) have an 
‘exhausted’ phenotype with upregulation of T cell immunoglobulin and mucin domain-
containing protein 3 (TIM3), lymphocyte activating gene 3 (LAG3), PD1 and cytotoxic 
T lymphocyte antigen 4 (CTLA-4) (Baitsch et al. 2011). The information gleaned from 
understanding tumour associated immune-modulatory mechanisms has led to the 
identification of novel approaches to target cancer through pharmacological agents, 
monoclonal-antibodies and reprogramming of T cells (Blankenstein et al. 2012). 
1.5.1 The role of CD8+ T cells in tumour immunity 
One of the major hallmarks of tumour cells is uncontrolled growth. Many of the 
unique tumour antigens are derived from intracellular proteins that are not expressed 
on the tumour cell surface but need to be processed internally into peptide 
fragments, loaded onto MHCI and presented on the surface. As MHCI is present on 
almost every nucleated cells, tumour specific MHCI restricted T cells are therefore 
theoretically able to directly engage and kill most tumours. Not surprisingly many 
published reports have focused on utilizing CD8+ T cells for cancer immunotherapy 
(Kast et al. 1989; Riddell & Greenberg 1995; Yee et al. 2000) including more recent 
publications on adoptive transfer of ex vivo expanded tumour reactive CD8+ T cells 
with response rates of up to 70% (Rosenberg et al. 2011). The principle mechanism 
of CD8+ cytotoxic T lymphocyte (CTL) killing is the release of specialized lytic 
granules containing perforin and granzymes upon recognition of cognate pMHCI in a 
focused manner, requiring polarisation of lytic machinery to destroy the target cells 
(Kägi et al. 1994; Lobe et al. 1986; Faroudi et al. 2003; Pasternack & Eisen 1985). 
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CTL can also release large amounts IFN-γ cytokine which further increases MHCI 
upregulation (Seliger et al. 2008) and mediates inhibition of tumour-induced 
angiogenesis (Prévost-Blondel et al. 2000; Qin et al. 2003). Cell mediated 
cytotoxicity is a rapid and low threshold process while IFN-γ production is prolonged 
and requires strong antigen stimulation (Wiedemann et al. 2006). As few as two 
cognate pMHCI interactions at the cellular interface have been shown to be sufficient 
to activate cytotoxicity (Purbhoo et al. 2004). The lethal hit is delivered rapidly which 
allows each CTL to kill large numbers of targets either serially (Isaaz et al. 1995) or 
by simultaneously engaging multiple targets (Wiedemann et al. 2006). CD8+ CTL are 
typically more potent lytic effectors than CD4+ CTL even though both contain equal 
amounts of lytic granules (Beal et al. 2008). CD8+ CTL were found to have a greater 
ability to accumulate lytic granules into the centre of the lytic synapse whereas in 
CD4+ CTL the lytic granules are located peripheral to the synapse (Beal et al. 2009). 
These differences were related to faster calcium mobilisation in CD8+ CTL after 
cognate antigen stimulation thus allowing granules to be delivered to the microtubule 
organising centre and subsequent polarisation to occur (Sykulev 2010).  
1.5.2 The role of CD4+ T cells in tumour immunity 
A critical role for CD4+ T cells in inducing tumour immunity has been demonstrated 
in mice depleted of or deficient in CD4+ T cells (Lin et al. 1996; Hock et al. 1991; 
Fearon et al. 1990). The mechanisms by which CD4+ T cells promote tumour 
immunity are numerous (Pardoll & Topalian 1998). Perhaps the most important role 
is the ability of CD4+ cells to augment CD8+ T cell responses (Castellino & Germain 
2006). CD4+ T cells are crucial during the activation and effector phases of tumour 
specific CD8+ T cells within the tumour microenvironment (Schietinger et al. 2010).  
The induction of a long-lived tumour specific IFN-γ producing CD8+ response has 
been demonstrated to require the priming of CD4+ tumour specific T cells through 
vaccination with MHCII peptides (Knutson et al. 2001). In other studies, co-transfer 
of melanoma specific CD4+ and CD8+ T cells (Rosenberg & Dudley 2004; Dudley et 
al. 2005) were found to be more effective than previous protocols using only CD8+ T 
cells (Dudley et al. 2001). A significant component of CD4+ T cell help in the tumour 
setting occurs via the paracrine production of IL-2 (Fearon et al. 1990), and through 
CD40-CD40L engagement via APC or directly with T cells (Shafer-Weaver et al. 
2009). Local effects of IL-2 lead to upregulation of cytolytic function in tumour 
specific CD8+ T cells (Bos & Sherman 2010). The use of immunotherapy by systemic 
administration of IL-2 and agonistic CD40 antibodies to replicate the CD4+ T cell help 
effects had some short-term benefits but led to detrimental secondary responses 
(Berner et al. 2007). The anti-tumour effects of IL-2 and CD40 antibodies were found 
to be dependent on IFN-γ, however systemic administration of IFN-γ led to apoptosis 
of CD4+ T cells. Another approach substituted CD4+ T cell help by inducing 
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activation of dendritic cells in the tumour environment through administration of the 
TLR3 agonist polyI:C (Hervas-Stubbs et al. 2007). Although this resulted in an 
increase in CD8+ effectors in the periphery, without chemokine-secreting tumour 
specific CD4+ T cells, CD8+ effectors were not recruited into the tumour 
environment (Bos & Sherman 2010). This may suggest that CD4+ T cells may be 
better able to persist within the tumour milieu better than CD8+ T cells. 
Even though most tumour cells do not normally express MHCII, CD4+ T cells are able 
to upregulate MHCII on cancer cells for direct recognition (Xie et al. 2010; Muranski 
et al. 2008). There have been historical observations that CD4+ T cells are able to 
target tumour cells directly (Greenberg et al. 1981). The mechanisms by which TCR 
transgenic CD4+ T cells can eradicate established tumour cells have been shown in 
detail by two recent studies (Xie et al. 2010; Quezada et al. 2010). These tumour-
specific cytotoxic CD4+ T cells had features characteristic of effector CD8+ T cells 
expressing perforin, granzyme, CD107 and Th1 cytokines. Endogenous CD8+ T, B, 
NK, and NKT cells together with endogenous IFN-γ producing cells were not required 
for the anti-tumour effects, however IFN-γ production by CD4+ T cells was crucial 
(Quezada et al. 2010).  
The effects of IFN-γ may extend beyond the tumour into the surrounding stromal 
cells (Qin & Blankenstein 2000; Muranski et al. 2008) explaining the observation that 
CD4+ T cells can eradicate MHCII deficient tumours in the absence of CD8+ T cells 
(Greenberg et al. 1985; Frey 1995; Monach et al. 1995). Cytokines secreted by 
tumour specific CD4+ T cells have been shown to activate macrophages and 
eosinophils (Hung et al. 1998; Corthay et al. 2005). A recent paper showed that 
CD4+ T cells were more efficient at eradicating tumour than CD8+ T cells because of 
the additional ability to engage stromal cells through MHCII (Perez-Diez et al. 2007). 
This finding was supported by a different study demonstrating that aggressive 
tumour can be eradicated by just targeting tumour stroma with Ag-specific CD4+ T 
cells (Schietinger et al. 2010). The bystander killing of tumour by targeting stromal 
cells required cooperation between CD4+ and CD8+ T cells (Schietinger et al. 2010). 
 
1.6 Cancer immunotherapy using adoptive T cell transfer  
1.6.1 Non-modified T cells  
The earliest example of using T cell transfer to eradicate tumour is now also known 
as the graft-versus-leukaemia (GVL) effect (Odom et al. 1978). The establishment of 
GVL requires allogeneic haemopoietic stem cell transplantation (HSCT) with or 
without subsequent donor lymphocyte infusion/s which is now used routinely to treat 
human leukaemia and lymphoma (Collins et al. 1997). The basic mechanism of the 
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GVL effect is the recognition of minor histocompatibility antigen (HLA) mismatch in 
leukaemic cells by donor T cells. As the minor-HLA mismatch also occur frequently in 
normal tissue it is difficult to separate the beneficial GVL effect from the adverse 
graft-versus-host-disease (GVHD) effects. Researchers have therefore attempted to 
refine adoptive T cell transfer by identifying antigen specific T cell clones, which only 
target disease associated anitgens (eg TSA or TAA). The early successful examples of 
adoptive transfer using donor CD8+ CTL lines post Allo-HSCT was for CMV disease 
and EBV associated post-transplant lympho-proliferative disease (PTLD) (Riddell et 
al. 1992; Rooney et al. 1995). 
Utilizing CD8+ CTL clones against tumour antigens in the autologous setting is a 
much more challenging proposition. Firstly, tumour-specific CTL clones have to be 
sourced from TILs. Although TILs have been found in patients with breast cancer 
(Ruffell et al. 2012), colon cancer (Ogino et al. 2011) and melanoma, only melanoma 
lesions have reproducibly yielded therapeutic TILs. The reasons are obscure but may 
be related to the high degree of mutations found in melanoma (Walia et al. 2012). 
Recent analysis of melanoma TIL cultures identified that the majority of specificities 
were directed against cancer testis or differentiation antigens (Andersen et al. 2012). 
Using a high throughput method to analyse melanoma TILs against 145 epitopes, 
Kvistborg et al found that TIL cell products from individual patients contained unique 
patterns of reactivity (Kvistborg et al. 2012).  
Adoptive immunotherapy using autologous T cells is technically challenging and 
involves the isolation of TILs from melanoma lesions, in-vitro expansion and 
functional characterisation of the T cells.  Adoptive transfer of melanoma-specific CTL 
clones typically follows a lymphodepleting conditioning regimen and short term IL-2 
cytokine administration (Restifo et al. 2012). Such an approach has been uniquely 
successful in the management of melanoma, with the adoptive transfer of CTL clones 
in three separate trials involving 93 patients resulted in 20 patients (22%) having 
complete remission of 5 years or more (Rosenberg et al. 2011).   
1.6.2 Genetically modified T cells 
T cells can be redirected to target tumour through gene transfer of tumour-specific 
TCR or chimeric antibody receptors (CAR). This form of gene therapy has the 
potential to redirect any T cell against any cancer epitope. To date the range of 
tumour types that can be targeted include melanoma, leukaemia, lymphoma, 
sarcoma and neuroblastoma (Morgan et al. 2006; Robbins et al. 2011; Savoldo et al. 
2011). 
The proof of principle that TCR gene transfer could be used to redirect T cells against 
TAAs was first shown more than a decade ago (Stanislawski et al. 2001). The TCRα 
and TCRβ genes is usually first isolated from high avidity T-cell clone and cloned into  
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lenti- or retro-viral vector which is used to transduce polyclonal T cells (Fig 1-6). The 
most commonly used retroviral vectors are the moloney sarcoma cell virus (MSCV) 
derived vectors as these induce stable DNA integration with high efficiency (Kieback 
& Uckert 2010). However, transduction with retroviral vectors requires T cell 
activation which may lead to reduce in-vivo functional activity. Alternatives to MSCV 
vectors include lentiviral, transposon based and zinc finger nuclease vectors which 
either improve the safety profile by reducing the risk of insertional mutagenesis or 
allow gene insertion into quiescent T cells without prior activation. 
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Figure 1-6 Schematic diagram showing the different stages of TCR gene transfer.  
1.) Isolation of high avidity T cell clone (lymphocyte represented by blue round cell with TCR 
represented by yellow dimer). 2.) Determination of TCR genes from T cell clone (black double 
helix structure). 3.) Cloning of TCR genes into retroviral vector (purple line). 4.) Transfection 
of the retroviral vector into phoenix packaging cells which produce retroviral particles 
(represented by hexagonal shape surrounding vector). 5.) Transduction of activated T cells 
(polyclonal TCR represented by other non-yellow dimers) using supernatant containing 
retroviral particles. 6.) Confirm the expression of transduced T cells by FACS (transduced cells 
express introduced TCR represented by yellow dimer). 
 
The TCR genes are isolated from T cell clones with high avidity for the relevant Ag. 
Previously, when the TCRα and TCRβ genes were cloned into two separate transfer 
vectors, transduction efficiency was suboptimal.  Relatively recent advances in vector 
technology have developed the use of internal ribosome entry site (IRES) or 
picornavirus-derived 2A linker peptides (Furler et al. 2001) to enhance equimolar 
expression of the two TCR chains cloned into bicistronic viral vectors. Some 
transgenic TCRs are expressed poorly on human cells but can be overcome by 
optimising the mRNA sequence for translation in the human host using a process 
known as codon optimisation.  
It is known that the introduced α and β chains may mispair with endogenous β and α 
chains, respectively, in transduced T cells, resulting in potentially deleterious/auto-
reactive new specificities (Bendle et al. 2010). Strategies to reduce this involve 
TCR from high avidity T 
cell clone
Activated T cells
TCR-td T cells all have 
same ‘redirected’ 
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structural modifications such as the introduction of new cysteine residues at position 
48 of the α-chain and position 57 of the β-chain constant regions. This modification 
permits the formation of an additional disulphide bond at a unique site between the 
introduced TCR chains (Boulter et al. 2003; Cohen et al. 2007). Another structural 
modification whereby replacing the human TCR constant region sequences with 
murine constant region sequences to form a human-murine hybrid TCR not only 
reduces mispairing but also increases introduced TCR expression at the cell surface 
(Cohen et al. 2006). The most recent approach utilised to reduce mispairing is the 
knock down of endogenous TCR expression using siRNA constructs at the same time 
as introducing tumour specific TCR  (Kuball et al. 2007; Nagai et al. 2011). 
The specificity and functional avidity of TCR transduced (TCR-td)  T cells to the 
redirected target is determined by properties intrinsic to the introduced TCR such as 
affinity for pMHC and ‘strength’  as determined by the ability to outcompete 
endogenous TCR for expression (Stauss et al. 2007). TCR isolated from T cells taken 
from nontolerogenic environments were found to be more effective against TAA 
which as elaborated in Section 1.5 are self-Ag. This is not only because high avidity T 
cells are not deleted and hence are available for isolation and also because tolerance 
may be regulated proximally at the level of the TCR and TCR transduced T cells do 
not become anergic in the presence of TAA (Teague et al. 2008). Nontolerized T cells 
are screened from MHC mismatch lymphocytes but are still required to be able to 
recognize TAA presented by host MHC, a concept known as allo-MHC-restriction. 
Using this approach high avidity human T cell clones against cyclin-D1, WT1 and 
MDM2 have been isolated. TCR genes from these high avidity T cells are then cloned 
into vectors for gene-therapy as shown in Fig 1.6. 
The functional avidity of TCR-td T cells can be improved by introducing molecular 
modifications to alter the TCR structure, which may improve antigen sensitivity or 
increase the level of TCR expression (Fig 1-7). Several approaches have been 
described; codon optimisation of the TCR sequence for optimal translation of RNA 
(Hart et al. 2008; Scholten et al. 2006), increasing the amount of available CD3 
molecules within the transduced T cell through the co-transfer of CD3 γ, δ, ε and ζ 
chains (Ahmadi et al. 2011), removal of TCR N-glycosylation (Kuball et al. 2009a) 
and modification of the framework CDR region (Robbins et al. 2008). 
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Figure 1-7 Molecular engineering of TCR signalling complex can improve T cell 
avidity.  
Using TCR/CD3 complex annotated in Fig 1.1, modifications are grouped into three 
topographical regions using TCR structure anotated in Fig 1-1; (1) TCR antigen-binding site 
(VαVβ) (2) TCR framework regions and (3) Components relevant to signal transduction. 
 
Tumour specific TCR-td CD8+ T cells have the ability to kill a broad range of tumour 
cell lines and tumour cells from patients (Stanislawski et al. 2001; Sadovnikova & 
Stauss 1996; Gao et al. 2000; Amir et al. 2011). Proof of principle studies have 
shown that TCR-td T cells can eradicate both mouse and human tumours in mouse 
models (Schumacher 2001; Xue et al. 2005; Xue et al. 2010).  The first clinical use 
of TCR-td T cells was published in 2006 by Morgan et al (Morgan et al. 2006); 15 
patients with metastatic melanoma were infused with autologous T cells transduced 
with a TCR specific for the melanoma associated peptide MART-1, a melanoma 
differentiation antigen. Two out of 15 patients (13%) showed full clinical regression 
of metastatic melanoma, with transferred cells persisting in the circulation for more 
than a year. A second trial targeting synovial cell carcinoma and melanoma using a 
TCR recognising NY-ESO-1 a cancer testes antigen had tumour shrinkage in five out 
of eleven patients (Robbins et al. 2011). 
(1) Improving antigen-binding
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a) Isolation of TCR genes from 
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1.6.2.1  Chimeric Antigen Receptor (CAR) gene transfer 
Effective targeting of tumour has also been performed with CAR-modified T cells. The 
chimeric antigen receptor (CAR) is an artificial molecule consisting of a single chain 
immunoglobulin based antigen-binding site fused to a CD3ζ domain (Fig 1-8). The 
antibody-based receptor is able to bind to surface molecules such as CD19 with high 
affinity but cannot recognise peptides derived from intracellular proteins presented 
by MHC molecules. Early clinical trials using CAR-transduced T cells showed a poor 
level of persistence of these cells after transfer (Park et al. 2007; Kershaw et al. 
2006). However advances in molecular engineering of CAR with the addition of CD28 
or CD27 co-stimulatory domains have improved the viability of transferred cells 
(Savoldo et al. 2011; Song et al. 2011). Several clinical trials have been published 
with the use of CAR-transduced T cells directed against CD19 and/or CD20 positive 
B-cell malignancies (Till et al. 2008; Savoldo et al. 2011; Heslop et al. 2010) and 
neuroblastoma (Pule et al. 2008). In one of these studies, of the eight patients given 
CAR-transduced T cells, six patients had remission of disease (Kochenderfer et al. 
2011). 
 
Figure 1-8 Schematic diagram showing the structure of chimeric antigen receptor 
(CAR).  
Unlike TCR (Fig 1-4), CAR bind to conformational epitopes on non-MHC antigen and is linked to 
a cytoplasmic ζ-chain molecule (orange) containing ITAMS (white stripes) within ζ-chain. 
Some of the TAAs targeted by CAR are expressed in normal tissues and the cross-
reactivity has resulted in toxicity; this is also known as ‘on-target’ toxicity. For 
example when the CAR with specificity for the TAA carbonic anhydrase IX (CAIX) was 
used to treat renal cell carcinoma, the first three patients developed liver enzyme 
disturbances as a result of cross reactivity with bile duct epithelial cells which also 
express CAIX (Lamers et al. 2006). In a separate study using anti-ERBB2-CAR 
transduced T cells to treat colonic carcinoma, one patient developed fatal lung 
ζ
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inflammation complications thought to be related to low levels of ERBB2 expression 
on epithelial cells (Morgan et al. 2010). 
1.7 Project background 
There is growing evidence that the efficacy of adoptive T cell immunotherapy is 
enhanced when tumour-specific CD8+ and CD4+ T cells are infused together (Kuball 
et al. 2005; Morris et al. 2005; Restifo et al. 2012). The exact mechanisms may be 
related to the ability of CD4+ T cells to augment the functional avidity, expansion 
and persistence of cytotoxic CD8+ T cells. CD4+ T cells also known as T-helper (Th) 
cells provide ‘help’ for the generation of CD8+ T cell effector and central memory 
responses (Bevan 2004). Furthermore, there is growing evidence that CD4+ T cells 
may kill cancer cells through direct tumour cytotoxicity, indirectly by targeting 
tumour-related stromal cells (Section 1.5.2) and rescue self-antigen tolerant tumour 
specific CD8+ cells (Shafer-Weaver et al. 2009).  
It has been difficult to date to isolate high avidity tumour-specific CD4+ T cells 
(Wang 2001). The majority of tumour cells do not express MHCII or co-stimulatory 
molecules (Hermans et al. 1998; Staveley-O’Carroll et al. 1998; Shrikant et al. 
1999). We have shown that MHCI restricted TCR can be transferred into CD4+ cells 
resulting in MHCI-restricted helper T cells (Morris et al. 2005). There are examples in 
the literature of CD8-independent MHCI restricted TCR which when transduced into 
CD4+ T cells are able to elicit Ag-specific responses such as IL-2, IFN-γ secretion and 
cytotoxicity (Chhabra et al. 2008; Ray et al. 2010; Engels et al. 2012). These include 
a TCR targeting the WT1-derived peptide (RMFPNAPYL) and an affinity-matured TCR 
targeting NY-ESO-1 peptide both presented by HLA-A2   (Tsuji et al. 2005; Robbins 
et al. 2008). However, some MHCI restricted TCR-td CD4+ T cells had a deficit in 
cytokine production (Morris et al. 2005) or were unable to recognise tumour cells 
endogenously expressing cognate Ag (Moore et al. 2009). The impairment of these 
transduced CD4+ T cells may have been due to deficits in TCR signalling. It is 
possible that these high affinity TCRs are unable to detect low antigen density on 
tumour cells because serial triggering is suboptimal (Valitutti et al. 1995; Thomas et 
al. 2011). As the CD8 co-receptor has been shown experimentally to enhance TCR 
serial triggering (Viola et al. 1997), dysfunction of MHCI restricted TCR-transduced 
CD4+ T cells may be related to absence of CD8 co-receptor. 
Perhaps it is surprising that the strategy of enhancing MHCI restricted TCR in CD4+ T 
cells by utilising the CD8 co-receptor has only been reported by a three groups 
(Willemsen et al. 2005; Morris et al. 2005; Kessels et al. 2006). The earlier papers 
from 2005 by Williamsen and our group co-introduced the CD8α gene with TCR into 
CD4+ T cells. The in vitro data from Willemsen showed that the MART-1 specific TCR 
transduced CD4+ T cells were able to produce antigen-specific responses in the form 
  Introduction 
45 
 
of IFN-γ, TNF-α and IL-2 secretion when the CD8α gene was introduced. Our group 
showed that F5-TCR-td murine CD4+ T cells were able to produce IL-2 but not IFN-γ 
in response to cognate Ag and this pattern was changed when CD8α was co-
transduced with co-transduced CD4+ T cells producing IFN-γ but smaller amounts of 
IL-2. To date, only Kessels et al have utilized both the CD8α and CD8β gene to 
generate CD8αβ+ TCR-transduced CD4+ T cells and showed convincing data of 
augmentation of antigen-specific CD8+ T cell function after invivo influenza-A 
challenge in mice. The results of these three studies are summarised in Table 1-1. 
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 Williamsen et al, 2005 Morris et al, 2005 Kessels et al, 2008 
MHCI restricted TCR Chimeric MAGE-A1 TCR F5-TCR OT1-TCR 
CD8 co-receptor Human CD8α Murine CD8α Murine CD8αβ 
In vitro data of 
TCR-td CD4+ T-cells 
No staining with HLA-A1/MAGE tetramer. Low 
levels of cytotoxicity against MAGE+/A1+ 
melarnoma. 
Positive staining with NP tetramer. Produce IL-
2 but not IFN-γ against EL4-NP tumour cells. 
Undergo proliferation in presence of EL4NP 
tumour cells 
Produce low levels of IL-2, IFN-γ and CD40L 
against splenocytes loaded with OT1 peptide. 
In vitro data of TCR 
and CD8 co-
transduced CD4+ T 
cells 
Positive staining with HLA-A1/MAGE tetramer. 
Moderate levels of cytotoxicity against 
MAGE+/A1+ melarnoma. 
Produce IFN-γ, TNF-α, and IL-2 with 
MAGE+/A1+ melanoma 
Positive staining with NP tetramer. Produce 
IFN-γ but lower levels of IL-2 against EL4NP 
tumour cells. No proliferation in presence of 
EL4NP tumour cells 
Produce higher levels of IL-2, IFN-γ and 
CD40L against splenocytes loaded with 
Ova257 peptide. 
In vivo function of 
TCR-td CD4+ T cells 
Not assessed Good tumour protection against EL4NP tumour 
cells only in the presence of F5-TCR 
transduced CD8+ T-cells. 80% of mice survive 
tumour challenge. 
Did not induce expansion of endogenous CD8+ 
against influenza-A detected by NP366 
tetramer, after MHCII deficient mice were 
challenged with Influenza A containing ova. 
In vivo function of 
TCR and CD8 co-
transduced CD4+ T 
cells 
Not assessed Poor tumour protection against EL4-NP tumour 
cells even in the presence of F5-TCR 
transduced CD8+ T-cells. Only 20% of mice 
survive tumour challenge. 
Did not induce expansion of endogenous CD8+ 
against influenza-A detected by NP366 
tetramer, after MHCII deficient mice were 
challenged with Influenza A containing ova. 
Table 1-1 Summary of results taken from three studies co-transducing CD8 co-receptor with MHCI restricted TCR into CD4+ T cells.
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The same paper by Kessels et al also explored mutating CD8 co-receptors to enhance 
T cell avidity.  They modified the intra-cytosolic signalling domain of the CD8α chain 
with the sequences from the CD4 co-receptor signalling domain which allowed 
increased Lck to bind with the aim of mediating greater signal transduction (Wiest et 
al. 1993; Shaw et al. 1989; Erman et al. 2006). However, the in vitro studies with 
CD4+ T cells co-transduced with the mutant CD8 co-receptor and OT1 TCR did not 
improve function compared to cells expressing the wild-type CD8 co-receptor. 
Another hypothetical way to augment the CD8 co-receptor is by increasing its affinity 
to MHCI. Anti-CD8 antibodies such as from the murine anti-CD8α 53.6.7 and human 
anti-CD8α OKT8 have been known to increase multimer staining of murine and 
human T cells (Daniels & Jameson 2000; Campanelli et al. 2002). The anti-CD8α 
antibody 53.6.7 bind to the T81 residue of the CD8α chain and does not direct 
contact MHCI (Devine et al. 2004). Devine et al therefore postulate that the 
improvement of MHCI affinity may be due to a more stabilised CD8 conformation. 
However there is no published data using the anti-CD8α antibody 53.6.7 to improve 
T cell function. The human anti-CD8α OKT8 however increased the antigen specific 
production of MIP-1β by T cell line 3G10 (Wooldridge et al. 2003). Wooldridge et al 
also studied the effects of increasing CD8 affinity by introducing the Q115E mutation 
to the α2 domain of HLA-A2 and found that peptide loaded APC harbouring HLA-A2 
Q115A molecules could significant increase the cytokine production and proliferation 
of naïve T cells (Laugel et al. 2007). 
1.8 Aim of the project 
This project aims to test mutations in the CD8 co-receptor for augmentation of 
effector function of genetically modified T cells expressing a tumour-specific TCR. 
CD8 co-receptor mutations that are shown to enhance T cell avidity in vitro will be 
tested in an in-vivo mouse model for the ability to afford improved tumour 
protection. The ability to augment the avidity of genetically modified T cells for 
cancer immunotherapy is an attractive proposition as most anti-tumour T cells are of 
low avidity (Uttenthal et al. 2012). Moreover an augmenting CD8 co-receptor could 
potentially improve the function many MHCI-restricted CD8 dependent TCR. Whereas 
modifications of the murine CD8α chain did not influence, in either a positive or 
negative manner, Kessels et al (Kessels et al. 2006) found that the CD8β was critical 
for the function of MHCI restricted OT1-TCR in CD4+ T cells. Around the same time, 
Devine et al (Devine et al. 2006) analysed 23 murine CD8β chain mutants in the 
CDR1, CDR2 and CDR3 loops and found both four CD8β mutants (S53L, S54V, L58R 
and L58R/I25A) that enhanced binding to MHCI molecule H2-Kb compared to wild-
type CD8β.  The CD8α chain and CD8β chain containing mutations were transfected 
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into COS-7 fibroblast. The transfected COS-7 cells were stained either with CD8α 
antibody, CD8β antibody or H2-Kb tetramer. The binding index was calculated based 
on the relative tetramer MFI to CD8β MFI of transfected cells. Two of the CD8β 
mutants S53L and I25A/L58R were transduced into T cell line expressing 2C-TCR and 
CD8α and found to enhance IL-2 production to peptide loaded RMAS target cells.   
The candidate mutations selected for investigation were within the CD8β chain and 
consisted of two categories. The first group of mutations were introduced into the 
MHC-binding region (S53L, S54V, L58R and L58R/I25A) previously identified by 
Devine et al as described above. The second group of mutations involved O-
glycosylation sites (T120A, T121A, T124A), following previous studies, which had 
demonstrated that the removal of these threonine sites prevented O-glycosylation 
sialylation. These mutations achieved a default desialylated state, which has been 
shown to enhance T cell avidity (Section 1.4.2). 
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Chapter 2. Materials and Methods 
2.1 Molecular techniques 
2.1.1 Retroviral vector backbones 
The pMX vector encodes the Moloney murine leukaemia virus (MLV) long terminal 
repeat (LTR) sequences, subgenomic envelope (env) and gag sequences which 
facilitates encapsidation and expression of inserted sequences. Protein coding 
sequences were inserted between the NotI and EcoRI sites. The pMP71 vector is a 
second generation retroviral vector with the MPSV LTR containing 5’ untranslated 
sequences derived from the murine embryonic stem cell virus (MESV). The pMP71 
vector has been shown to enhance transgene expression by more than ten times 
compared to the MLV based vectors (2003 HGT Uckert) and was a kind gift from Dr 
Wolfgang Uckert (Institute of Biology, Humbult-University Berlin). 
Details of the cloning strategy used to generate specific retroviral vectors used in this 
project are given in Chapter 3. 
2.1.2 Bacterial culture 
2.1.2.1 Preparation of LB broth and agar 
To prepare 10 litres of LB broth, 250 g of LB broth (Fisher Scientific, Loughborough, 
UK) was dissolved in 10 litres of distilled H2O. Broth was aliquoted into 500 ml bottles 
and autoclaved prior to use. Ampicillin (0.1mg/ml) was added to the LB broth and 
mixed well before use under sterilizing conditions. 
To prepare 8 litres of LB agar, 200 g of LB broth and 60 g of LB agar (Fisher 
Scientific, Loughborough, UK) were dissolved in 8 litres of distilled H2O. Broth was 
aliquoted into 400 ml bottles and autoclaved prior to use. 
To prepare 10 plates of LB agar containing ampicillin, 400 ml of LB agar in a bottle 
was heated in a microwave until agar was fully melted and left to cool. 4 mg of 
Ampicillin was added to the liquid agar and mixed well before plating out under 
sterilizing conditions.   
2.1.2.2 Transformation of competent bacterial cells 
For transformation, DH5α competent bacterial cells (Invitrogen) were thawed on ice 
and divided into 50 μl per tube. These were then incubated on ice for ten minutes. 
The 10 μl ligation reaction or low concentration plasmid (10 ng/μl) was then mixed 
with the DH5α. These were placed onto ice for a further 30 mins, before heat shock 
at 42˚C for 30 seconds and then placed back onto ice for a further two minutes. Five 
volumes of SOC medium (Invitrogen) was then mixed with the bacteria and shaken 
at 220 rpm at 37˚C for one hour. After this time, the bacterial cells were spread onto 
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LB agar plates containing 0.1 mg/ml ampicillin (Sigma-Aldrich). The plates were 
incubated at 37˚C overnight until colonies were visible. The plates were stored at 
4˚C for up to one week before colonies were picked. 
2.1.3 Large scale preparation of plasmids  
A single colony from LB agar plates was picked and inoculated into 2-5 mls of LB 
broth containing 0.1mg/ml ampicillin then shaken at 220 rpm at 37˚C for 6-10 
hours. Glycerol stocks for each sample were prepared at this stage by mixing 300μl 
of the bacterial culture with 300μl sterile glycerol (Sigma-Aldrich) and storing at -
80˚C. After 6-10 hours of shaking when the inoculated LB broth became cloudy, 
0.1ml of the starter culture was then inoculated into 100ml (1:1000 dilution) of LB 
broth containing 0.1 mg/ml ampicillin and then shaken at 220rpm at 37˚C overnight 
for 12-16 hours. Plasmid DNA was extracted using a Midiprep or Maxiprep Kit 
(QIAGEN 12143/12163), following the protocol supplied with the kit. Typically, 50-
500 μg of plasmid DNA was recovered. The DNA pellet was re-dissolved in the 
required volume of low concentration Tris-EDTA (LCTE) buffer to give a final DNA 
concentration of 1 μg/μl. 
2.1.4 PCR amplification 
This technique was used primarily to introduce unique restriction sites on the 5’ and 
3’ ends of DNA fragments containing the gene of interest to allow insertion into the 
retroviral vector backbones described in Section 2.1.1. Forward and reverse primers 
containing the desired restriction and annealing sequences were designed using 
Netprimer software (premierbiosoft). This programme analyses the primer secondary 
structures and determines the predicted melting temperatures. The PCR solution 
contained the following: Pfu-Mix containing 2mM dNTP and 10x Buffer (66 μl), Pfu (2 
μl), forward and reverse primers (6 μl each), DNA (gene construct or negative 
control) 10 ng/μl (6 μl), and H2O (8 μl). 36 cycles of PCR were performed. The PCR 
product was checked for the presence of the amplified gene construct by analysis of 
PCR products on a1% agarose gel, alongside a 200bp to 10kb HyperLadder I 
(Bioline). 
2.1.5 PCR mutagenesis 
Oligonucleotide primers were designed to contain nucleotide changes at the desired 
position within the gene construct using Stratagene primer design software and 
shown in Chapter 3 Table 3-2.  The primers were synthesized and purified by 
Invitrogen. PCR mutagenesis was performed utilizing these primers and the retroviral 
vector containing gene construct using the QuikChange XL II site directed 
mutagenesis kit (Strategene 200521). XL-10 gold ultracompetent bacteria were 
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transformed using the PCR product as described using kit protocol. DNA was 
extracted by using QIAprep Miniprep Kit (QIAGEN 27106) as described above. 
2.1.6 Restriction digestion and gel extraction 
Restriction digests were performed to separate the gene construct from vector. 1μg 
of miniprep DNA was digested for 1-2 hours at 37˚C with the appropriate restriction 
endonuclease and buffer. The restriction enzymes (NotI, XhoI, RsrII, BstZ17I and 
EcoRI) were obtained from New England BioLabs. Digested DNA samples were then 
separated on a 1% agarose gel containing 0.2 μg/ml Ethylene bromide (Sigma-
Aldrich), alongside a 200bp to 10kb HyperLadder I (Bioline). The desired DNA 
fragment was isolated by gel extraction and PCR purification (QIAGEN 28106). 
2.1.7 Ligation 
The ligation of genes (inserts) into the linearized pMP71 vector backbone was 
performed using a 10μl reaction containing 1μl 10x T4 DNA ligase buffer (New 
England BioLabs), 0.5μl (200U) T4 DNA ligase (New England BioLabs), 30-50 ng of 
insert and 10-30 ng of linearized pMP71 at a molar ratio of 3-6:1. The reactions were 
incubated at 14˚C overnight. Samples were then separated on a 1% agarose gel 
containing 0.2 μg/ml Ethylene bromide (Sigma-Aldrich E1510), alongside a 200 bp to 
10kb HyperLadder I (Bioline). 
2.1.8 Sequencing of DNA 
Plasmid DNA was sequenced at Beckman Coulter Genomics, Takeley, Essex. 
Sequencing of gene constructs in the pMP71 vector was performed using appropriate 
primers. DNA sequences were analysed using an open source programme, A Plasmid 
Editor (APE) (http://www.biology.utah.edu/jorgensen/wayned/ape/). 
 
2.2 Cells, Cell lines, and culturing conditions 
All cell culture work was performed under strict sterile conditions in tissue culture 
hoods to minimize and prevent infection from microbes.   
2.2.1 Media 
Cell culture growth media were based on IMDM (Lonza BE12-722F) or RPMI 1640 
(Lonza BE12-167F) with addition of 100 U/ml penicillin and 100μg/ml streptomycin 
(Gibco 15070), 2mM L-glutamine (Gibco 25030) and 50 µM 2-mercaptoethanol 
(Sigma M6250) and 10% foetal calf serum (FCS). For cell lines, heat inactivated 
South American Origin FCS was used (Biosera S1810). Validated batches of heat-
inactivated FCS were added to RPMI medium used for the culture of primary murine 
splenocytes/T cells (Sigma F7524) and human PMBC/T cells (Gibco 10270). 
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2.2.2 Antigen presenting cells and tumour cell lines 
RMAS cells (H2b) are derived from a Rauscher virus-induced C57BL/6 T cell 
lymphoma and are TAP-deficient due to a point mutation in the TAP2 gene. RMAS 
were used as antigen presenting target cells for murine T cells by overnight 
temperature induction at 25°C and loaded with exogenous peptides for 2 hours. 
RMAS cells were split every 2-3 days 1:8 with fresh RPMI cell line medium and kept 
humidified at 37˚C and 5% CO2. 
HLA-A2+ T2 cells are also a TAP-deficient cell line and used as antigen presenting 
target cells for human CD4+ T cells by loading with exogenous peptides for 2 hours 
at 37˚C. T2 cells were split every 2-3 days 1:8 with fresh RPMI cell line medium and 
kept humidified at 37˚C and 5% CO2. 
Fresh murine splenocytes harvested from C57BL/6mice (H2b) were used as antigen 
presenting target cells for murine CD4+ T cells (Chapter 4) and were loaded with 
exogenous peptide for 2-6 hours. 
EL4 cells are a murine lymphoma cell line which expresses H2-Db MHCI and do not 
express any MHCII molecules. EL4 cells that stably express the Influenza-A virus 
derived nucleoprotein (EL4NP) were a kind gift from Dr B Stockinger (National 
Institute of Medical Research, Mill Hill, London) and were used as target cells for both 
murine CD8+ and CD4+ T cells as discussed in detail in Chapters 4 and 5. In 
addition, EL4NP cells were transfected with a luciferase plasmid (EL4NPluc), which 
was a kind gift of Dr M Pule (University College London, UK). These cells were used 
for in vivo monitoring of tumour growth by bioluminescence as described in Chapter 
6. EL4, EL4NP and EL4NPluc cells are split every 2-3 days 1:8 with fresh RPMI 
medium and kept humidified at 37˚C and 5% CO2. 
2.2.3 Retroviral packaging cell lines 
Phoenix-Ecotrophic (PhEco) cells (Orbigen, Santa Cruz labs) are retroviral packaging 
cells capable of producing trans proteins (env, gag and pol) that are required for the 
packaging, processing, reverse transcription, and integration of recombinant 
genomes. Viral envelope particles produced using PhEco cells have tropism for 
murine cells due to expression of mouse cationic aa transporter (mCAT1). For 
optimal transfection, fresh aliquots of 3-5 x106 PhEco cells were thawed and seeded 
onto the flat side of T75 tissue culture flasks (TPP 90076) with fresh IMDM medium. 
Each batch of PhEco cells were maintained in continuous culture for a maximum of 
four weeks. For maintenance, sub-confluent PhEco cells were split by 1:6-1:8 with 
EDTA/Trypsin (Gibco 25300) into a new T75 flask every 2-3 days and kept humidified 
at 37˚C and 5% CO2.  
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Phoenix-Amphotrophic (PhAmpho) cells are retroviral packaging cells similar to PhEco 
but the viral envelope protein recognizes the amphotrophic receptor RAM1 a 
phosphate transported found on human cells. For optimal transfection, fresh aliquots 
of 3-5 x106 PhAmpho cells were thawed and seeded onto the flat side of T75 flasks 
with fresh IMDM medium and used for transfection for up to four weeks after 
thawing. For maintenance, sub-confluent PhAmpho cells were split 1:6 with 
EDTA/Trypsin (Gibco) and seeded into a new tissue culture-treated T75 flask every 
2-3 days and kept humidified at 37˚C and 5% CO2. 
2.2.4 T cell lines 
The 58α-β- (BW) T cell line are CD8+ TCR- cells, a variant of the D0–11.10 T cell 
hybridoma and were used for TCR transfer experiments. CD8β negative BW cells 
expressing only CD8α were used to validate co-transfer of TCR and CD8β molecules. 
For maintenance, BW cells were split 1:8 with fresh RPMI medium and kept 
humidified at 37˚C and 5% CO2. 
2.3 Generation of TCR-transduced T cells 
2.3.1 Transfection and production of recombinant retroviral particles 
Sub-confluent PhEco or PhAmpho cells maintained in T75 flasks were removed with 
EDTA-Trypsin, washed with fresh IMDM medium and counted. 1.4-2.0 x106 
PhEco/PhAmpho cells were resuspended in 8ml fresh IMDM growth medium and 
seeded into 60 cm2 sterile tissue culture-treated petri dishes (TPP 93100) and kept 
humidified at 37˚C and 5% CO2 for 24 hours. The next day, the cell medium was 
changed and replaced with 5 ml fresh IMDM and kept humidified at 37˚C and 5% 
CO2 for 4-8 hours.  Each dish containing PhEco/PhAmpho cells were then transfected, 
by adding drop-wise, a mixture containing 2.4μg vector (TCR or Cd8) DNA, 1.5μg 
pCL-Eco/pCL-Amp DNA, 50 μl dH2O and 150 μl Opti-MEM solution (Sigma 31985) and 
kept humidified at 37˚C and 5% CO2 for 12-16 hours. The retroviral vectors pCL-Eco 
and pCL-Amp encode an ecotropic or amphotropic envelope, respectively, which are 
used to enhance retroviral transduction of murine/human cells (Naviaux et al. 1996). 
These vectors were kindly provided by Dr T Schumacher (Netherlands Cancer 
Institute).  For mock-transfection controls, TCR-expressing vector was omitted and 
replaced with an equivalent volume of dH20. The next day, IMDM growth medium 
was gently removed from PhEco/PhAmpho cells, without disturbing adherent cells, 
and replaced with fresh 5  ml RPMI T cell medium for a further 16 hours during which 
virus particles were produced. For optimal production of retroviral particles the 
PhEco/PhAmpho cells should be sub- confluent when supernatant is harvested. 
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2.3.2 Preparation of T cells before and after transduction 
Wild-type C57BL/6 mice were bought from Harlan, UK or acquired from in-house 
breeding colonies maintained at UCL Medical School.  The CD8β-deficient C57BL/6 
mice which originated from a breeding colony maintained at the National Institute of 
Medical Research and were a kind gift from Dr R Zamoyska (University of 
Edinburgh). All procedures performed on these mice were carried out in accordance 
with UK Home Office regulations under an approved Project License. 
2.3.2.1 Murine CD8+ T cell purification 
To enrich for CD8+ T cells, 1-5 x108 splenocytes harvested from wild-type C57BL/6 
mice or CD8β-deficient C57BL/6 mice were labelled with anti-CD8α MicroBeads 
(Miltenyi 130-049-401) and passed through LS or LD magnetized separation columns 
as directed by the manufacturer (Miltenyi 130-042-401, 130-042-901) and the cells 
eluted from the column were collected for transduction. In earlier experiments 
(Chapter 4), CD8β-deficient CD8+ T cells were depleted of Vβ11+ cells after staining 
with anti-Vβ11-FITC antibodies (BD Pharmingen) and anti-FITC MicroBeads (Miltenyi 
130-048-701). The labeled cells were passed through magnetized LD column (130-
042-901) and the flow through containing Vβ11 negative cells were collected for 
transduction. 
After transduction, F5-TCR and CD8β co-transduced CD8β-/- CD8+ T cells were 
enriched by positive selection using anti-mouse CD8β-FITC (BD Pharmingen) and 
anti-FITC Microbeads (Miltenyi, 130-048-701) and re-stimulated with splenocytes 
and NP peptide. The re-stimulated cells were rested for 7 days before functional 
assays were performed (Chapter 4). 
2.3.2.2 Murine CD4+ T cell purification 
To deplete CD8+ T cells, 1-5 x108 splenocytes harvested from wild-type C57BL/6 
mice or CD8β-deficient C57BL/6 mice were labelled with anti-CD8α MicroBeads 
(Miltenyi 130-049-401) and passed through magnetized LD magnetic columns 
(Miltenyi 130-042-901). The flow-through cells from the column were subsequently 
enriched for CD4+ T cells by labelling with anti-CD4 MicroBeads (Miltenyi 130-049-
201) and passage through LS magnetic columns (Miltenyi 130-042-401). The CD4+ T 
cells eluted from the column were retained for transduction. 
After transduction, F5-TCR and CD8 co-transduced CD4+ T cells were further 
enriched by positive selection using anti-mouse CD8α-APC (Abcam ab22504) and 
anti-APC Microbeads (Miltenyi, 130-048-701). The CD8+ enriched cells were used for 
functional assays the following day (Section 5.3.2). 
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2.3.2.3 Human CD4+ T cell purification 
CMV-negative HLA-A2+ PBMCs from healthy donors were isolated by density gradient 
centrifugation of buffycoats obtained from the National Blood Service (London, United 
Kingdom). 2 x107 PBMCs from each donor were aliquoted and stored in liquid 
Nitrogen. For transduction, 4 x107 frozen PBMCs were thawed, washed and examined 
with tryphan-blue.  To deplete CD8+ T cells, PBMCs were labelled with anti-CD8α 
MicroBeads (Miltenyi 130-045-201) and passed through LD magnetic columns 
(Miltenyi). Flow-through cells were collected and enriched for CD4+ cell enrichment 
after labelling with anti-CD4 MicroBeads (Miltenyi 130-045-101) as described above. 
2.3.3 Transduction of T cells 
2.3.3.1 Murine T cells 
The sorted CD8+ or CD4+ T cells were activated for 1.5 days with mouse CD3/CD28 
Dynabeads (Invitrogen 11453), 100 units/ml of IL-2 (Chiron, Emeryville, CA) and 
fresh Roswell Park Memorial Institute (RPMI) T cell medium (Day 0) and incubated at 
37˚C and 5% CO2 for 48 hours in tissue culture plate (TPP 92006). The next day 
(Day 1), wells on a suspension culture plate (Cellstar 657185) were coated with 
1.5ml Retronectin (Takara-Bio T100B) and incubated overnight at 4˚C. The following 
day (Day 2), Retronectin was recovered and stored at -20˚C (for up to eight 
repeats).   For each condition, 1.5-3.0 ml of retroviral supernatant with viral particles 
containing TCR alone or a 1:1 mixture of TCR and CD8 constructs were mixed with 5-
10 x106 T cells. The T cell and retroviral supernatant mixture was then added to the 
Retronectin coated wells and spun at 440G for 90 minutes. After centrifugation, the 
plate was kept humidified at 37˚C and 5% CO2 for 24 hours.  The next day (Day 3), 
Dynabeads were removed and fresh medium/ IL-2 (100 U/mL) (Chiron, Emeryville, 
CA) was added to the splenocyte cultures. Cells were analysed by flow cytometry 
from day 5-7. Transduced T cells were used for functional assays from Day 6-8.  
2.3.3.2 Human T- cells 
The sorted CD4+ T cells were activated for 1.5 days with anti-CD3 OKT3 antibodies, 
600 units/ml of IL-2 (Chiron, Emeryville, CA) and fresh RPMI T cell medium (Day 0) 
and incubated at 37˚C and 5% CO2 for 48 hours. The next day (Day 1), wells on 
suspension culture plate (Cellstar 657185) were coated with 1.5ml of Retronectin 
(Takara-Bio, Japan) and incubated at 4˚C overnight. The following day (Day 2), 
Retronectin was recovered and frozen for future use (up to eight repeats).   For each 
condition, 1.5-3 ml of retroviral supernatant with viral particles containing CMV-
TCR/CD8 constructs was mixed with 5-10 x106 T cells. The Retronectin coated plate 
containing T cells and viral supernatant was kept humidified at 37˚C and 5% CO2 for 
24 hours.  The next day (Day 3) fresh medium and IL-2 (100 U/mL) (Chiron, 
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Emeryville, CA) were added to culture wells containing T cells. Cells were analyzed by 
flow cytometry from day 5-7. At day 7-10 after activation, transduced T cells were 
re-stimulated with PBMC, pp65 peptide and IL-2 (Roche). This process was repeated 
every 7-10 days for not more than four cycles to obtain a high purity of transduced 
cells (Chapter 5). 
2.4 Flow cytometry 
Samples were stained on ice in PBS (1% FCS) with the appropriate dilution of the 
relevant monoclonal antibodies (mAbs). Propidium iodide was used to stain dead 
cells. Samples were acquired on an LSR2 or Fortessa flow-cytometer (BD 
Biosciences), with compensation first performed using single stained lymphocytes 
and FACS Diva software. The following mAbs were used for flow cytometric staining: 
rat anti-mouse CD4-APC-H7 (BD 560181), rat anti-mouse CD8α-APC (BD 553035), 
rat anti-mouse CD8α-CyChrome (BD 553034) and rat anti-mouse CD8β-FITC (BD 
553040). As MDM-TCR contain a c-Myc sequence tag in the TCRβ chain it was 
detected using mouse anti-c-Myc (A-14) (Santa Cruz Biotechnology sc-789) and anti-
mouse IgG1 PE (BD 550083) mAbs were used to determine TCR expression. The F5-
TCR utilizes Vβ11 chain and was identified with rat anti-mouse Vβ11-PE (BD 553198) 
or ASNENMDAM/H-2Db Pentamer (Proimmune F009-2A-G).  
Adoptively transferred murine T cells were also examined using, rat anti-mouse 
thy1.1-PECy7 (eBioscience 25-0900-82), rat anti-mouse CD44-V450 (BD 560451) 
and rat anti-mouse CD62L-APC antibodies (BD 553132). Human T cells were 
analysed using anti-human CD4-FITC (BD 555346), CD8α-PECy7 (BD 557746), 
CD8β-APC (BD 544058), rat anti-mouse TCRβ-PE (BD 553172). Acquired FACS data 
was exported as FCS files and analysed using FlowJo software version 7.6.5 
(Treestar). The gating strategy was performed consistently by first gating on live 
lymphocytes followed gating on CD8α+ or CD4+ populations. As the fluorescence 
intensity was expressed on a log scale, the geometric MFI was measured using 
FlowJo software. 
2.5 In-vitro functional assays 
2.5.1 Peptides 
The following synthetic MHCI restricted peptides were used: MDM100 (YAMIYRNL) of 
the MDM2 protein is presented by H2-Kb, NP366 (ASNENMDAM) of the Influenza-A 
virus nucleoprotein, and the control peptide SV9 (FAPGNYPAL) derived from the 
Sendai virus are both presented by H2-Db. Peptides were reconstituted in PBS to a 
concentration of 2 mM and stored at –20˚C. All peptides were synthesised by 
ProImmune (Oxford, UK). 
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2.5.2 Peptide loading of RMAS and T2 target cells 
The standard concentration of saturating peptide used for all functional assays was 
10 μM. To perform peptide titration experiments, the standard peptide concentration 
(10 μM) was first constituted followed by ten-fold dilutions (1 μM, 100 nM, 10 nM, 1 
nM, 100 pM, 10 pM). 1 x106 temperature-induced RMAS cells or T2 cells were 
incubated for 2 hour in 500 μl of RPMI medium with each cognate peptide 
concentration (or control peptide at 10 μM). The target cells were irradiated with 80 
Gy to stop proliferation before incubation with transduced T cells. 
2.5.3 IFN-γ and IL-2 ELISA assay 
TCR-td T cells (1-5 x 103) were incubated with peptide loaded irradiated RMAS cells 
(1 x 104) or EL4 cells (1 x 104) in triplicate in 96 well plates (TPP 92097) and kept 
humidified at 37˚C and 5% CO2 for 16 hours. The next day, either 50 μl of 
supernatant was harvested and tested in the IFN-γ or IL-2 ELISA assay or the plate 
was frozen for future analysis.  
Cytokines IFN-γ and IL-2 of both murine and human origins were measured in the 
culture supernatant of TCR-td T cells using protocols derived from BD ELISA kits (cat 
no. 555138, 555148, 555142, 555190). 96-well Microtest ELISA plates (BD Falcon 
353279) were coated overnight at 4˚C with 50 μl per well with rat anti-mouse IFN-γ 
or IL-2 capture antibody at 2 μg/ml in coating buffer at pH 9.5. ELISA reagents were 
taken from a set kit (BD OptEIA Reagent Set B 550534) and the assay was 
performed at room temperature (RT). Plates were washed five times with wash 
buffer and then blocked with 200 μl per well of assay diluent for 1 hour. Plates were 
then washed a further five times with wash buffer. Recombinant mouse and human 
IFN-γ or IL-2 was prepared in assay diluent as standards. The maximum standard for 
the different cytokines were as follows: 2000 ng/ml for murine IFN-γ, 200 ng/ml for 
murine IL-2, 300 ng/ml for human IFN-γ and 500 ng/ml for human IL-2. Serial 1:2 
dilutions from the maximum standard were performed six times and the assay 
diluent was used as the zero concentration standards. 50 μl of standard or culture 
supernatant sample was added to each well and incubated for two hours. Plates were 
then washed five times with wash buffer and 50 μl per well of biotinylated anti-IFN-γ 
or anti-IL-2 antibody diluted in assay diluent was added at 2 μg/ml. Plates were 
incubated for one hour and washed five times. 50 μl of streptavidin-horserasdish 
peroxidase was added to each well at RT for an hour and washed eight times. 50 μl 
of TMB substrate solution was next added and plates were incubated in the dark for 
30 min to allow the colour to develop. At the end of incubation 50 μl per well of 
0.25M sulphuric acid was added. The OD results from individual wells were read with 
a plate reader at 450 nm wave length. The standard curve is drawn using an Excel 
spreadsheet and the converted results was transferred onto Prism5 (Graphpad) to 
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generate graph and statistical analysis. Data are presented as the mean IFN-γ 
concentration (ng/ml) ± standard deviation of triplicate values. 
2.5.4 IFN-γ and IL-2 intracellular cytokine assay 
TCR-td T cells (1-5 x 103) were mixed with peptide loaded EL4NP or EL4 cells (1 x 
104) in triplicate along with controls: T cells stimulated with 50ng/ml PMA (Sigma 
P1585) and ionomycin (500 mg/ml) (Sigma-Aldrich I9657) or T cells alone. After 1 
hour, Brefeldin-A (1 μg/ml) was added to every well and the cells were maintained at 
humidified at 37˚C and 5% CO2 for 6 hours. 
At the end of the incubation period, the cells were stained for CD4, CD8α and CD8β 
then fixed and permeabilised using reagents from a kit (BD 554714) and stained for 
intracellular cytokines using anti-IL-2 APC (BD 554429) antibodies and anti-IFN-γ PE 
antibodies (BD 554412). The cells were washed using Fix and Perm wash and FACS 
analysis was performed. 
2.5.5 Cytotoxicity assay 
The ability of F5-TCR-td CD4+ T cells to kill EL4 tumour cells (Chapter 5) was 
determined using a standard 4-hour 51chromium (51Cr)-release assay, which was 
performed on day 5 after transduction. EL4NP or EL4 (control) cells were then 
labeled with 37 MBq 51Cr (Perkin Elma) for one hour at 37˚C. 51Cr-labelled target 
cells were then plated out in 100 μl at 5 x 103 cells per well in a round bottom 96-
well plate. TCR-td cells were then added in 100 μl to achieve a starting effector to 
target ratio (E:T) of 50:1. Three additional T cell doubling dilution conditions were 
performed (25:1, 12:1, and 6:1). Spontaneous and maximal lysis was assessed by 
adding 100μl of media or 100μl 1% trifluoroacetic acid (TFA) (Sigma Aldrich 76-05-1) 
respectively to 5 x 103 51Cr-labelled target cells. Cells were incubated for 4 hours in a 
37˚C humidified incubator with 5% CO2, after which time 100 μl of supernatant was 
collected. Samples were assessed for 51Cr-release using a gamma-counter.  
Specific killing was calculated as follows: 
% specific killing = (experimental 51Cr-release – spontaneous 51Cr-release) 
maximum 51Cr-release - spontaneous 51Cr-release 
2.6 In-vivo studies 
All procedures were carried out in accordance with UK Home Office regulations under 
an approved Project License.  
2.6.1 Mouse lines 
Female C57BL/6 thy1.1 (homozygous) mice were bred in house. Female C57BL/6 
thy1.2 mice of the same age (three months) were bought from Harlan, UK. 
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Splenocytes were harvested from female C57BL/6 thy1.1 (homozygous) mice and 
used for T cell transduction. The donor mice were typed to confirm thy1.1 expression 
by analysing lymphocytes by tail bleed for presence of thy1.1 and absence of thy1.2.  
Prior to transduction and adoptive transfer the splenocytes were enriched for CD4+ T 
cells as previously described in section 2.3.2. The donor TCR-td T cells were 
predominantly CD4+ T cells (>95%) and the CD8+ T cells make up less than 0.5% 
of total lymphocyte population. 
Female C57BL/6 thy 1.2 mice of the same age (4-6) months were used as recipient 
mice. Before irradiation, all mice were given Enrofloxacin (Bayer) in water and the 
right flank tumour injection site was shaved. 
2.6.2 Bioluminescence 
Growth of subcutaneously (sc) injected EL4NP tumour cells was monitored using 
bioluminescence at various time points. The EL4NP tumour cells were transfected 
with luciferase plasmid containing a CD34 marker. The EL4NP tumour cells were 
>80% CD34+ before injection. 
To monitor bioluminescence in mice bearing EL4NPluc tumour cells, mice were 
anaesthetized and injected intraperitoneally with D-Luciferin firefly (Biosynth) at 7.5 
mg/kg. Six minutes after injection, anaesthetized mice were imaged by Xenogen 
IVIS-100 (Caliper Life Sciences) using standard acquisition settings (f1.2, 10 
seconds). The acquired images were analysed with living image 3.2 (Caliper Life 
Sciences) and graphs generated using Graphpad5 (Prism). 
2.6.3 Tumour protection experiment 
2.6.3.1 Tumour challenge and T cell transfer 
Recipient female C57BL/6 mice were irradiated with 5.5 Gy at day 0, 6 hours before 
subcutaneous injection with 50 μl of 1 x 106 EL4NPluc cells in matrigel matrix (BD 
354234) and PBS on the left flank. After injection, mice were imaged for presence of 
bioilluminescence and mice with no signal were re-injected. The next day (Day 1), 
mice were injected with TCR-td CD4+ T cells via the tail vein. 
2.6.3.2 Monitoring tumour growth 
Tumours were measured with calipers at different intervals and the growth evaluated 
by applying the formula (a2 x b/2), where a=horizontal diameter and b=vertical 
diameter of the tumour. Mice were culled when tumour diameter exceeds 16mm or 
when ulceration occurs. Mice showing distress were culled in line with our UK Home 
Office project license which states that mice with weight loss greater than 20% or 
weight gain of more than 20% of the expected body weight, and mice with signs of 
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health deterioration or respiratory distress were killed according to a distress scoring 
system (Table X). Human endpoints stated by NCRI guidelines (Workman et al. 
2010) were complied with throughout this project. 
Animal identification Score 
Appearance 
Normal  
Lack of grooming 
Coat staring/ Piloerection, hunched up 
 
0 
1 
2 
Food and water intake 
Normal 
Body weight down<5% 
Body weight down <5-10% 
Body weight down >15% 
 
0 
1 
2 
3 
Natural behaviour 
Normal 
Minor changes 
Less mobile and alert, isolated 
Self-mutilation, cachexia 
 
0 
1 
2 
3 
Provoked behaviour 
Normal 
Minor depression 
Less mobile 
Very weak and precomatose 
 
0 
1 
2 
3 
Table 2-1 Distress scoring system used to determine end point. Mice is culled if total 
score >8, or scoring a 3 in any category, or any losing >20% of body weight, or 
tumour >16mm.  
 
2.6.3.3 Monitoring of transferred CD4+ T cells 
Blood sampling was performed on mice at Day 14-18 by removing 100-200 μl of 
blood by tail bleeding onto microvette containing Lithium heparin (Sarstedt 16.443). 
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To prepare blood samples for flow cytometry, each sample was exposed to 500 μl of 
dH2O for 5 seconds before addition of 4.5 ml of isotonic PBS. Cells were then stained 
for flow cytometry as described in Section 2.3.2. 
Mice were culled and spleen (Spl), lymph nodes (LN) and bone marrow (BM) 
removed to identify the presence of transferred T cells. Harvested lymphoid organs 
were mashed with RPMI medium and passed through a cell strainer (BD Falcon 
352340). The lymphocytes were counted and made-up to 1 x106 cells/100 μl prior to 
staining for flow cytometry as described in Section 2.3.2. Total transferred T cells can 
be calculated by the multiplying the proportion of thy1.1+ CD4+ T cells with the total 
cell count. 
2.6.4 Antigen re-challenge 
Mice which became tumour free for >90 days were re-challenged with irradiated 1 
x106 EL4NPluc tumour cells which was injected subcutaneously with PBS/Matrigel 
matrix (BD 354234) into the right lower limb. Seven days after re-challenge, mice 
were culled for analysis of TCR-td CD4+ T cells in draining and non-draining lymph 
nodes in the inguinal and popliteal regions. The preparation of the lymph nodes was 
as described in section 2.6.3. 
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Chapter 3. Molecular biology 
This chapter describes the molecular cloning performed to produce original vector 
constructs and the optimization of these constructs for transduction. The molecular 
and transduction techniques used were detailed in Section 2.1. The relevant vectors 
used in this project contain TCR and/or CD8 co-receptor transgenes. 
3.1 TCR vectors 
Some of the vector constructs were already used routinely by members of the 
department. These include the TCR constructs MDM-TCR (Bendle et al. 2007), F5-
TCR (Morris et al. 2005) and CMV-TCR-CD8 constructs (Xue et al. 2013), all in the 
pMP71 vector backbone (Engels et al. 2003). The TCR vectors had been modified for 
enhanced expression by codon optimization, the introduction of additional cysteine 
residues, usage of picornavirus-derived 2A linker peptides between gene vectors and 
murine constant regions as detailed in Section 1.6.2. A summary of the TCR used is 
shown in table 3-1. 
The MDM-TCR is in a bi-cistronic pMP71 vector with the TCRα and TCRβ chain 
separated by 2A-peptide sequences. The base sequences had previously been codon 
optimized to enhance expression in murine cells and a c-myc tag was added after the 
leader sequence of the TCRα chain to enable identification of the MDM-TCR.  
The F5-TCR is also in a bi-cistronic pMP71 vector backbone with the TCRα and TCRβ 
chain also separated by 2A-peptide sequences. The base sequences were codon 
optimized for enhanced expression in murine cells. The CMV-TCR-CD8 construct was 
in quad-cistronic pMP71 vector with TCRα, TCRβ, CD8α and CD8β chains separated 
by 2A-peptide sequences. The base sequences had previously been codon optimized 
for expression in human cells and the constant regions were cloned from murine TCR 
constant regions, which has been demonstrated to enhance expression of the TCR in 
human t cells following transduction. 
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TCR MHCI Peptide 
specificity 
Cells 
transduced 
Identification 
MDM H2-Kb YAMIRYNL Murine T cells Vβ11 
F5 H2-Db ASNENMDAM Murine T cells Vβ7 or c-myc tag on TCRα 
chain 
CMV HLA-A2 NLVPMVATV Human T cells Murine TCR constant chain* 
Table 3-1 Summary of characteristics of modified TCR constructs used. 
*The CMV-TCR is a hybrid TCR containing murine TCR constant regions. 
3.2 CD8 vectors 
3.2.1 Cloning the CD8β gene into the pMP71 retroviral vector  
Figure 3.1 shows a schematic diagram of the cloning process used to produce the 
CD8β-pMP71 vector, which was used to transduce CD8β-/- CD8α+ T cells. The CD8β 
gene transcript containing wild-type (WT) DNA sequence in the Bluescript SK vector 
was a kind gift from Dr R Zamoyska (University of Edinburgh), the cloning sites were 
SalI and HINDIII. The CD8β chain was isolated by digestion of CD8β-SK vector with 
SalI and HINDIII restriction enzymes followed by gel electrophoresis and extraction 
(method shown in section 2.1.6). New NotI and EcoRI restriction sites at the 5’ and 
3’ ends of the CD8β chain construct by PCR amplification (Section 2.1.4) using 
specific primers. The CD8β chain construct was then ligated into the pMP71 retroviral 
vector (method shown in Section 2.1.7) to produce the CD8β-pMP71 vector (Fig 3-1). 
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Figure 3-1 Derivation of CD8β-pMP71 vector.  
The CD8β transgene (yellow) in Bluescript SK vector (green ring) was cloned into pMP71 
(black ring) for the purposes of retroviral transduction of T cells. 
 
3.2.2 CD8β gene mutagenesis 
The CD8 co-receptor modification was focused on the CD8β chain due to its unique 
ability to enhance co-receptor function as highlighted in Section 1.4. The CD8β vector 
construct consists of a leader sequence and a coding sequence of 576 bp which 
encodes a 192 aa protein (Fig 3-2). Some CD8β chain mutations, in the 
immunoglobulin domain, have been shown to increase CD8 binding affinity with MHCI 
and enhanced the Ag-specific function of BW cell lines (Devine et al. 2006). These 
CD8β MHCI binding site mutants (S53L, S54V, L58R and L58R/I25A) were therefore 
candidate mutations for this project. The positions of the CD8β chain residues in the 
immunoglobulin-like domain that are involved in MHCI binding and that were 
targeted for mutagenesis (S53, S54 and L58) are shown in Fig 3-3. A second group 
of mutations involving O-glycosylation sites (T120A, T121A, T124A) were generated 
by the removal of threonine sites thus preventing O-glycosylation and sialylation. The 
position of these seven sites for mutagenesis is shown in upper case letters and 
coloured background in the CD8β gene sequence in (Fig 3-2). 
 
CD8β-Bluescript SK 
vector
PCR amplify 
using 5’ primers 
with NOT1 and 
3’ primers with 
BsrG1
CD8βNot1 BsrG1
LMP-TCR-pMP71 
vector
Not1/BsrG1 
digest
Not1 BsrG1
pMP71 vector shell
Ligation
CD8β-pMP71 
vector
Sal HindIII Not1 BsrG1
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Figure 3-2 Mutagenesis of the murine CD8β gene.  
The wild type CD8β gene sequence is shown here [base sequence (top row) and aa sequence 
(bottom row)]. Mutated positions where bases are indicated by coloured base code with 
capitalised alphabet. 
 
 
Figure 3-3 Graphic representation of the CD8 co-receptor showing the position of 
mutations known to enhance MHC-binding.  
The CD8 co-receptor is shown as a ribbon/surface diagram based on crystallographic studies 
with the α-chain (green) and β-chain (red). The positions of mutations known to enhance 
MHC-binding are 53S (green), 54S (brown) and 58L (red). 
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Mutations were introduced within the murine CD8β chain transgene by site directed 
PCR mutagenesis (Section 2.1.5) using primers encoding the relevant base changes 
designed with Strategene primer design software (Table 3-2). A schematic diagram 
of this process for the MHC binding site mutants is shown in Fig 3-3 and for the 
glycosylation site mutants in Figure 3-4. Two of the desired CD8β sequences required 
the introduction of multiple mutations (L58R/I25A and T120A/T121A/T124A [TglyM]) 
and were produced by performing serial PCR mutagenesis. After PCR mutagenesis, 
the vectors were analysed by NotI and EcoRI digestion followed by gel 
electrophoresis (Fig 3-6) prior to sequencing to confirm the presence of the correct 
base mutations (Fig 3-7 and Fig 3-8). 
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CD8β mutants  
I25A gatgtcctgtgaggttaaaagcgcctctaagttaacaagcatctac 
L58R ggagttcttccaaaggagttcggtatggtgaaagtgtggaca 
S53L gttcctggcctcctggagtctttccaaaggagttttgtat 
S54V cctggcctcctggagttctgtcaaaggagttttgtatggt 
T120A ggttgatgtccttcctgcaactgccccaaccaa 
T121A ttgatgtccttcctacagctgccccaaccaagaag 
T124A cttcctacaactgccccagccaagaagactaccc 
T120A/T121A/T124A 
(TglyM) 
tgatgtccttcctgcagctgccccaaccaagcagctgccccagccaagaagactaccc 
Table 3-2 PAGE purified oligonucleotide primers. 
Primers are designed using STRATAgene containing base changes (shown in red) used for PCR 
mutagenesis of CD8β (Anti-sense primers not shown). 
 
Figure 3-4 Introduction of CD8β MHC-binding site mutations by PCR mutagenesis.  
The CD8β transgene is shown in yellow and mutagenesis in the transgene denoted by red (1st 
step) and blue (2nd step). 
  
CD8β (WT)-
pMP71 vector
CD8β (S53L)-
pMP71 vector CD8β (S54V)-
pMP71 vector
CD8β (L58R)-
pMP71 vector
CD8β (I25A/L58R)-
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Figure 3-5 Introduction of CD8β- glycosylation site mutations by PCR mutagenesis.  
The CD8β transgene is shown in yellow and mutagenesis in the transgene denoted by red (1st 
step) and blue (2nd step). 
 
Figure 3-6 Agarose gel showing Not1 and BsrG1 digestion of all mini-prep DNA of E 
Coli colonies transformed using CD8β-pMP71 products 
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Figure 3-7 Sequence chromatograms confirming CD8β transgene base mutations. 
Mutations (highlighted in red rectangles) are introduced to the CD8β wild-type transgene (top 
row) to create CD8β MHC binding site mutants (S53L, S54V and L58R) using primers shown in 
Figure 3-2. 
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Figure 3-8 Sequence chromatograms confirming CD8β transgene base mutations. 
Mutations (highlighted in red rectangles) are introduced to the CD8β wild-type transgene (top 
row) to create CD8β glycosylation site mutants T120A, T121A, T124A and TglyM using primers 
shown in Figure 3-2. 
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3.3 Generation of retroviral vectors encoding both the TCR and 
CD8 co-receptor 
At the start of the project the available F5-TCR and CD8 transgenes were cloned into 
separate vectors. Moreover the CD8 containing vector, CD8α-IRES-CD8β, has the 
less efficient pMX backbone (see section 2.1.1), which had been used in a previous 
project supervised by Dr E Morris. Therefore to study the effect of modified CD8 co-
receptors on Ag-specific responses, a single vector construct was generated 
combining all the transgenes of the F5-TCR (TCRα and TCRβ chains) and CD8 co-
receptor (CD8α and CD8β chains) into the optimised pMP71 vector backbone.  
3.3.1 Construction of the F5-TCR-CD8 pMP71 retroviral vector 
The available F5-TCR pMP71 construct which had been optimized and validated in our 
laboratory was used. The wild-type murine CD8 transgene synthesized by GeneArt 
(Invitrogen) was designed to be inserted into the F5-TCR pMP71 vector. The diagram 
showing the cloning strategy used is shown in Fig 3-9 and Fig 3-10. The proposed 
construct was designed to contain part of the TCR-constant β chain (Cβ) with a 
restriction site XhoI in the 5’ end followed by CD8β and CD8α coding sequences 
separated by picornavirus-derived 2A linker peptides (Figure 3-10) which undergoes 
self-cleavage during translation (Donnelly et al. 2001). As the XhoI sequence was not 
unique in the pMP71 vector, an intermediate step using the pGA4 cloning vector was 
required (Figure 3-9). 
  
  Molecular biology 
74 
 
  
 
Figure 3-9 Schematic representation of the generation of the pMP71 vector 
containing F5-TCR, CD8α and CD8β coding sequences.  
The F5-TCR transgene in pMP71 vector (red block in black circle) was combined with the 
CD8αβ transgene in pc3.1 vector (blue block in green circle) to form the large F5-TCR-CD8αβ 
transgene (yellow block) through an intermediary pGA4 vector (purple circle) before cloning 
into pMP71 vector (yellow block in black circle. 
 
Figure 3-10 Summary of the molecular cloning required to derive the F5-TCR-CD8αβ 
pMP71 vector. 
The combination of F5-TCR (red block) and CD8 transgene (blue block) was performed through 
overlapping of the TCR constant β chain (Cβ) present in both vectors and restriction sites XhoI 
and EcoRI in the pGA4 vector (purple ring). 
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3.3.2 Construction of the F5-TCR-CD8α and F5-TCR-CD8β pMP71 
vectors  
Variations of the F5-TCR-CD8 gene vector were made by the removal of either the 
CD8α or the CD8β transgenes through restriction site digestion followed by re-
ligation of the vector. Removal of the CD8β transgene was designed to create the F5-
TCR-CD8α vector, which could be used to transduce CD4+ T cells (Fig 3-11). 
Removal of CD8α transgene created the F5-TCR-CD8β vector for the transduction of 
CD8β-/- CD8α+ T cells (Fig 3-12). This strategy afforded flexibility to study the 
effects of F5-TCR-CD8α transduced CD4+ T cells as the CD8α expression may be 
important for memory responses (Madakamutil et al. 2004). The F5-TCR-CD8β vector 
was subsequently used to determine the efficacy of CD8β mutants in CD8+ T cells 
(Section 5.2). 
 
Figure 3-11 Schematic representation of the generation of the pMP71 vector 
encoding F5-TCR and CD8α coding sequences. 
Digestion using restriction site RSRII removed the CD8β gene and the remaining vector ligated 
to form the F5-TCR and CD8α transgene.   
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Figure 3-12 Schematic representation of the generation of the pMP71 vector 
containing F5-TCR and CD8β coding sequences. 
Digestion using restriction site BstZ17I removed the CD8α gene and the remaining vector 
ligated to form the F5-TCR and CD8β transgene.    
3.3.3 In vitro analysis of murine CD4+ T cells transduced with the F5-
TCR-CD8 pMP71 vector  
To test the F5-TCR-CD8 vectors, CD8neg CD4+ T cells taken from C57BL/6 mice 
were transduced with F5-TCR, F5-TCR-CD8α or F5-TCR-CD8αβ vectors. The FACS 
analysis (Fig 3-13) showed that although there was an increase in Vβ11 expression in 
all transduced populations compared to the negative control (CD4 unmodified), there 
was no detectable expression of either the CD8α or CD8β molecules. To determine 
why transduction with the above vectors failed to efficiently transfer the CD8 
molecules the F5-TCR-CD8β vector was used to transduce CD8β-/- CD8α+ T cells 
taken from CD8β-deficient C57BL/6 mice with similar controls as above. FACS 
analysis of the transduced CD8β-/- T cells demonstrated CD8β successful expression 
(Fig 3-14).  
The F5-TCR-CD8β transduced T cells were able to recognise NP peptide loaded RMAS 
or EL4-NP target cells and were of higher avidity than F5-TCR transduced CD8β-/- T 
cells (Fig 3-15), despite similar levels of F5-TCR expression as measured by Vβ11+ 
MFI (132 vs 112), as shown in Figure 3-14. 
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VαCα P2A VβCβ F2A CD8β
Digest to remove CD8α
Ligate 
complementary 
vector ends
F5-TCR-CD8β
gene insert
  Molecular biology 
77 
 
 
Figure 3-13 FACS plots showing transduction of CD4+ T cells using F5-TCR, F5-TCR-
CD8α and F5-TCR-CD8αβ vectors.  
Mock transduced CD4 T cells (unmodified) were used as control for gating purposes. The first 
row show that the sorted live lymphocytes were predominantly CD4+ T cells which were gated 
(red circle) and examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each 
column represents a separate condition. 
 
Figure 3-14 FACS plots showing transduction of CD8β-/- CD8+ T cells using pMP71 
vectors containing the F5-TCR or F5-TCR-CD8β vectors.  
Mock transduced CD8β-/- CD8+ T cells (unmodified) were used as control for gating purposes. 
The first row show that the sorted live lymphocytes were predominantly CD8α+ T cells which 
were gated (red square) and examined for expression of CD8β and TCR (Vβ11) on subsequent 
rows. Each column represents a separate condition. 
CD4
CD8β
CD8α
Vβ11
CD8α
CD8β
CD4 
Unmodified
CD4 
F5-TCR
CD4 
F5-TCR-CD8α
CD4 
F5-TCR-CD8αβ
  Molecular biology 
78 
 
 
Figure 3-15 Enhanced Ag-specific IFN-γ secretion of CD8β-/- T cells transduced with 
the F5-TCR-CD8β (green line) retroviral vector compared to the F5-TCR vector (black 
line).  
Transduced cells were incubated with RMAS loaded with different concentrations of relevant NP 
peptide or irrelevant (Irr) SV9 peptide. The transduced cells were also incubated with EL4 or 
EL4NP tumour cells. Supernatant was harvested 16 hours later and analysed for IFN-γ using 
ELISA. 
3.3.4 Further development of the of F5-TCR-CD8 pMP71 vector  
The F5-TCR-CD8αβ vector was revised due to null expression of both CD8α and 
CD8β. One obvious fault in vector design was related to the 2A peptide sequences. 
The two identical F2A peptide sequences were used in the GeneArt CD8 gene 
construct resulting in duplication of homologous regions, also known as direct 
repeats. The base sequence of GeneArt CD8 gene construct is shown in Appendix II. 
The presence of these repeats had been shown to cause deletion of the sequences in 
between the direct repeats (Julias et al. 1995). In the case of the F5-TCR-CD8 
vector, the CD8β gene between the two F2A sequences may have been deleted (Fig 
3-10). One of the F2A sequences was therefore replaced with a different 2A self-
cleaving peptide (T2A).   
The original vector contained a shorter version of the CD8α transgene (GenBank 
BC030679.1) because the longer CD8α transgene (GenBank: U34881.1) contained 
an untranslated region. However, in the revised vector, we reinstated this 
untranslated region in the CD8α transgene (Appendix III). The schematic diagram of 
the cloning process in which the revised T2A-CD8α transgene (synthesized by 
GeneArt, Appendix III) was inserted into the F5-TCR-CD8β vector is shown in Fig 3-
16.  
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Figure 3-16 Schematic representation of the generation of the revised F5-TCR-CD8αβ 
pMP71 retroviral vector. 
The original F5-CD8 transgene (yellow) was revised through removal of the F2A-CD8α 
transgene (cyan) using restriction sites BstZ17I and EcoRI and ligating with T2A-CD8α using 
the same restriction sites to produce the revised F5-CD8 transgene (green). 
3.3.5 Transduction of murine CD4+ T cells with the revised F5-TCR-
CD8 pMP71 retroviral vector  
CD8neg CD4+ T cells were transduced with the F5-TCR, revised F5-TCR-CD8α or 
revised F5-TCR-CD8αβ vectors using our standard transduction protocols. Successful 
expression of TCR, CD8α and CD8β was demonstrated following transduction of 
CD4+ T cells (Fig 3-17). The increase in CD8α expression using the revised F5-TCR-
CD8αβ and F5-TCR-CD8α vectors was 17% and 46% respectively compared to no 
CD8α expression (<0.5%) when the F5-TCR alone vector was used. The increase in 
CD8β expression using the revised F5-TCR-CD8αβ was 13.2% compared to no CD8β 
expression (<0.5%) when the F5-TCR vector was used. In the condition using the 
combined F5-TCR-CD8αβ vector expression of CD8α molecules was proportional to 
the CD8β molecules indicating heterodimer formation. 
Subsequent FACS analysis demonstrated an increase in Vβ11 expression in all 
transduced cell populations compared to the untransduced cells, however the Vβ11+ 
percentage using the larger vectors F5-TCR-CD8αβ and F5-TCR-CD8α vectors were 
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considerably lower than the F5-TCR vector (6.72% and 22.65% vs 48.69%). More 
importantly the Vβ11+ MFI of the CD4+ T cells was inversely proportional to the size 
of the vectors used for transduction; F5-TCR-CD8αβ, F5-TCR-CD8α and F5-TCR 
vectors result in Vβ11 MFI: 55, 74 and 255 respectively. 
Both the F5-TCR-CD8αβ and F5-TCR-CD8α transduced CD4+ T cells were able to 
recognise EL4-NP target cells and produce IL-2 in an Ag-specific manner (Fig 3-18). 
However when comparing the same number of Vβ11+ CD4+ T cells, the magnitude 
of IL-2 production of F5-TCR-CD8αβ and F5-TCR-CD8α were lower than F5-TCR 
transduced CD4+ T cells (Fig 3-18). This may be related to the lower F5-TCR 
expression as a result of using large F5-TCR-CD8 and F5-TCR-CD8α vectors to 
transduce CD4+ T cells.  
The largest F5-TCR-CD8 vector consistently gave the lowest Vβ11 and CD8α 
expression as measured by MFI in primary CD4+ T cells. The low expression may be 
related to the size of the vector reducing the efficiency of protein production and 
expression. To reconfirm this observation, the F5-TCR-CD8 vectors were used to 
transduce TCR-negative CD8β-negative BW-cells and (Fig 3-19). Similar to the CD4+ 
T cells, the Vβ11+ MFI of the BW cells was inversely proportional to the size of the 
vectors used for transduction; F5-TCR-CD8αβ and F5-TCR vectors result in Vβ11 MFI 
of 342 and 536 respectively. Therefore despite the efforts put into producing the F5-
TCR-CD8αβ gene construct, this was inferior compared to the F5-TCR alone vector 
and was not used further in this project. 
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Figure 3-17 FACS plots showing transduction of CD4+ T cells using F5-TCR, F5-TCR-
CD8α and F5-TCR-CD8αβ vectors.  
Mock transduced CD4+ T cells (unmodified) were used as control for gating purposes. The first 
row show that the sorted live lymphocytes were predominantly CD4+ T cells which were gated 
(red circle) and examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each 
column represents a separate condition. 
 
Figure 3-18 IL-2 ELISA assay comparing function of transduced CD4+ T cells. 
CD4+ T cells are transduced with F5-TCR, F5-TCR-CD8α or F5-TCR-CD8αβ MP71 vectors and 
incubated EL4 tumour cells transfected with or without NP. Supernatant was harvested 16 
hours later and analysed for IL-2 using ELISA. 
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Figure 3-19 FACS plots showing transduction of BW cells using F5-TCR, F5-TCR-
CD8αβ (original) or F5-TCR-CD8 (revised) vectors. 
Mock transduced BW cells (unmodified) were used as control for gating purposes. The first row 
show that the sorted live BW cells were predominantly CD8α+ T cells which were gated (red 
square) and examined for expression of CD8β and TCR (Vβ11) on subsequent rows. Each 
column represents a separate condition. 
3.4 Summary 
Two murine TCR (MDM-TCR and F5-TCR) and one human TCR (CMV-TCR) were 
utilised in this project. All TCR constructs had been optimized for expression and 
were inserted into pMP71 retroviral vectors. The CD8β gene was inserted into pMP71 
vectors before specific mutations were introduced by PCR mutagenesis and confirmed 
by sequencing. The CD8β mutants S53L, S54V, L58R, L58R/I25A, T120A, T121A, 
T124A and TglyM were created. A quad-cistronic vector combining F5-TCR and CD8 
co-receptor transgene was created using molecular techniques. This large vector was 
less efficient for gene transfer with reduced F5-TCR expression compared to TCR 
alone vector following transduction, with a concomitant reduction in antigen specific 
functional responses. This was confirmed in both CD4+ T cells and BW cells. 
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Chapter 4. In-vitro analysis in CD8β-/- T cells 
4.1 Introduction 
Chapters 2 and 3 described the generation of the retroviral viral constructs used in 
this project. As the F5-TCR-CD8 quad-cistronic vector was not functional, comparison 
of CD8 mutants was only possible using co-transduction of T cells with two separate 
vectors, a TCR vector (either the F5-TCR or the MDM-TCR) and the relevant CD8 
vector. 
CD8β mutants with enhanced MHCI binding have previously been reported by Devine 
et al and were shown to augment IL-2 production when introduced into a T-cell line. 
To investigate if similar effects could be observed in primary T cells, the ‘augmenting’ 
CD8β mutants were tested on CD8β-/- CD8+ T cells. The CD8β-/- T cells were 
derived from CD8β knockout mice obtained as a kind gift from Dr R Zamoyska 
(University of Edinburgh). Although these mice had five-fold less circulating mature 
CD8+ T cells (expressing the CD8αα-homodimer form of CD8 co-receptor) they were 
able to mount primary and secondary anti-viral responses (Angelov et al. 2009) and 
were not susceptible to opportunistic infections. Therefore the CD8β-/- CD8+ T cells 
were considered ideal for testing the impact of CD8β chain mutations. Eight 
candidate CD8β mutants were identified at the start of the project, which included 
four MHC-binding site mutants (S53L, S54V, L58R and L58R/I25A) and four O-
glycosylation site mutants (T120A, T121A, T124A and T120A/T121A/T124A [TglyM]). 
The generation of the CD8β vectors containing the mutations was described in detail 
in Section 3.4. 
 The MDM(3f3b)-TCR used in this project was one of two MDM100/H2-Kb 
specific TCRs isolated and characterised by the laboratory (Sadovnikova & Stauss 
1996). The MDM(3f3b)-TCR and the MDM(6a5d)-TCR both recognise the same 
MDM100 peptide derived from  the murine double minute-2 (MDM2) protein, which is 
a TAA over expressed in many cancers such as lymphomas, sarcomas, breast and 
urothelial cancers. As the T cell clones containing the MDM(3f3b)-TCR were high 
avidity and CD8 co-receptor dependent (McNicol et al. 2007), this TCR was chosen to 
be tested with various CD8 co-receptor mutants. The MDM(6a5d)-TCR was of lower 
avidity and CD8 independent and was not used in this project. The MDM(3f3b)-TCR is 
codon optimised and contain a c-myc tag in the leader sequence of the TCR-α chain. 
Introduction of c-myc tag into this position in OT1-TCR, gp100-TCR and P14-TCR was 
shown not to alter TCR function (Kieback et al. 2008). The c-myc tag was introduced 
and tested in our laboratory by Dr Sara Ghorashian  and was found to have similar 
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functional properties to the original MDM-TCR based on peptide titration cytokine 
release and cytotoxicity assays. 
The second TCR examined was the F5-TCR which recognises the NP366 peptide 
derived from Influenza virus-A nucleoprotein. Tumour protection studies have been 
performed using both CD8+ and CD4+ T cells transduced to express the F5-TCR. Ag-
specific IFN-γ production was used as the main functional read out for the TCR-td 
CD8+ T cells in this chapter.  
4.2 Co-transduction of CD8β mutants and the MDM-TCR into 
CD8β-/- CD8+ T cells  
4.2.1 Successful cell surface expression of the MDM-TCR and CD8β 
mutants following transduction of CD8β-/- CD8+ T cells  
CD8β-/- CD8α+ T cells were transduced with pooled viral supernatant containing a 
1:1 mixture of MDM-TCR and CD8β (wild-type WT, or mutated) vectors. The CD8β 
constructs used were either WT or one of four MHC-binding site mutants (S53L, 
S54V, L58R and L58R/I25A) or one of four O-glycosylation site mutants (T120A, 
T121A, T124A and T120A/T121A/T124A [TglyM]). Mock-transduced (unmodified) or 
MDM-TCR alone transduced CD8β-/- CD8α+ T cells were used as controls. Three 
days after transduction, T cells were analysed for surface expression of TCR and/or 
CD8β using fluorochrome-conjugated antibodies (Fig 4-1 to 4-3). As separate 
retroviral vectors were used for transduction, two distinct populations were seen: a 
single-transduced c-myc+ population and a double-trandsuced CD8β+ c-myc+ 
population. The proportion of single-transduced c-myc+ CD8+ T cells (ie., MDM-TCR 
expressing) in each condition was observed to be broadly equivalent at between 
31.65% and 41.98% of total CD8+ T cells. The double-transduced CD8β+ c-myc+ 
population comprised between 1.94% and 10.96% of total CD8+ T cells in all 
conditions except the mock-transduced negative control and the MDM-TCR alone 
conditions, as expected. Interestingly, most CD8β+ transduced T cells were also c-
myc+, indicating that successful expression of CD8β may have improved TCR-
transduction or expression in CD8β-/- T cells. The expression of CD8β in the 
transduced populations was proportional to the endogenous CD8α expression. The 
expression level of transduced CD8β as measured by MFI was similar between WT 
(MFI: 237) and all mutations (MFI: 187 to 261) except S53L (MFI: 77). Even the 
CD8β mutation with three glycosylation sites mutated (TglyM) had good expression 
(MFI: 191). These expression features were consistently observed in at least three 
repeat transductions. 
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Figure 4-1 FACS analysis of CD8β-/- T cells transduced with retroviral vectors 
encoding the MDM-TCR and CD8β (WT) in separate vectors.  
Mock transduced CD8β-/- T cells (unmodified) were used as control for gating purposes. The 
sorted live lymphocytes were predominantly CD8α+ T cells which were examined for 
expression of CD8β and TCR (c-myc). Each column represents a separate condition.         
 
Figure 4-2 FACS analysis of CD8β-/- T cells transduced with the MDM-TCR and CD8β 
MHC-binding site mutants (S53L, S54V, L58R and L58R/I25A) in separate vectors.  
Mock transduced CD8β-/- T cells (unmodified) were used as control for gating purposes. The 
sorted live lymphocytes were predominantly CD8α+ T cells which were examined for 
expression of CD8β and TCR (c-myc). Each column represents a separate condition.         
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Figure 4-3 FACS analysis of CD8β-/- T cells transduced with the MDM-TCR and CD8β 
glycosylation mutants in separate vectors.  
Mock transduced CD8β-/- T cells (unmodified) were used as control for gating purposes. The 
sorted live lymphocytes were predominantly CD8α+ T cells which were examined for 
expression of CD8β and TCR (c-myc). Each column represents a separate condition.         
4.2.2 Antigen-specific IFN-γ production of MDM-TCR-td CD8β-/- T 
cells 
As the MDM-TCR-td cells were known to be highly CD8 co-receptor dependent with 
respect to Ag-specific function (McNicol et al. 2007) and the proportion of single 
MDM-TCR-td cells were similar between different conditions, cell sorting was not 
performed to separate the single and double transduced populations prior to 
functional assays being performed. To compare the effect of expressing CD8β WT or 
CD8β mutants in TCR-td CD8β-/-  T cells, the same number of double transduced 
CD8β+ and MDM-TCR + T cells from each condition (various CD8β constructs) were 
incubated with saturating peptide-loaded RMAS target cells (in triplicate). After 
overnight incubation, supernatant was removed and assessed for IFN-γ production 
by ELISA (Fig 4-4 and 4-5). Singly transduced MDM-TCR-td CD8β-/- T cells produced 
relatively small amounts of IFN-γ (<50 pg/ml) (Fig 4-4) in response to NP peptide 
loaded RMAS cells. However, the expression of CD8β WT or any CD8β mutant 
(except S53L) resulted in an increase in Ag-specific IFN-γ production (>100 pg/ml). 
Overall, the concentration of IFN-γ produced was low and background responses 
were high. Therefore comparisons made between the functional effect of expressing 
the various CD8β constructs were limited. Despite such constraints, the co-transfer 
of CD8β (L58R) and CD8β (L58R/I25A) co-receptors produced greater amounts of 
IFN-γ.  
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Figure 4-4 Recognition of RMAS cells loaded with saturating concentrations of 
peptide induces IFN-γ production by TCR transduced CD8α+ T cells.  
ELISA assay using CD8β-/- CD8+ T cells transduced with MDM-TCR vector and CD8β vector 
containing wild-type (WT) or MHC binding site mutant (S53L, S54V, L58R or L58R/I25A) DNA 
sequences stimulated with RMAS cells loaded with saturating concentrations (10µM) of 
relevant MDM100 peptide or irrelevant SV9 peptide for 16 hours in triplicate. This is a 
representative result of at least two independent experiments. 
 
Figure 4-5 Recognition of RMAS cells loaded with saturating concentrations of 
peptide induces IL-2 production by TCR transduced CD8α+ T cells.  
ELISA assay using CD8β-/- CD8+ T cells transduced with MDM-TCR vector and CD8β vector 
containing WT or glycosylation site mutant (T120A, T121A, T124A and TglyM) DNA sequences 
stimulated with RMA-S cells loaded with saturating concentrations (10µM) of relevant MDM 
peptide or irrelevant SV9 peptide for 16 hours in triplicate wells. This is a representative result 
of at least two independent experiments.  
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To show that the low levels of Ag-specific IFN-γ production were related to the MDM-
TCR rather than the functional capacity of CD8β-/- CD8+ T cells, CD8+ T cells taken 
from wild-type C57BL/6 mice were transduced with the same MDM-TCR and the F5-
TCR as a control. When the same number of TCR-td CD8+ T cells was incubated 
overnight with saturating peptide loaded RMAS target cells, the Ag-specific IFN-γ 
response of F5-TCR-td CD8+ T cells was four-fold that of MDM-TCR-td CD8+ T cells 
(Fig 4-6). In subsequent experiments with F5-TCR transduced CD8β-/- CD8 T cells, 
significant Ag-specific responses were observed (Section 4.4.2). 
The dysfunction of MDM-TCR transduced C57Bl/6 CD8+ T cells was studied by Dr 
Sara Ghorasian who found that these transduced T cells were more activated in vitro 
(CD44/CD62L, blasted) and showed upregulation of exhaustion markers, including 
PD-1, LAG-3, 2B4. The reduced viability related to increased apoptosis was attributed 
to native MDM expression by activated C57Bl/6 T cells. MDM-TCR transduced Balb/c 
CD8+ T cells had lower levels of apoptotic markers, greater viability and Ag-specific 
cytokine production.  Absence of fratricide was inferred because the fraction of 
apoptotic cells was not greater than the transduction efficiency. The dysfunction of 
MDM-TCR transduced C57Bl/6 CD8+ T cells was noted before the introduction of the 
c-myc tag by Dr Downing a previous PhD student in the laboratory. 
 
Figure 4-6 Recognition of RMAS cells loaded with saturating concentrations of 
peptide induces IFN-γ production by TCR transduced CD8+ T cells.  
ELISA assay using wild type CD8+ T cells transduced with MDM-TCR or F5-TCR stimulated with 
RMA-S cells loaded with saturating concentrations (10µM) of MDM100 peptide or NP peptide in 
triplicate wells. This is a representative result of at least two independent experiments. 
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4.3 In-vitro functional analysis of CD8β-/- CD8+ T cells following 
co-transduction with F5-TCR and CD8β 
4.3.1 Cell surface expression of CD8β-/- CD8+ T cells following 
transduction with F5-TCR and CD8β 
Due to the limitations observed with the MDM-TCR, the index TCR used for 
subsequent testing of CD8 co-receptor mutants was the F5-TCR. CD8β-/- CD8α+ T 
cells were transduced with viral supernatant containing a 1:1 mixture of F5-TCR and 
the CD8β constructs either of wild-type sequence (WT) or one of the four MHC-
binding site mutants (S53L, S54V, L58R and L58R/I25A) or one of the four O-
glycosylation mutants (T120A, T121A, T124A and T120A/T121A/T124A [TglyM]). The 
controls were CD8β-/- CD8α+ T cells mock transduced (unmodified) or transduced 
with the F5-TCR alone. Three days after transduction, the transduced T cells were 
analysed for surface expression of F5-TCR and CD8β using fluorochrome conjugated 
antibodies to the Vβ11 and to CD8β (Fig 4-7 to 4-9). As transduction was with two 
separate vectors, there were two distinct populations seen, a single-transduced 
Vβ11+ population and a double-transduced CD8β+ Vβ11+ population. The single-
transduced Vβ11+ CD8+ T cells comprised between 12.81% and 19.96% of total 
CD8+ T cells in all conditions except mock negative control. This indicates slight 
variation in transduction efficiency as the same volume of a common F5-TCR 
supernatant mix was used in the different conditions. The double-transduced CD8β+ 
Vβ11+ population comprised between 13.40% and 20.74% of total CD8+ T cells in 
all conditions except mock negative control and the F5-TCR alone condition. Similar 
to transduction shown above using the F5-TCR, most CD8β+ transduced T cells were 
also Vβ11+. The expression level of CD8β as measured by MFI was similar between 
WT (MFI: 280) and the different mutations (MFI: 276 to 368) with once again S53L 
having the lowest MDI expression (238). These expression features were consistent 
between at least three repeat transductions. 
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Figure 4-7 FACS analysis following F5-TCR and CD8β (WT) transduction of CD8β-/- 
CD8+ T cells.  
Mock transduced CD8β-/- CD8+ T cells (unmodified) were used as control for gating purposes. 
The first row show that the sorted live lymphocytes were predominantly CD8α+ T cells which 
were gated (red square) and examined for expression of CD8β and TCR (Vβ11) on subsequent 
rows. Each column represents a separate condition.        
 
Figure 4-8 FACS analysis following transduction of CD8β-/- CD8+ T cells with the F5-
TCR vector and CD8β vector containing MHC-binding site mutations (S53L, S54V, 
L58R or L58R/I25A).  
Mock transduced CD8β-/- CD8+ T cells (unmodified) were used as control for gating purposes. 
The first row show that the sorted live lymphocytes were predominantly CD8α+ T cells which 
were gated (red square) and examined for expression of CD8β and TCR (Vβ11) on subsequent 
rows. Each column represents a separate condition.            
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Figure 4-9 FACS analysis following transduction of CD8β-/- CD8+ T cells with the  
F5-TCR vector and CD8β vector containing glycosylation site mutations (T120A, 
T121A, T124A, and TglyM).  
Mock transduced CD8β-/- CD8+ T cells (unmodified) were used as control for gating purposes. 
The first row show that the sorted live lymphocytes were predominantly CD8α+ T cells which 
were gated (red square) and examined for expression of CD8β and TCR (Vβ11) on subsequent 
rows. Each column represents a separate condition.  
Cell sorting was performed to enrich the CD8β+ population using anti-CD8β-FITC 
antibodies and anti-FITC magnetic beads (Figure 2.3.3.1). The enriched T cell 
populations were re-stimulated and rested for one week to reduce the effects of anti-
CD8β antibodies on functional comparisons of the CD8β transduced cells. The control 
‘F5-TCR alone’ transduced T cells were re-stimulated without any enrichment.  
After 1 round of stimulation, the different cell populations were analysed by FACS 
before use in functional assays. The FACS analyses (Figure 4-10 to 4-12) showed 
significant enrichment of the CD8β+ Vβ11+ doubly transduced CD8+ T cells (80.34% 
- 91.15% purity) except for the CD8β(S54V) transduced cells which had a purity post 
bead-sort and re-stimulation of 58.76%. The MFI for the transduced molecules were 
similar in the different cell populations; CD8β MFI varied between 176 and 222 and 
Vβ11 MFI varied between 119 and 123.  
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Figure 4-10 Enrichment of F5-TCR and CD8β (WT) transduced CD8β-/- CD8+ T cells. 
Sorted TCR (Vβ11+) transduced lymphocytes were analysed 7 days after in-vitro peptide 
stimulation. F5-TCR (Vβ11+) transduced CD8β-/- CD8+ T cells (unmodified) were used for 
gating purposes. The first row show that the sorted live lymphocytes were predominantly 
CD8α+ T cells which were gated (red square) and examined for expression of CD8β and TCR 
(Vβ11) on subsequent rows. Each column represents a separate condition.             
 
Figure 4-11 Enrichment of the F5-TCR and CD8β transduced CD8β-/- CD8+ T cells 
containing CD8β MHC-binding site mutations (S53L, S54V, L58R and L58R/I25A). 
Sorted TCR (Vβ11+) transduced lymphocytes were analysed 7 days after in-vitro peptide 
stimulation. F5-TCR (Vβ11+) transduced CD8β-/- CD8+ T cells (unmodified) were used for 
gating purposes. The first row show that the sorted live lymphocytes were predominantly 
CD8α+ T cells which were gated (red square) and examined for expression of CD8β and TCR 
(Vβ11) on subsequent rows. Each column represents a separate condition. 
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Figure 4-12 Enrichment of F5-TCR and CD8β transduced CD8β-/- CD8+ T cells 
containing CD8β glycosylation site mutations (T120A, T121A or T124A and TglyM). 
Sorted TCR (Vβ11+) transduced lymphocytes were analysed 7 days after in-vitro peptide 
stimulation. F5-TCR (Vβ11+) transduced CD8β-/- CD8+ T cells (unmodified) were used for 
gating purposes. The first row show that the sorted live lymphocytes were predominantly 
CD8α+ T cells which were gated (red square) and examined for expression of CD8β and TCR 
(Vβ11) on subsequent rows. Each column represents a separate condition. 
4.3.2 Antigen specific IFN-γ production of F5-TCR transduced CD8β-/- 
CD8+ T cells  
To determine the effect of mutated CD8β co-receptor expression in F5-TCR-td CD8+ 
T cells, the same number of purified CD8β+ and F5-TCR double transduced CD8+ T 
cells were incubated with peptide loaded RMAS target cells, with a range of peptide 
concentration from 10μM to 100pM. After overnight stimulation, supernatant was 
removed and IFN-γ production measured by ELISA. These results were used to 
derive a log dose response curve generated using Prism5 (Graphpad). F5-TCR-td T 
cells expressing the CD8β MHC-binding site mutants (Fig 4-13) and CD8β 
glycosylation site mutants (Fig 4-14) were compared to those expressing CD8β wild-
type (WT) in two different sets of experiments. 
The introduction of CD8β (WT) enhanced the maximal Ag-specific IFN-γ production of 
F5-TCR-td CD8+ T cells (587 vs 266 pg/ml) and also increased the functional avidity, 
that is the T cells recognised lower peptide concentration (logEC50: -6.947 vs -
6.509). Of the eight CD8β mutants tested, only the CD8β (L58R) and CD8β 
(L58R/I25A) mutants demonstrated enhanced in comparison to the CD8β (WT) F5-
TCR-td CD8+ T cells. CD8+ cells transduced with the CD8β (L58R) mutant and the 
CD8β (L58R/I25A) mutant had more than twice the maximal IFN-γ response 
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compared with CD8+ T cells transduced with CD8β (WT) (2072 and 1567 vs 586 
pg/ml). Moreover, the cells transduced with the CD8β (L58R) and CD8β (L58R/I25A) 
mutants recognised lower concentrations of relevant NP peptide than CD8+ T cells 
transduced with CD8β WT (logEC50: -7.276 and -7.131 vs -6.947). Both the CD8β 
(S53L) and CD8β (S54V) mutants were inferior to the CD8β (WT) in augmenting the 
avidity of F5-TCR-td CD8+ T cells. 
CD8β co-receptor constructs with single glycosylation site mutations (T120A, T121A, 
or T124A) did not alter IFN-γ production and peptide sensitivity in response to 
peptide loaded RMAS cells compared to equivalent T cells expressing the CD8β (WT) 
co-receptor (Fig 4-14). However, the CD8β mutant containing all three glycosylation 
site mutations (TglyM) was inferior to the CD8β (WT) when transduced into F5-TCR-
td CD8+ T cells as determined by a lower maximal Ag-specific IFN-γ  production 
(1532 vs 1910 pg/ml) and a decrease in relevant peptide sensitivity (logEC50: -
7.965 vs -8.186). 
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Figure 4-13 In vitro functional avidity of F5-TCR CD8β-/- CD8+ T cells is augmented 
by CD8β L58R and L58R/I25A mutations compared to CD8β wild-type (WT).  
Ag-specific IFN-γ secretion was determined by ELISA following overnight stimulation with 
RMAS cells loaded with different concentrations of relevant NP peptide. The NP peptide 
concentration required to elicit a response halfway between maximum and minimum (EC50) is 
shown in the table on the top right.  This is a representative result of at least two independent 
experiments. 
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Figure 4-14  In vitro functional avidity of F5-TCR CD8β-/- CD8+ T cells is not 
augmented by CD8β glycosylation site mutations (T120A, T121A, T124A or TglyM) 
compared to CD8β wild-type (WT).  
Ag-specific IFN-γ secretion was determined by ELISA following overnight stimulation with 
RMAS cells loaded with different concentrations of relevant NP peptide. The NP peptide 
concentration required to elicit a response halfway between maximum and minimum (EC50) is 
shown in the table on the top right.  This is a representative result of at least two independent 
experiments. 
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Further experiments were performed where the various F5-TCR transduced T cell 
populations were stimulated with tumour cells endogenously expressing the NP 
peptide.  The transduced T cells were incubated overnight with EL4NP target or EL4 
control tumour cells. All F5-TCR-td CD8+ T cells only recognized EL4NP target and 
not EL4 control tumour cells, confirming appropriate recognition of the NP epitope 
through the F5-TCR. The CD8β L58R and CD8β L58R/I25A mutated co-receptors 
were used in these experiments as they had previously been shown to enhance IFN-γ 
responses to peptide-loaded RMAS cells. All F5-TCR-td CD8+ T cells produced five to 
ten fold more IFN-γ in response to EL4NP target cells than EL4 control tumour cells 
(Fig 4-15). The introduction of CD8β (WT) enhanced the Ag-specific IFN-γ production 
of F5-TCR-td CD8+ T cells (589 vs 266 pg/ml; p=0.0043). CD8+ T cells transduced 
with the CD8β (L58R) mutant and the CD8β (L58R/I25A) mutant produced 
significantly more IFN-γ compared with CD8+ T cells transduced with CD8β (WT) 
(1672 and 1315 vs 589 pg/ml; p=0.022 and p=0.026) in response to NP-expressing 
tumour cells.  
Therefore the CD8β L58R mutated co-receptor, when expressed alongside the F5-
TCR was consistently superior to the CD8β wild-type co-receptor in augmenting the 
Ag-specific IFN-γ production by F5-TCR-td CD8+ T cells.  As the CD8β (L58R) mutant 
enhanced effector function marginally better than the CD8β (L58R/I25A) mutation it 
was chosen as the key ‘augmenting mutant’ for subsequent experiments described in 
Chapters 5 and 6. 
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Figure 4-15 Higher Ag-specific IFN-γ production by CD8β L58R and L58R/I25A 
compared to CD8β wild-type (WT) co-transduced F5-TCR CD8α+ T cells to EL4NP 
tumour cells which express endogenously processed NP peptide.  
IFN-γ ELISA assay using CD8β-/- CD8+ T cells transduced with F5-TCR vector and CD8β 
vector containing wild-type (WT) or MHC-binding site mutant (L58R or L58R/I25A) were 
incubated with EL4NP target or EL4 control tumour cells for 16 hours with each condition 
replicated six times. This is a representative result of at least two independent experiments. (* 
p <0.05, ** p <0.01). 
 
4.4 Summary 
This chapter has described the in vitro analysis of T cells transduced with the CD8β 
mutants discussed in Chapter 3. The effect of CD8β mutant expression was tested in 
CD8β-/- CD8+ T cells. The early experiments used the ‘CD8-dependent’ MDM-TCR 
which recognises the MDM100 peptide sequence YAMIYRNL from the tumour 
oncogene Murine double-minute 2 (MDM) in the context of H-2Kb. While the MDM-
TCR and CD8β expression in co-transduced T cells were reasonable (Fig 4-1 to 4-3), 
the function of transduced T cells were sub-optimal; the overall IFN-γ production was 
low and MDM peptide-specific responses were poor (Fig 4-4 and 4-5). Therefore 
comparison of the effect of CD8β variants on peptide specific responses was not 
possible with the MDM-TCR. 
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As the cloned MDM-TCR was unsuitable it was replaced with the F5-TCR for the 
remainder of this project. The F5-TCR recognizes the NP366 peptide sequence 
ASNENMDAM from the Influenza-A nucleoprotein (NP) and is also known to be 
dependent on the CD8 co-receptor for optimal function (Morris et al. 2005; Jiang et 
al. 2011). CD8β-/- CD8+ T cells were co-transduced with the F5-TCR and the CD8β 
variants (Fig 4-7 to 4-9). These transduced cells were sorted using antibodies to 
CD8β and analysed one week post antigen-specific stimulation (Fig 4-10 to Fig 4-12). 
The F5-TCR-td T cells expressing the CD8β L58R mutation, CD8β (L58R), were able 
to augment T-cell response above that observed with T cells expressing the CD8β 
with wild-type sequence, CD8β (WT) (Fig 4-13 and Fig 4-14). This enhancement of 
Ag-specific IFN-γ production was also seen in response to EL4 tumour cells 
endogenously expressing the NP peptide (Fig 4-15). 
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Chapter 5. In-vitro analysis in CD4+ and CD8+ T cells 
5.1 Introduction 
The previous chapter demonstrated that introducing CD8β molecules with wild-type 
sequence or containing the L58R mutation improved the function F5-TCR transduced 
into transgenic CD8β-/- CD8+ T cells. In this chapter CD8β co-transfer into wild-type 
C57Bl/6 T cells is examined. In CD8+ T cells there is physiological expression of 
endogenous CD8 co-receptor and it is unknown if the introduction of additional CD8β 
molecules containing augmenting mutations will confer additional benefits.  
In CD4+ T cells, the addition of CD8α molecules is required for the expression of the 
CD8β chain and therefore the complete CD8 transgene needs to be transferred. As 
summarised in Table 1-1, the MHCI restricted F5-TCR and CD8 molecule had been 
previously transduced together into CD4+ T cells and examined in a model of viral 
infection (Kessels et al. 2006). The co-transfer of CD8α with the F5-TCR into CD4+ T 
cells had mixed results on the recognition of tumour cells (Morris et al. 2005); 
improving Ag-specific IFN-γ production but abolishing proliferative responses.  
To study the effects of CD8 molecules and MHCI restricted TCR on CD4+ T cells, 
peptide loaded splenocytes expressing both MHCI and MHCII and EL4 tumour cells, 
which express MHCI only were used as in-vitro targets. Of the panel of mutated 
CD8β constructs generated only the CD8β L58R ‘augmenting’ mutant and the ‘less 
effective’ CD8β TglyM mutant were studied in detail. 
In order to investigate the possibility that the homologous human I59R mutation 
could also be augmenting, in vitro experiments were designed using human CD4 T 
cells transduced with MHCI restricted CMV-TCR. This TCR has been recently shown 
by other members of the laboratory to be CD8 dependent in terms of cytokine 
production and cytotoxicity. Human CD4+ T cells co-transduced with CMV-TCR and 
CD8 coreceptor could protect NOD/SCID mice against tumour (Xue et al. 2013). 
5.2 In-vitro characterisation of F5-TCR and CD8 co-receptor 
transduced CD8+ T cells  
5.2.1 Transduction of CD8+ T cells with the F5-TCR-CD8β vector  
As wild-type C57Bl/6 CD8+ T cells express endogenous CD8β, it was not possible to 
directly monitor the introduction of CD8β mutants. The F5-TCR-CD8β (WT) vector 
was already available (Section 3.5.3) and CD8+ T cells co-transduced with the F5-
TCR and CD8β molecules could be identified by staining for Vβ11 expression 
assuming both transgenes were expressed simultaneously. To confirm, CD8β-/- 
CD8+ T cells were used to validate co-expression of both F5-TCR and CD8β. 
Transduction with the F5-TCR-CD8β (WT), F5-TCR-CD8β (L58R) or F5-TCR-CD8β 
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(TglyM) vectors resulted in proportional expression of Vβ11+ and CD8β with Vβ11hi 
transduced cells also CD8hi (Fig 5-1).  
 
 
Figure 5-1 FACS analysis of transduced CD8β-/- CD8+ T cells using F5-TCR-CD8β 
vector containing CD8β (WT), CD8β L58R or CD8β TglyM.  
Mock transduced CD8 T cells (unmodified) were used as controls for gating purposes. The first 
row show that the sorted live lymphocytes were predominantly CD4+ T cells which were gated 
(red square) and examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each 
column represents a separate condition. 
 
5.2.2 Cell surface expression of F5-TCR and CD8β on transduced 
CD8+ T cells  
Wild-type C57Bl/6 splenocytes enriched for CD8+ T cells (Section 2.3.2.1) were 
transduced with F5-TCR and CD8β (WT, L58R or TglyM) using the F5-TCR-CD8β 
vectors. FACS analysis three days post transduction (Fig 5-2) showed a similar level 
of F5-TCR transduction, as determined by Vβ11 expression (42.01%, 36.54% and 
38.64%). Endogenous Vβ11 expression was 9.71% in the mock transduced CD8+ 
control T cells. 
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Figure 5-2 FACS analysis of transduced CD8+ T cells using F5-TCR-CD8β vector 
containing CD8β (WT or L58R or TglyM).  
Mock transduced CD8+ T cells (unmodified) were used as controls for gating purposes. The 
first row show that the sorted live lymphocytes were predominantly CD8+ T cells which were 
gated (red square) and examined for expression of CD8β and TCR (Vβ11) on subsequent rows. 
Each column represents a separate condition. 
 
5.2.3 In vitro Ag-specific cytokine production of transduced CD8+ T 
cells 
To compare the functional avidity of F5-TCR-td CD8+ T cells, expressing additional 
CD8β wild-type or mutants, F5-TCR-CD8β (WT), F5-TCR-CD8β (L58R) or F5-TCR-
CD8β (TglyM) transduced CD8+ T cells were incubated with splenocytes loaded with 
a range of NP peptide concentration from 10μM to 1nM. After overnight incubation, 
supernatant was analysed for IFN-γ and IL-2 production by ELISA (Fig 5-3 and 5-4). 
The CD8β (L58R) and (TglyM) transduced T cells were compared with CD8β (WT). No 
significant differences in IFN-γ and IL-2 production were observed. 
To test for in vitro recognition of endogenously expressed cognate antigen the F5-
TCR-CD8β (WT), F5-TCR-CD8β (L58R) or F5-TCR-CD8β (TglyM) transduced CD8+ T 
cells were incubated with EL4NP or EL4 control tumour cells. After overnight 
incubation, supernatant was removed and analysed for the amount of IFN-γ and IL-2 
produced by ELISA (Fig 5-5 and 5-6). No significant difference in cytokine production 
was observed between the CD8β (WT) and CD8β (L58R) transduced T cells, however 
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the CD8β (TglyM) IFN-γ and IL-2 response to EL4NP tumour cells was significantly 
impaired (p=0.03).  
 
 
 
Figure 5-3 In vitro Ag-specific IFN-γ production of transduced CD8+ T cells showed 
no difference between CD8β wild-type or mutants (L58R and TglyM).  
CD8+ T cells transduced with F5-TCR-CD8β vector containing wild-type (WT), L58R or TglyM 
mutations were incubated with splenocytes loaded with different concentrations of relevant NP 
peptide. A representative result of at least two independent experiments is shown. 
 
Figure 5-4 In vitro Ag-specific IL2 production of transduced CD8+ T cells showed no 
difference between CD8β wild-type or mutants (L58R and TglyM). 
CD8+ T cells, transduced with F5-TCR-CD8β vector containing wild-type (WT), L58R or TglyM 
mutations were incubated with splenocytes loaded with different concentrations of relevant NP 
peptide. A representative result of at least two independent experiments is shown. 
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Figure 5-5 Recognition of EL4NP tumour cells expressing endogenously processed 
NP peptide induces IFN-γ production by F5-TCR transduced CD8+ T cells  that was 
inferior in CD8β TglyM compared to CD8β wild-type or L58R.  
CD8+ T cells, transduced with F5-TCR-CD8β vector containing wild-type (WT), L58R or TglyM 
mutations were incubated with EL4NP target or EL4 control tumour cells. IFN-γ production was 
measured by ELISA. A representative result of at least two independent experiments is shown. 
(*p<0.05). 
 
 
Figure 5-6 Recognition of EL4NP tumour cells expressing endogenously processed 
NP peptide induces IL-2 production by F5-TCR transduced CD8+ T cells  that was 
inferior in CD8β TglyM compared to CD8β wild-type or L58R.  
CD8+ T cells, transduced with F5-TCR-CD8β vector containing wild-type (WT), L58R or TglyM 
mutations were incubated with splenocytes loaded with EL4NP target or EL4 control tumour 
cells. IL-2 production was measured by ELISA. A representative result of at least two 
independent experiments is shown. (*p<0.05). 
Intracellular cytokine staining (ICS) was also performed to determine the proportion 
of F5-TCR-CD8β (WT), F5-TCR-CD8β (L58R) or F5-TCR-CD8β (TglyM) transduced 
CD8+ T cells that produced Ag-specific responses to EL4NP or EL4 tumour cells (Fig 
5-7). The experimental set up was similar to the ELISA assay detailed above, except 
that the cells were incubated for a shorter 6 hours prior to permeabilisation and 
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fixation (Section 2.5.4). ICS showed that there were no significant differences 
observed between CD8β (WT) and CD8β (L58R) and CD8β (TglyM) transduced T cell 
secretion of IFN-γ (13.82%, 13.90% vs 10.64%) or IL-2 (3.33%, 3.03% vs 2.78%). 
 
Figure 5-7 In vitro Ag-specific intracellular IFN-γ and IL-2 production to EL4NP 
tumour cells by transduced CD8+ T cells was inferior in CD8β TglyM compared to 
CD8β WT or L58R .  
Intracellular cytokine staining was performed after incubation of transduced CD8+T cells with 
EL4NP (red line) target or EL4 control (grey line) tumour cells for 6 hours. Transduced CD8+ T 
cells were gated (red squares) and analysed for IFN-γ and IL-2 production in respective 
columns. This result is representative of at least two independent experiments. 
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5.3 In-vitro characterisation of F5-TCR and CD8 co-receptor 
transduced CD4+ T cells  
5.3.1 Cell surface expression of F5-TCR and CD8 co-receptor on 
transduced CD4+ T cells  
Wild-type C57Bl/6 splenocytes enriched for CD4+ T cells (Section 2.3.2.2) were 
transduced with F5-TCR and CD8αβ molecules containing CD8β wild-type (WT) or 
CD8β mutations (L58R or TglyM) using separate vectors. FACS analysis three days 
after transduction (Fig 5-8) showed a similar level of F5-TCR transduction by Vβ11 
expression (73.64%, 69.43% and 67.57% respectively) compared with mock 
transduced or F5-TCR alone transduced CD8+ T cells expressing endogenous Vβ11 
(7.27% and 86.74% respectively). For the three conditions with transduction of CD8 
(WT), CD8 (L58R) and CD8 (TglyM), the percentage of CD8α+ CD8β+ T cells were 
similar at 50.01%, 49.17% and 48.02% respectively. The cell surface expression of 
CD8α molecules was proportional to the CD8β molecules indicating heterodimer 
formation. The CD8α expression (as measured by MFI) was similar between the three 
conditions (MFI: 746, 795, 893) as was the CD8β expression (MFI: 301, 265, 257). 
CD8hi expressing T cells were enriched using anti-CD8α-APC antibodies and anti-APC 
microbeads to ensure similar numbers of T cells expressing the transduced CD8 co-
receptor were compared in functional assays. The anti-CD8α-APC antibody was 
derived from the KT15 clone and is known not to augment or diminish Ag-specific T 
cell responses in subsequent functional assays (Devine et al. 2004).  
FACS analysis (Fig 5-9) sorted CD4+ T cells showed significant enrichment of the 
double transduced CD8+ Vβ11+ CD4+ T cells with 84.22% (CD8WT), 82.06% 
(CD8L58R), and 78.65% (CD8TglyM) of total cells expressing both the co-receptor 
and the F5-TCR. The observed MFI for F5-TCR expression (as measured by Vβ11+ 
staining) were similar in the three T cell populations (MFI: 581, 529 and 538). The 
sorted cells were also stained pentamer (ASNENDAM/H-2Db). The co-transfer of CD8 
co-receptor with the F5-TCR was shown to enhance pentamer binding compared to 
introduction of F5-TCR alone (MFI: 316, 315, 307 vs 233).  
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Figure 5-8 F5-TCR and CD8 co-receptor expression of transduced CD4+ T cells.  
Mock transduced CD4 T cells (unmodified) were used as controls for gating purposes. The first 
row show that the sorted live lymphocytes were predominantly CD4+ T cells which were gated 
(red circle) and examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each 
column represents a separate condition. 
 
Figure 5-9 F5-TCR and CD8 co-receptor expression of transduced CD4+ T cell 
populations was similar between CD8 wild-type and mutants.  
The sorted live lymphocytes from Fig 5-8 were examined for expression of CD8, TCR (Vβ11) 
and H2Db/NP pentamer staining on subsequent rows. Each column represents a separate 
condition. 
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5.3.2 In vitro Ag-specific cytokine secretion of transduced CD4+ T 
cells 
Functional avidity of the different transduced T cell populations was compared using 
peptide titration experiments, where the target cells were peptide loaded syngeneic 
splenocytes. The double transduced CD4+ T cells enriched for CD8α were stimulated 
with congenic splenocytes loaded with a range of NP peptide concentration from 1  
μM to 100pM. ‘F5-TCR alone’ transduced CD4+ T cells were included as control.  
After overnight incubation, supernatant was analysed for IL-2 and IFN-γ by ELISA 
(Fig 5-10 and 5-11). F5-TCR-td CD4+ T cells without CD8 molecules produced little 
IL-2 or IFN-γ to splenocytes pulsed with the different NP peptides concentrations. 
CD4+ T cells transduced with CD8 (L58R) produced more IL-2 than those transduced 
with CD8 (WT), especially at lower NP peptide concentrations, but there was little 
difference in IFN-γ secretion. The CD4+ T cells transduced with CD8 (TglyM) 
produced less IL-2 and IFN-γ than those with CD8 (WT). 
Recognition of tumour cells endogenously expressing cognate antigen was tested by 
stimulation of the transduced CD4+ T cells with EL4NP target or EL4 control tumour 
cells. ‘F5-TCR alone’ transduced CD4+ T cells were included as a control. After 
overnight incubation, supernatant was removed and analysed for IL-2 and IFN-γ by 
ELISA (Fig 5-12 and 5-13). CD4+ T cells transduced with CD8 (L58R) had 
significantly higher Ag-specific IL-2 production than those transduced with CD8 (WT) 
(62.67 vs 38.84 pg/ml; p=0.0022).  No significant difference in IFN-γ secretion was 
observed. The CD4+ T cells transduced with CD8 (TglyM) produced less IL-2 (32.8 vs 
38.8 pg/ml) and IFN-γ (62.0 vs 159 pg/ml) than those expressing CD8 (WT). 
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Figure 5-10 In vitro IFN-γ functional avidity of F5-TCR and CD8 transduced CD4+ T 
cells was higher in CD8 L58R compared to CD8 WT and TglyM.   
CD4+ T cells, transduced with F5-TCR and CD8 vectors containing CD8β wild-type (WT), L58R 
or TglyM mutations were incubated with splenocytes loaded with different concentrations of 
relevant NP peptide or irrelevant SV9 peptide and supernatant examined for IL-2 secretion was 
measured by ELISA. This result is representative of at least two independent experiments. 
 
Figure 5-11 In vitro IL-2 functional avidity of F5-TCR and CD8 co-receptor T cells was 
similar between CD8 wildtype and mutants.   
CD4+ T cells, transduced with F5-TCR and CD8 vectors containing CD8β wild-type (WT), L58R 
or TglyM mutations were incubated with splenocytes loaded with different concentrations of 
relevant NP peptide or irrelevant SV9 peptide and supernatant examined for IFN-γ secretion 
was measured by ELISA. This result is representative of at least two independent experiments. 
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Figure 5-12 Ag-specific IL-2 production by F5-TCR transduced CD4+ T cells was 
highest in CD8 L58R compared to CD8 wild-type and TglyM against EL4NP tumour 
cells expressing endogenously processed NP peptide.  
CD4+ T cells transduced with F5-TCR and CD8 vectors containing CD8β wild-type (WT), L58R 
or TglyM mutations were incubated with EL4NP target or EL4 control tumour cells for 16 hours 
and supernatant examined for IL-2 secretion was measured by ELISA. This result is 
representative of at least two independent experiments. (*** p <0.005). 
 
Figure 5-13 Ag-specific IL-2 production by F5-TCR transduced CD4+ T cells was 
highest in CD8 L58R compared to CD8 wild-type and TglyM against EL4NP tumour 
cells expressing endogenously processed NP peptide.  
CD4+ T cells transduced with F5-TCR and CD8 vectors containing CD8β wild-type (WT), L58R 
or TglyM mutations were incubated with EL4NP target or EL4 control tumour cells for 16 hours 
and supernatant examined for IFN-γ secretion was measured by ELISA. This result is 
representative of at least two independent experiments. (*** p <0.005). 
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Intracellular cytokine staining (ICS) was also performed to determine the proportion 
of F5-TCR-td CD4+ T cells co-transduced with CD8 (WT), CD8 (L58R) or CD8 (TglyM) 
that produce Ag-specific responses to EL4NP or EL4 tumour cells. The set up was 
similar to the ELISA assay except that the cells were incubated for a shorter 6 hours 
before permeabilisation and fixation (Section 2.5.4). ICS demonstrated that only the 
CD8+ Vβ11+ double-transduced CD4+ T cells displayed Ag-specific production of IL-
2 and IFN-γ and up-regulation of CD40L. Transduced CD4+ T cells expressing CD8 
(L58R) compared with CD8 (WT) had greater Ag-specific production of IL-2 (27.79% 
vs 18.69%) and IFN-γ (3.51% vs 2.97%) and enhanced up-regulation of CD40L 
(63.42% vs 53.17%). Although ‘F5-TCR alone’ transduced CD4+ T cells produced 
poor Ag-specific IFN-γ (0.49%) and IL-2 (0.49%), the up-regulation of CD40L was 
more obvious (41.74%). 
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Figure 5-14 In vitro Ag-specific intracellular IFN-γ and IL-2 production by F5-TCR 
transduced CD4+ T cells production was highest in CD8 L58R compared to CD8 wild-
type and TglyM against EL4NP tumour cells expressing endogenously processed NP 
peptide.  
Intracellular cytokine staining was performed after incubation of transduced CD4+T cells with 
EL4NP (red line) target or EL4 control (grey line) tumour cells for 6 hours. Conditions of 
untransduced (Vβ11-/CD8α-) (first column red square) or F5-TCR alone (Vβ11+) (second 
column red square) or double transduced (Vβ11+/CD8α+) (third/fourth column red square) 
CD4+ T cells were gated and analysed for IFN-γ and IL-2 production in subsequent rows. This 
result is representative of at least two independent experiments. 
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5.3.3 In-vitro cytotoxicity of F5-TCR and CD8 co-receptor transduced 
CD4+ T cells 
Transgenic and transduced CD4+ T cells had been shown by others to target tumour 
cells through direct cytotoxicity (Section 1.5.2). In vitro cytotoxicity experiments 
were performed to compare the ability of the F5-TCR and CD8 co-receptor 
transduced CD4+ T cells to kill tumour cells. CD4+ T cells enriched for CD8α were 
incubated with chromium labelled EL4NP target tumour cells. ‘F5-TCR alone’ 
transduced CD4+ T cells were included as a control. The cells were incubated for four 
hours and supernatant removed to determine the amount of chromium released. 
Without CD8 molecules, F5-TCR-td CD4+ T cells induced tumour lysis only at the 
highest 50:1 effector/target (E:T) ratio. The expression of CD8 co-receptor improved 
cytotoxicity, but this was markedly reduced to that observed with with F5-TCR CD8+ 
T cells, which were known to induce tumour lysis of >50% at E:T ratio of 50:1 
(McNicol et al. 2007). No differences in cytotoxicity were observed with the different 
transduced CD4+ T cell populations. 
 
 
Figure 5-15 In vitro cytotoxicity of F5-TCR and CD8 transduced CD4+ T cells was 
similar between CD8 WT and L58R or TglyM mutants.  
Sorted transduced CD4+ T cells shown in Fig 5-9 (transduction efficiency >78%) were 
incubated with 51Cr loaded EL4NP tumour cells for 16 hours and supernatant examined for 
using a gamma counter. Each condition was replicated six times. 
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5.4 In-vitro characterisation of human CD4+ T cells following 
transduction of CMV-TCR and CD8 co-receptor 
5.4.1 Cell surface expression of human CD4+ T cells following 
transduction with CMV-TCR and CD8 co-receptor 
HLA-A2+ human peripheral blood mononuclear cells (PBMC) were enriched for CD4+ 
T cells (Section 2.3.2.3) then transduced with CMV-TCR and CD8αβ molecules 
containing CD8β wild-type (WT) or CD8β mutations (I59R). The human CD8β I59R 
mutation is homologous to the murine CD8β L58R mutation. Transduction was 
performed using the CMV-TCR-CD8 pMP71 vector which is a quad-cistronic vector 
previously produced by Dr S Xue and Dr S Ghorasian (Section 3.2). PCR mutagenesis 
was performed to introduce the CD8β I59R mutation as described previously for the 
generation of murine CD8β mutations but using human CD8β specific primers. FACS 
analysis three days after transduction (Fig 5-16) showed that the transduced CD4+ T 
cells expressed CMV-TCR as detected by antibodies to murine Cβ (constant region of 
the beta chain), CD8α and CD8β. The expression of CD8α molecules was proportional 
to the CD8β molecules indicating heterodimer formation. The CD8α expression by 
MFI was higher in the CD8β (WT) transduced than the CD8 (I59R) transduced T cells 
(MFI: 1479 vs 1057) but the CD8β expression was similar between the two 
conditions (MFI: 223 vs 215).  
Re-stimulation with irradiated pp65 peptide loaded T2 cells and syngeneic PBMC 
feeder cells enhanced the enrichment of CMV-TCR-CD8 transduced CD4+ T cells. 
After one round of re-stimulation approximately 40% of the cells were CMV-TCR 
positive by staining for murine-Cβ (Fig 5-17) and following two rounds of re-
stimulation around 80% of the cells were CMV-TCR positive by staining for murine-Cβ 
(Fig 5-18). At this stage, the expression level of the CMV-TCR was similar in the two 
transduced populations (MFI: 64 vs 72). The CD8α expression remained higher in the 
CD8 (WT) transduced T cells than the CD8 (I59R) transduced T cells (MFI: 1145 vs 
733). 
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Figure 5-16 TCR and CD8 expression of human CD4+ T cells following transduction 
with the CMV-TCR-CD8 vector containing CD8β wild-type or I59R mutation.  
Mock-transduced CD4+ T cells (unmodified) were used as controls for gating purposes. The 
first row show that the sorted live lymphocytes were predominantly CD4+ T cells which were 
gated (red circle) and examined for expression of CD8 of TCR (using murine TCR constant-β 
chain staining) expression on subsequent rows. Each column represents a separate condition. 
 
Figure 5-17 FACS analysis of CMV-TCR and CD8 transduced human CD4+ T cells after 
one re-stimulation show enrichment of TCR expressing cells.  
Mock-transduced CD4+ T cells (unmodified) were used as controls for gating purposes. The 
first row show that the sorted live lymphocytes were predominantly CD4+ T cells which were 
gated (red circle) and examined for expression of CD8 and TCR (using murine TCR constant-β 
chain staining) on subsequent rows. Each column represents a separate condition. 
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Figure 5-18 FACS analysis of CMV-TCR and CD8 transduced human CD4+ T cells after 
two re-stimulations show further enrichment of TCR expressing cells.  
Mock-transduced CD4+ T cells (unmodified) were used as controls for gating purposes. The 
first row show that the sorted live lymphocytes were predominantly CD4+ T cells which were 
gated (red circle) and examined for expression of CD8 and TCR (using murine TCR constant-β 
chain staining) on subsequent rows. Each column represents a separate condition. 
 
5.4.2 In-vitro Ag-specific cytokine secretion of transduced human 
CD4+ T cells 
Functional avidity of the different transduced human CD4+ T cell populations were 
compared using peptide titration experiments, where the target cells were peptide 
loaded T2 cells. The re-stimulated CMV-TCR-td CD4+ T cells with CD8 (WT) or CD8 
(I59R) were incubated with peptide loaded T2 cells in triplicates. The T2 cells were 
loaded with a range of CMVpp65 peptide concentrations from 100 nM to 10 nM. After 
overnight incubation, supernatant was analysed for IL-2 and IFN-γ by ELISA (Fig 5-
19 and 5-20). CD4+ T cells transduced with CD8 (I59R) produced higher 
concentrations of IL-2 between 100 pM and 1 nM concentration but at higher peptide 
loading concentrations IL-2 production was similar to T cells transduced with the CD8 
(WT). No difference in IFN-γ production was observed. 
Recognition of tumour cells endogenously expressing cognate antigen was tested by 
incubating the restimulated CD4+ T cells with KA2 tumour cells transfected with 
pp65 (KA2pp65) or KA2 without pp65 (KA2). After overnight incubation, supernatant 
was analysed for IL-2 and IFN-γ by ELISA (Fig 5-21 and 5-22). No significant 
differences were observed between the CD8 (WT) or CD8 (I59R) transduced CD4+ T 
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cells with respect to Ag-specific IL-2 (655 vs 715 pg/ml; p=0.700) or IFN-γ 
responses (1850 vs 1673 pg/ml; p=0.658). 
 
 
Figure 5-19 In vitro functional avidity of CMV-TCR and CD8 transduced human CD4+ 
T cells was similar between CD8 wild-type and I59R mutant.  
CD4+ T cells, transduced with CMV-TCR-CD8 vector containing CD8β wild-type (WT) or I59R 
mutation were incubated with T2 cells loaded with different concentrations of relevant pp65 
peptide or irrelevant (SV9) peptide. IL-2 secretion was measured by ELISA. This is a 
representative result of at least two independent experiments from two different human 
donors. 
 
 
Figure 5-20 In vitro functional avidity of CMV-TCR and CD8 transduced human CD4+ 
T cells was similar between CD8 wild-type and I59R mutant.  
CD4+ T cells, transduced with CMV-TCR-CD8 vector containing CD8β wild-type (WT) or I59R 
mutation were incubated with T2 cells loaded with different concentrations of relevant pp65 
peptide or irrelevant (SV9) peptide. IFN-γ secretion was measured by ELISA. Shown is a 
representative result of at least two independent experiments from two different human 
donors. 
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Figure 5-21 Recognition of KA2pp65 tumour cells expressing endogenously 
processed pp65 peptide induce IL-2 production by transduced CD4+ T cells was 
similar between CD8 wild-type and I59R mutant.  
CD4+ T cells, transduced with CMV-TCR-CD8 vector containing CD8β wild-type (WT) or I59R 
mutation were incubated with KA2pp65 target or KA2 control tumour cells. IL-2 secretion was 
measured by ELISA. Shown is a representative result of at least two independent experiments 
from two different human donors. 
 
Figure 5-22 Recognition of KA2pp65 tumour cells expressing endogenously 
processed pp65 peptide induce IFN-γ production by transduced CD4+ T cells was 
similar between CD8 wild-type and I59R mutant.  
CD4+ T cells, transduced with CMV-TCR-CD8 vector containing CD8β wild-type (WT) or I59R 
mutation were incubated with KA2pp65 target or KA2 control tumour cells. IFN-γ secretion was 
measured by ELISA. Shown is a representative result of at least two independent experiments 
from two different human donors. 
 
Intracellular cytokine staining (ICS) was also performed to determine the proportion 
of CMV-TCR-td CD4+ T cells co-transduced with CD8 (WT) or CD8 (I59R) that 
produced Ag-specific responses to KA2pp65 or KA2 tumour cells (Fig 5-23). The set 
up was similar to the ELISA assay except that the cells were incubated for a shorter 6 
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hours before permeabilisation and fixation (Section 2.5.4). The transduced CD4+ T 
cells were identified by gating on CD8+ transduced CD4+ T cells. The CD4+ T cells 
transduced with CMV-TCR-CD8 (WT) compared to CMV-TCR-CD8 (I59R) vectors had 
similar levels of Ag-specific IL-2 (18.23% vs 17.13%) and IFN-γ (46.33% vs 
44.01%) secretion. 
 
Figure 5-23 Recognition of KA2pp65 tumour cells induce IL-2 and IFN-γ production 
by transduced CD4+ T-cells was similar between CD8 wild-type and I59R mutant.  
Intracellular cytokine staining assay using human CD4+ T cells transduced with CMV-TCR-CD8 
vector containing CD8β wild-type (WT) or I59R mutation following incubation with KA2pp65 
target or KA2 control tumour cells for 6 hours. Transduced CD4+ T cells were gated (red 
circles) and analysed for IL-2 and IFN-γ production in respective columns. This result is 
representative of at least two independent experiments. This is a representative result of at 
least two independent experiments. 
 
5.5 Summary 
This chapter has described the effects of co-transfer of the wild-type CD8 co-receptor 
or CD8 co-receptors containing mutations into wild-type murine CD8+ T cells and 
CD4+ T cells. In the previous chapter, an augmenting CD8β L58R mutation and a 
diminishing CD8β TglyM were identified using functional assays performed with 
transduced CD8β-/- CD8+ T cells. These two mutations were chosen for further 
testing in wild-type CD8+ T cells and CD4+ T cells. 
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Perhaps it was not surprising that in F5-TCR transduced CD8+ T cells the introduction 
of CD8β L58R mutation did not further enhance Ag-specific IFN-γ or IL-2 production 
over CD8β wild-type. This was probably due to the presence of endogenous CD8 
molecules minimizing the effects of additional CD8β co-receptor expression at the cell 
surface alongside the introduced TCR. 
In F5-TCR transduced CD4+ T cells, the addition of the CD8 co-receptor significantly 
enhanced the Ag-specific IL-2 and IFN-γ production and this was further augmented 
by introducing the L58R mutation into the CD8 molecule. (Fig 5-10 to 5-14). The 
degree of augmentation in CD4+ T cells was much smaller than that observed in 
CD8β-/- CD8+ T cells and the degree of augmentation was only significant for the IL-
2 cytokine after T cell stimulation with EL4NP tumour cells. In CD4+ T cells the 
expression of CD8β was limited by CD8α expression as transduction was performed 
using the CD8α-IRES-CD8β pMX vector. This was unlike the situation with the CD8β-
/- T cells, with endogenous CD8α, in which the CD8β-pMP71 vector was used.  The 
more obvious augmentation of IL-2 secretion compared to IFN-γ may be related to 
CD4+ T cells naturally favouring IL-2 to IFN-γ production. Lastly, the EL4NP cells 
were more potent at inducing Ag-specific responses than peptide loaded splenocytes, 
this may have been because of the greater surface expression of cognate antigen. 
The in-vivo effect of co-expression of CD8 (L58R) in TCR-transduced CD4+ T cells 
described in the following chapter (Chapter 6).                                                                                                                                                                                                                                    
Lastly, utilizing the CD8 co-receptor with MHCI restricted TCR in human CD4+ T cells 
has also been explored by other members of the laboratory. Dr S Xue had showed 
that CMV-TCR and CD8 co-transduced CD4+ T cells function better than ‘CMV-TCR 
alone’ transduced CD4+ T cells. As the human and murine CD8 molecules are 
conserved the homologous mutation in the human CD8 co-receptor I59R was 
hypothesized to also be augmenting with respect to Ag-specific function. However 
experiments failed to show any enhancing properties using the CD8 I59R mutation 
(Fig 5-19 to Fig-23). This may be because the I59R mutation does not enhance MHCI 
binding due to differences between the human MHCI and the mouse MHCI, which 
were not explored here. 
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Chapter 6. In-vivo work 
6.1 Introduction 
The in-vitro functional analysis of CD4+ T cells transduced with MHCI restricted F5-
TCR demonstrated improved function after the CD8 co-receptor was introduced. The 
CD4+ T cells co-transduced with both F5-TCR and CD8 co-receptor produced both IL-
2 and IFN-γ and had direct cytotoxic effects on EL4 tumour cells expressing the 
cognate peptide (EL4NP). Recent studies using transgenic murine CD4+ T cells (Xie 
et al. 2010; Quezada et al. 2010) and human CD4+ T cell clones (Hunder et al. 
2008) have shown that adoptively transferred CD4+ T cells were able to eradicate 
tumour in-vivo through granzyme and IFN-γ production.  
Although a few groups recently showed that CD4+ T cells transduced with TCR can 
eradicate tumours without requiring the addition of anti-tumour CD8+ T cells 
(Frankel et al. 2010; Kerkar et al. 2011; Soto et al. 2012), this required the use of a 
MHCII restricted TCR or a CD8 independent MHCI restricted TCR. In the situation 
where CD4+ T cells are transduced with a CD8 dependent TCR such as the F5-TCR, 
the addition of  anti-tumour CD8+ T cells was required to induce tumour protection 
(Morris et al. 2005). As the CD8 co-receptor had augmented the in vitro cytokine 
production of F5-TCR transduced CD4+ T cells, the CD8 co-receptor may also 
augment the ability of F5-TCR co-transduced CD4 T cells to provide tumour 
protection.   
6.2 Tumour protection with CD4+ T cells transduced with F5-
TCR and CD8 co-receptor. 
A schematic diagram of the in vivo experiment used is shown in Fig 6-1. To 
differentiate transferred T cells from endogenous T cells, transduced cells were taken 
from thy1.1+ C57Bl/6 mice and transferred into thy1.2 C57Bl/6 mice. Thy1.1 is 
found in T cells and commonly used as a congenic marker in cell transfer 
experiments. C57Bl/6 mice were sub-lethally irradiated (5.5 Gy) in order to improve 
engraftment and expansion of transferred thy1.1+ CD4+ T cells. Mice were injected 
with one million EL4NP tumour cells subcutaneously in the left flank. This dose of 
tumour cells was sufficient to induce 100% fatality in untreated mice (data from 
EL4NP tumour titration experiments performed by Dr E Nicholson). Mice challenged 
with EL4NP tumour were given different doses of CD4+ T cells transduced with F5-
TCR and CD8 co-receptor by intravenous injection through a tail vein. This tested 
migration of transferred CD4+ T cells through the systemic circulation to the tumour 
site in the skin. Three T cell doses were chosen based on previous experiments from 
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5x103 to 5x105 transduced CD4+ T cells. The control mice were given 5x105 mock 
transduced CD4+ T cells. In this pilot study there were two mice per group. Tumour 
progression was monitored using direct measurement and when the tumour size was 
beyond 16mm or ulcerated the mice were culled. Surviving mice were examined for 
the persistence of the transferred CD4+ T cells using a congenic marker thy1.1.  
 
Figure 6-1 Schematic representation of the in-vivo model used to assess the ability 
of different doses of CD4+ T cells transduced with both F5-TCR and CD8 co-receptor 
to eradicate EL4NP tumour and persist.  
Mice were sublethally irradiated (yellow sign) before injected with EL4NP tumour cells 
transduced with luciferase (EL4NPluc) followed by mock or different amounts of transduced 
CD4+ T cells into the tail vein. The time line is coloured orange. 
 
6.2.1 Characterization of transferred transduced CD4+ T cells 
Splenocytes taken from female thy1.1+ C57Bl/6 mice were enriched for CD4+ T cells 
then transduced with F5-TCR and CD8 molecules using separate vectors as described 
in Section 5.3.1. The population with high level CD8 co-receptor expression was 
enriched using anti-CD8α-APC antibodies and anti-APC microbeads. FACS analysis 
(Fig 6-2) of the CD8α CD4+ T cells following FACS sort showed enrichment of CD8+ 
CD4+ T cells, where >85% of CD4+ T cells expressed CD8α, with 38.6% of these 
also expressing Vβ11. The expression of CD8α molecules was proportional to the 
CD8β molecules, indicating heterodimer formation.  
Day 0: Sublethally irradiated C57Bl/6
(thy1.2+) mice with 5.5Gy.
Day 0 + 6hr: Inject 1x106 EL4NPluc+
tumour cells subcutaneously on right
flank
Day 1: Inject thy1.1+ CD4+ T-cells into tail vein
1. CD4 Mock 5x105 cells
2. CD4 F5-TCR + CD8 5x105 cells
3. CD4 F5-TCR + CD8 5x104 cells
4. CD4 F5-TCR + CD8 5x103 cells
Each group n=2
Monitor tumour size
Cull mice if tumour 
>16mm in any diameter
D120: Take down mice
and analyse lymph
nodes, spleen and bone
marrow
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Figure 6-2 FACS analysis of CD8α sorted thy1.1+ CD4+ T cells transduced with F5-
TCR and CD8 co-receptor.  
Mock transduced CD4+ T cells were used for control. The first row show that the sorted live 
lymphocytes were predominantly CD4+ T cells which were gated (fine black line) and 
examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents 
a separate condition. 
 
6.2.2 Identification of adoptively transferred CD4+ T cells  
Two weeks post T cell transfer, the persistence of transferred CD4+ T cells in the 
tumour bearing mice was confirmed by analysis of peripheral blood (Section 2.6.3.3). 
Transferred thy1.1+ CD4+ T cells were detected in all eight mice (Fig 6-3). At this 
time point, the transferred thy1.1+ transduced CD4+ T cells accounted for a greater 
proportion of live lymphocytes than thy1.1+ mock transduced CD4+ T cells (23.21% 
and 27.58% vs 5.84% and 4.59%) suggesting a potential survival advantage of 
transduced CD4+ T cells. The number of transduced CD4+ T cells found in the 
periphery at two weeks was also proportional to the dose transferred. When cell 
surface expression of the transduced CD8 and F5-TCR molecules were assessed in 
mice receiving the higher two doses of CD4+ T cells, down regulation of the CD8 co-
receptor was observed with between 7.9% and 16.1% of the thy1.1+ CD4+ T cells 
still expressing the CD8 co-receptor. The F5-TCR expression using Vβ11 staining 
varied between 16.5% and 52.0%. 
CD8α
CD8β
CD4
CD8β
CD8α
Vβ11
CD4 Mock CD4 F5-TCR
+CD8 (WT)
Pre-transfer
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Figure 6-3 FACS analysis of peripheral bloood at D14 post transfer confirming the 
presence of transduced CD4+ T cells .  
Mock transduced CD4+ T cells were used as control for gating purposes. The first row show 
the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and examined for 
expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents a separate 
condition. 
Mouse 1
CD4 Mock 
5x105 cells
Mouse 2
CD4 Mock 
5x105 cells
Mouse 3
CD4 F5+CD8 
5x105 cells
Mouse 4
CD4 F5+CD8 
5x105 cells
CD4
Thy1.1
CD8α
CD8β
CD8α
Vβ11
Day 14- tail bleed
Mouse 5
CD4 F5+CD8 
5x104 cells
Mouse 6
CD4 F5+CD8 
5x104 cells
Mouse 7
CD4 F5+CD8 
5x103 cells
Mouse 8
CD4 F5+CD8 
5x103 cells
CD4
Thy1.1
CD8α
CD8β
CD8α
Vβ11
Day 14- tail bleed
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6.2.3 Tumour protection and survival 
Tumour bearing mice were monitored at regular time intervals. The tumour mass 
was measurable from one week after injection.  Mice receiving mock transduced 
CD4+ T cells had uncontrolled tumour growth with frequent ulceration. In addition, 
after two weeks these mice developed signs of distress and were culled. Mice 
receiving the lowest dose of transduced CD4+ T cells had uncontrolled tumour 
growth similar to mice receiving mock transduced CD4+ T cells (Fig 6-4). Mice 
receiving the highest dose of transduced CD4+ T cells had tumour protection 
evidenced by slower growth from day seven and subsequent tumour regression and 
undetectable tumour by day 38 (Fig 6-4). Of the two mice given the intermediate 
dose of transduced CD4+ T cells, one had uncontrolled tumour growth but the other 
developed significant tumour burden before tumour regression at a slower rate with 
undetectable tumour around day 42. Therefore a dose dependent effect was 
observed in mice receiving transduced CD4+ T cells where the highest dose (5x105 
cells) resulted in rapid and sustained tumour control and the lower doses (5x104 and 
5x103) resulted in poorer tumour control and reduced survival (Fig 6-5). Of the three 
mice protected from tumour, no recurrence was observed even after 120 days of 
monitoring (Fig 6-5). Therefore the threshold for tumour protection may be around 
5x104 CD4+ T cells transduced with CD8 co-receptor and F5-TCR, which would need 
to be confirmed with experiments including larger groups of animals. 
 
Figure 6-4 Titration experiment showing in vivo tumour protection is achieved by 
transferring as few as 5x104 transduced CD4+ T cells into tumour bearing mice.  
Different amounts of transduced CD4+ T cells shown in Section 6.2.1 were transferred into 
tumour bearing mice. Coloured lines representing shown indicate tumour volume recorded in 
individual mice at various time points (days). 
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Figure 6-5 Survival curve showing in vivo tumour protection is achieved by 
transferring as few as 5x104 transduced CD4+ T cells into tumour bearing mice. 
Different amounts of transduced CD4+ T cells shown in Section 6.2.1 were transferred into 
tumour bearing mice. Coloured lines show the percentage survival in each condition of two 
mice given the same amount of transduced CD4+ T cells. 
6.2.4 Persistence of transferred CD4+ T cells in surviving mice 
The three surviving mice were monitored for a total of 120 days after T cell transfer. 
After eradication of the primary tumour, the mice remained tumour-free for more 
than 60 days. To determine if transferred transduced CD4+ T cells persisted, the 
lymphoid organs spleen (spl), lymph node (LN) and bone marrow (BM) were 
examined at the end of the monitoring period. Thy1.1+ CD4+ T cells were found in 
all three lymphoid niches of all three mice (Fig 6-6 to 6-8). The two surviving mice 
given the highest dose of transduced CD4+ T cells had higher proportions of thy1.1 
CD4+ T cells than the animal given the lower dose: spl 0.67%, 0.52% vs 0.09%, LN 
0.33%, 0.41% vs 0.16%; BM 0.79%, 0.92% vs 0.09%.  
To examine for cell surface expression of the transduced TCR and co-receptor 
together with the phenotype of persisting transduced cells, bulk cells taken from the 
lymphoid organs were stained for thy1.1, CD4, CD8α, CD8β, Vβ11, CD44 and CD62L. 
As there were no surviving mice given mock transduced thy1.1+ CD4+ T cells, the 
endogenous thy1.1neg CD4+ T cells were used to set the gates for the FACS 
analyses as shown in Fig 6-9 to 6-11. The majority of persisting transferred thy1.1+ 
CD4+ T cells expressed Vβ11+ suggesting a preferential survival advantage of F5-
TCR transduced cells (Fig 6-6 to 6-8). There were two distinct Vβ11+ populations in 
the transferred thy1.1+ CD4+ T cells, the smaller Vβ11hi population, which may be 
related to the small population of CD4+ T cells that constitutively express Vβ11 (ie, 
endogenous Vβ11+ cells in the transduced population) which was of a similar level to 
endogenous thy1.1neg Vβ11+ CD4+ or CD8+ T cells as shown in Figure 6-9 to 6-11. 
Significant down regulation of transduced CD8 co-receptor was observed with fewer 
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than 50% of the transferred thy1.1+ CD4+ T cells expressing CD8 at this time point. 
The level of expression of CD8 co-receptor on the transduced thy1.1+ CD4+ T cells 
was lower than the CD8 expression observed on endogenous thy1.1neg CD8+ CD4+ 
T cells. This was most evident from the intensity of CD8α staining in lymph node cells 
(MFI 88 vs 152). 
Finally, the transferred thy1.1+ CD4+ T cells mostly (>80%) expressed the memory 
marker CD44 indicating exposure to antigen. The majority of persisting thy1.1+ 
CD4+ T cells had the effector memory CD44+ CD62Lneg phenotype (~70-80%) 
while the remainder were of the central memory CD44+ CD62L+ phenotype (Fig 6-6 
to 6-8). The lymph nodes contained the greatest proportion of transferred CD4+ T 
cells with the central memory phenotype (26%-37%).  
 
Figure 6-6 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken 
from spleen 120 days after adoptive transfer.  
The first row show the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
Mouse 5
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Mouse 3
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Mouse 4
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Figure 6-7 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken 
from lymph nodes 120 days after transfer.  
The first row show the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
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Figure 6-8 Ex vivo phenotypic analysis of CD4+ thy1.1+ (transferred) cells taken 
from bone marrow 120 days after transfer.  
The first row show the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
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Figure 6-9 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken 
from spleen 120 days after transfer.  
The first row show the gating of endogenous CD4+ T cells that were thy1.1neg (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
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Figure 6-10 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken 
from lymph nodes 120 days after transfer.  
The first row show the gating of endogenous CD4+ T cells that were thy1.1neg (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
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Figure 6-11 Ex vivo phenotypic analysis of CD4+ thy1.1neg (endogenous) cells taken 
from bone marrow 120 days after transfer.  
The first row show the gating of endogenous CD4+ T cells that were thy1.1neg (red circle) and 
examined for expression of CD8 and TCR (Vβ11) as well as memory markers CD44 and CD62L 
on subsequent rows. Each column represents a separate mouse. 
 
6.3 In vivo tumour protection following adoptive transfer of 
transduced CD4+ T cells  
With the knowledge that transduced CD4+ T cells have the potential to eradicate 
tumour in an antigen specific manner and persist indefinitely, the subsequent in-vivo 
experiment was designed to compare F5-TCR transduced CD4+ T cells with or 
without CD8 co-receptor and also to compare the effects of CD8 co-receptor 
containing CD8β wild-type (WT) or CD8β containing the L58R mutation. The model 
used to study this is shown in a schematic diagram (Fig 6-12). As in the preliminary 
in vivo experiment described above, C57Bl/6 mice were sublethally irradiated with 
5.5 Gy in order to enhance engraftment and expansion of transferred CD4+ T cells. 
Mice were injected with one million EL4NP tumour cells expressing luciferase (EL4luc) 
subcutaneously in the left flank. Mice challenged with EL4NP tumour were given 
1x105 F5-TCR transduced CD4+ T cells with or without CD8 co-receptor by 
intravenous injection through a tail vein. This sub-therapeutic dose of transduced 
CD4+ T cells was chosen in order to compare the efficacy of CD8 co-receptor 
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containing the CD8β WT or CD8β L58R. The control mice received tumour followed by 
1x105 mock transduced CD4+ T cells. Tumour progression was monitored using 
direct measurement and detection of bioluminescence. When the tumour size was 
beyond 16mm or had ulcerated mice were culled. Surviving mice were re-challenged 
with irradiated EL4NP tumour cells and then culled five days later in order to study 
recall responses. Each of the two in-vivo tumour protection experiments had a total 
of 18 mice (ie, 36 mice in total).  Each group of mice were housed in the same cage 
and ear tagged for identification. 
 
Figure 6-12 Schematic representation of the experimental model used to compare 
the ability of F5-TCR transduced CD4+ T cells with or without CD8 co-receptor to 
eradicate EL4NP tumour, persist and respond to Ag re-challenge.  
Mice were sublethally irradiated (yellow sign) before injected with EL4NP tumour cells 
transduced with luciferase (EL4NPluc) followed by mock or different types of transduced CD4+ 
T cells into the tail vein. The time line is coloured orange. Two independent experiments were 
performed. 
6.3.1 Characterization of transferred transduced CD4+ T cells  
Splenocytes taken from female thy1.1+ C57Bl/6 mice were enriched for CD4+ T cells 
and transduced with F5-TCR alone or with the CD8 co-receptor containing CD8β WT 
or CD8β L58R using separate vectors as described in Section 5.3.1. The CD8 
transduced populations were enriched using anti-CD8α-APC antibodies and anti-APC 
microbeads. FACS analysis of CD4+ T cells (Fig 6-13) post sorting showed 
enrichment of CD8+ CD4+ T cells of (>80% of CD4+ T cells) and enrichment for 
Vβ11 expression in the CD8 WT and CD8 L58R transduced populations (both 51%). 
Day 0: Sublethally irradiated C57Bl/6
(thy1.2+) mice with 5.5Gy.
Day 0 +6hr: Inject 1x106 EL4NPluc
tumour cells (sc) on right flank
Day 1: Inject thy1.1+ CD4+ T-cells into tail vein
1. CD4 Mock 1x105 cells n=3
2. CD4 F5-TCR 1x105 cells n=5
3. CD4 F5-TCR + CD8 (WT) 1x105 cells n=5
4. CD4 F5-TCR + CD8 (L58R) 1x105 cells n=5
Monitor tumour size
Cull mice if tumour 
>16mm in any diameter
D95: Cull mice
and analyse
lymph nodes
D90: Rechallenge
surviving mice with
irradiated 1x10^6
EL4NP (sc) on
right flank
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The expression of CD8α was proportional to CD8β expression indicating appropriate 
heterodimer formation at the cell surface. Of the adoptively transferred transduced 
CD8+ CD4+ T cells about half of the cells expressed the F5-TCR and were able to 
recognize tumour. 
 
Figure 6-13 FACS analysis of CD8α sorted thy1.1+ CD4+ T cells transduced with F5-
TCR alone or with CD8 co-receptor containing CD8β WT or CD8β L58R.  
Mock transduced CD4+ T cells were used for control. The first row show that the sorted live 
lymphocytes were predominantly CD4+ T cells which were gated (fine black line) and 
examined for expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents 
a separate condition. 
 
6.3.2 Identification of transferred cells  
Two weeks post cell transfer, in vivo persistence of transferred thy1.1+ CD4+ T cells 
was confirmed by analysis of peripheral blood (Section 2.6.3.3). The number of 
transduced thy1.1+ CD4+ T cells identified in the periphery at two weeks was similar 
in all the conditions, range 1-10% (Fig 6-14 to 6-17). Significant down regulation of 
the CD8 co-receptor was seen previously in the CD4+ T cells transduced with the 
CD8 co-receptor. The proportion of cells in the periphery still expressing CD8 co-
receptor was significantly lower in the CD8 WT condition than in the CD8 L58R 
condition (8.5% vs 22.5%; p=0.0252). The F5-TCR expression using Vβ11 antibodies 
range from 27% to 89%. 
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Figure 6-14 FACS analysis of peripheral bloood at D14 post transfer confirming the 
presence of mock transduced CD4+ T cells in all three mice.  
Mock transduced CD4+ T cells were used as control for gating purposes. The first row show 
the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and examined for 
expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents a separate 
condition. 
 
Figure 6-15 FACS analysis of peripheral bloood at D14 post transfer confirming the 
presence of F5-TCR transduced CD4+ T cells in all five mice.  
Mock transduced CD4+ T cells were used as control for gating purposes. The first row show 
the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and examined for 
expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents a separate 
condition. 
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Figure 6-16 FACS analysis of peripheral bloood at D14 post transfer confirming the 
presence of F5-TCR and CD8 co-transduced CD4+ T cells in all five mice.  
Mock transduced CD4+ T cells were used as control for gating purposes. The first row show 
the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and examined for 
expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents a separate 
condition. 
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Figure 6-17 FACS analysis of peripheral bloood at D14 post transfer confirming the 
presence of mock transduced CD4+ T cells in all three mice.  
Mock transduced CD4+ T cells were used as control for gating purposes. The first row show 
the gating of transduced CD4+ T cells marked with thy1.1 (red circle) and examined for 
expression of CD8 and TCR (Vβ11) on subsequent rows. Each column represents a separate 
condition. 
 
6.3.3 Effect of adoptively transferred transduced CD4+ T cells on 
tumour protection and survival 
Tumour bearing mice were monitored at regular time intervals as described above. 
The tumour became evident and could be measured from one week by direct 
measurement (Fig 6-18 and 6-19) or by bioluminescence. The bioluminescence 
produced by EL4NPluc could be visualized through pseudo-colouring of intensity or by 
quantification the photons/s produced from each individual mouse (Fig 6-20 and 6-
21). Mice receiving mock transduced CD4+ T cells had uncontrolled tumour growth 
(Fig 6-18 and 6-20) resulting in ulceration with central necrotic plaques which 
artificially reduced bioluminescence readings. After two weeks even when tumour 
growth diameter did not exceed limits these mice became distressed and were culled. 
Mice receiving F5-TCR-td CD4+ T cells had uncontrolled tumour growth resulting in 
large tumours but the condition of the mice was better than those receiving CD4 
mock transduced CD4+ T cells (Fig 6-18, 6-20 and 6-21). Only 2 out of the 10 mice 
given F5-TCR transduced CD4+ were protected and survived beyond one month. 
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Mice receiving CD4+ T cells transduced with F5-TCR and CD8 co-receptor had slower 
tumour growth rate between day 7 and day 14 before tumour shrinkage from around 
day 21 and eventual tumour eradication. This was evident from both direct tumour 
measurements (Fig 6-18 and 6-19) as well as bioluminescence measurements (Fig 6-
20 and 6-21). Mice receiving CD4+ T cells transduced with the CD8 L58R beta chain 
co-receptor had marginally enhanced tumour protection. The average tumour volume 
at day 21 in the CD8 L58R treated mice was smaller than in the CD8 WT treated mice 
(491mm3 vs 882mm3; p=0.104) as shown in Figure 6-19. In a few mice, two in the 
CD8 WT condition and one in the CD8 L58R condition, there was recurrence of 
tumour after some tumour shrinkage (Fig 6-18). The tumour recurrence may have 
been due to antigen loss resulting in tumour escape as one mice examined had 
thy1.1+ CD4+ T cells that produced IL-2 and IFN-γ to fresh EL4NP tumour cells but 
not to EL4NP tumour cells isolated from the recurrent tumour. This has recently been 
described by our laboratory during the use of F5-TCR transduced CD8+ T cells in 
same EL4NP tumour model (Velica 2012). 
Data was combined from the two independent experiments to generate a survival 
curve. The survival of mice given F5-TCR transduced CD4+ T cells was poor with only 
2/10 surviving. Co-transducing CD8 co-receptor (WT) improved the survival rate to 
5/10 and co-transducing CD8 containing the L58R mutation further improved the 
survival rate to 8/10 (Fig 6-21).  
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Figure 6-18 In vivo tumour protection was superior when F5-TCR/CD8 CD4+ T cells 
compared to F5-TCR CD4+T cells was transferred into tumour bearing mice.  
The results of two independent experiments are shown here with the first (left) and the second 
(right) separated by a vertical line. Each condition received the same 1x105 numbers of mock 
or transduced CD4+ T cells shown in Section 6.3.1. Coloured lines representing shown indicate 
tumour volume recorded in individual mice at various time points (days). 
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Figure 6-19 Control of tumour growth after transfer of F5-TCR transduced CD4+ T 
cells show superior early tumour control when CD8 coreceptor is co-transduced.  
Mean tumour volume measured from day 6 after CD4+T cell transfer. This is pooled data from 
two independent experiments (n=6 for CD4 mock and n=10 for the F5 TCR-td groups). 
 
 
 
Figure 6-20 CD4+ T cells transduced with F5-TCR and CD8 co-receptor reduce 
tumour burden visualised using bioluminescence.  
Visualisation of bioluminescence from EL4NPluc tumour in mice after injection of D-luciferin 
and shown at the indicated time points. Each individual mice from each condition is lined up in 
columns. The bioluminescence is processed using living image 3.2 software and expressed in a 
logarithmic colour scale. One of two independent experiments is shown. 
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Figure 6-21 CD4+ T cells co-transduced with F5-TCR and CD8 co-receptor reduces 
tumour burden based on objective measures using bioluminescence.  
Tumour growth of individual tumour bearing mice from both in-vivo experiments was 
monitored by IVIS-100 bioluminescence camera at the indicated time points. The graph shows 
the bioluminescence signals of individual mice in photons/s expressed on a logarithmic scale. 
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Figure 6-22 CD4+ T cells transduced with F5-TCR and CD8 co-receptor improve 
survival of tumour bearing mice.  
Combined results of two independent experiments n=6 for CD4 mock and n=10 for the F5 
TCR-td groups. For survival analysis curves were analysed by the log-rank test; *, P < 0.05; 
** P < 0.005. 
6.3.4 In vivo Ag-specific re-call responses of adoptively transferred 
transduced CD4+ T cells 
The in vivo persistence of transferred CD4+ T cells for prolonged periods provided an 
opportunity to examine the Ag-specific secondary responses against EL4NP tumour. 
It was noted from the earlier preliminary experiment in section 6.2 that the mouse 
given sub-therapeutic 0.5x105 CD4+ T cells had low numbers of persisting cells in 
the lymph node, spleen and bone marrow even at 120 days post introduction (Fig 6-
6 to 6-8). To determine if the small numbers of persisting transduced CD4+ T cells 
could proliferate on re-encounter with antigen, irradiated EL4NP was injected 
subcutaneously into the right lower leg of the surviving mice from the subsequent in-
vivo experiment (described above in Section 6.3.3). There were different numbers of 
surviving mice from the different groups; the F5-TCR alone group had only two 
surviving mice, the F5-TCR and CD8 (WT) group had five surviving mice and the F5-
TCR and CD8 (L58R) group had eight surviving mice. Five days after re-challenge, 
the mice were culled and lymph nodes analysed for the presence of transferred 
thy1.1+ CD4+ T cells.  
The lymph nodes from the right popliteal and inguinal LN which were the tumour 
draining lymph nodes (TDLN) and the left popliteal and inguinal LN which were the 
non-draining lymph nodes (NDLN) were analyzed separately. FACS analysis 
demonstrated the persistence of transferred thy1.1+ CD4+ T cells, with the majority 
(>50%) of cells expressing Vβ11 (Fig 6-23 and 6-24). Enumeration of the transferred 
thy1.1+ CD4+ from each set of lymph nodes showed that a greater absolute number 
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of thy1.1+ CD4+ T cells were detected in the TDLN than in the NDLN consistent with 
secondary expansion (Fig 6-25). However, the tumour induced proliferation of 
thy1.1+ CD4+ T cells was not significantly different between the different groups of 
transferred thy1.1+ CD4+ T cells (Fig 6-25). In the mice given CD4+ T cells with 
CD8 co-receptor, most of this increase was accounted by CD8+ CD4+ T cells (Fig 6-
26) but no significant difference was observed between CD4+ T cells transduced with 
CD8 WT or CD8 L58R. 
When the memory phenotype of the CD8neg or CD8+ transferred thy1.1+ CD4+ T 
cells from TDLN were compared, it was demonstrated that the CD8+ T cells were 
skewed to a central memory (CD44+ CD62+) phenotype rather than an effector 
(CD44+ CD62neg) phenotype (Fig 6-27 and 6-28).  
 
Figure 6-23 Ex vivo phenotypic analysis of lymphoid cells taken from draining 
(TDLN) with non-draining (NDLN) lymph nodes after Ag re-challenge in mice 
previously treated with thy1.1+ CD4+ CD8(WT) F5-TCR transduced T cells.  
Example FACS plots shown from one surviving animal. Endogenous thy1.1neg CD4+ T cells 
were used as controls for gating purposes. The F5-TCR was detected by anti-Vβ11 antibodies. 
The cells shown were first gated on live lymphocytes and then thy1.1+ CD4+ T cells (red 
circle). CD8α+ (green square) and CD8α- (purple square) Vβ11+ T cells were examined 
separately for memory phenotype using CD44 and CD62L. 
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Figure 6-24 Ex vivo phenotypic analysis of lymphoid cells taken from draining 
(TDLN) with non-draining (NDLN) lymph nodes after Ag re-challenge in mice 
previously treated with thy1.1+ CD4+ CD8 L58R F5-TCR transduced T cells.  
Example FACS plots shown from one surviving animal. Endogenous thy1.1neg CD4+ T cells 
were used as controls for gating purposes. The F5-TCR was detected by anti-Vβ11 antibodies. 
The cells shown were first gated on live lymphocytes and then thy1.1+ CD4+ T cells (red 
circle). CD8α+ (green square) and CD8α- (purple square) Vβ11+ T cells were examined 
separately for memory phenotype using CD44 and CD62L. 
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Figure 6-25 In vivo expansion of transferred thy1.1+ CD4+ T cells in tumour draining 
(TDLN) compared to non-draining (NDLN).  
Surviving mice were re-challenged with irradiated 1 x 106 EL4-NPluc tumour cells injected into 
right lower leg and then culled for analysis 5 days later. The Thy1.1+ CD4+ T cells counts 
taken from the NDLN and TDLN of each individual mouse are linked. 
 
Figure 6-26 Preferential in vivo expansion of CD8+ CD4+ T cells after tumour re-
challenge.  
The fold increase was calculated by dividing the absolute count of the CD8- or CD8+ thy1.1+ 
Vβ11+ CD4+ population in TDLN divided by the absolute count of the same population in 
NDLN. Lines connect the values found in each individual mouse.  
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Figure 6-27 In vivo Ag re-challenge affected the proportion of central memory 
phenotype CD8+ CD4+ T cells isolated from tumour draining lymph nodes (TDLN).  
Values were derived from FACS analysis as shown in Figures 6-23 and 6-24. Lines connect the 
values found from each individual mouse before and after Ag re-challenge.  
 
 
Figure 6-28 In vivo Ag re-challenge affected the proportion of effector memory 
phenotype CD8+ CD4+ T cells in the tumour draining lymph nodes (TDLN).  
Values were derived from FACS analysis as shown in Figures 6-23 and 6-24. Lines connect the 
values found from each individual mouse before and after Ag re-challenge. 
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6.3.5 Summary 
The data presented in this chapter has demonstrated the efficacy of transduced 
CD4+ T cells to target tumour in-vivo. Our previous study showed that F5-TCR-td 
CD4+ T cells without transduced CD8+ T cells could not eradicate tumour and 
transducing CD8α with F5-TCR into CD4+ T cells was actually less effective than 
using F5-TCR alone in tumour eradication, possibly through a mechanism of impaired 
proliferation. However, when the CD8(WT) co-receptor containing the CD8β chain 
was co-transduced with F5-TCR into CD4+ T cells the EL4NP tumour could be 
completely eradicated in mice receiving higher doses of CD4+ T cells. After tumour 
eradication, the transferred CD4+ T cells persisted for at least four months but CD8 
co-receptor down-regulation in these cells was observed.  
Two subsequent independent experiments confirmed that the CD8 co-receptor was 
able to augment the anti-tumour effects of CD4+ T cells transduced with the MHCI 
restricted F5-TCR. The CD4+ T cells transduced with the CD8 L58R co-receptor 
cleared tumour faster and conferred improved survival rates compared to the CD4+ 
T cells transduced with the CD8 WT co-receptor. Although there was significant down 
regulation of CD8 co-receptor in co-transduced CD4+ T-cells, the secondary 
proliferative responses of CD4+ T cells retaining CD8 expression were better than 
those that downregulated CD8 co-receptor. The CD8+ CD4+ T cells also expressed 
more central memory phenotype after tumour re-challenge. There was however no 
detectable qualitative differences between CD8 WT and the CD8 L58R co-receptor 
transduced CD4+ T cells in the secondary responses. 
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Chapter 7. Discussion 
Since the discovery and recognition of immunosurvelliance, various means of 
harnessing the immune system to target cancer have been attempted. However 
these early attempts to boost the immune system through vaccination such as using 
tumour cells with adjuvants were not effective.  One important breakthrough came 
from the use of tumour infiltrating lymphocytes (TIL), which were expanded in-vitro 
following isolation from tumour biopsies and reinfused. However, this form of 
adoptive immunotherapy is limited by the complexity of ex vivo expansion on a per-
patient basis as discussed in Section 1.6.1.  
Gene transfer of TCR or CAR presents an opportunity to redirect large numbers of 
polyclonal T cells to target cancer cells with greater ease. TCR gene transfer relies on 
the isolation of TCR genes from clones of high avidity T cells, which respond to 
cancer in an Ag-specific manner.  
The TCR genes isolated are amenable to genetic modifications such as codon 
optimization, introduction of cysteine residues and the replacement of constant 
regions with murine sequences; all of which have been shown to improve the level of 
TCR expression and promote correct pairing of the introduced TCR. These 
modifications are important as the level of TCR expression influences T cell signalling 
thresholds and may enhance effector function (Hart et al. 2008; van Loenen et al. 
2011). The cloned TCRs used in this project incorporated many of the above 
molecular modifications.  
Attempts to improve the ‘strength’ of TCR artificially by affinity maturation have 
generated TCR that have in excess of 100x increased affinity compared to the 
unmodified TCR. However, in our hands, the affinity matured TCRs when transduced 
into T cells did not result in improved functional avitidy (Thomas et al. 2011). It has 
been proposed that there is a natural ceiling for increasing TCR affinity as natural 
affinity exist within a narrow range (Slifka & Whitton 2001) in order to allow for serial 
triggering when antigen is limited (Valitutti et al. 1995).  
One group modified TCR not by manipulating the antigen-binding residues but 
removing N-glycosylation sites within the TCR constant domain. The rationale for this 
is based on a study in which CD8+ T cells from MGAT5 enzyme deficient mice with 
reduced N-glycosylation have lower threshold for activation (Demetriou et al. 2001). 
To remove N-glycosylation sites, asparagine residues on the TCR constant domains 
were replaced with glutamine by site directed mutagenesis (Kuball et al. 2009a). 
Three TCR with different specificities were modified in this manner and when 
transduced into CD8+ T cells all showed enhanced multimer binding, increased 
functional avidity and improved recognition of tumour cells. Because the non-variable 
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region of the TCR is modified, this approach could potentially be used for TCR of any 
specificity. 
Apart from manipulating TCR structure, the signalling threshold of transduced TCR 
may be improved by changes in the amount or quality of proximal signalling 
molecules. Examples in the literature include the up-regulation of Lck, a natural 
phenomenon associated with increases in functional avidity and maturation of naïve T 
cells after antigen encounter (Slifka & Whitton 2001). Others have modified LAT 
molecules to be resistant to ubiquitination resulting in improvement of T cell 
signalling (Balagopalan et al. 2011).  
Our group tested whether the amount of endogenous CD3 available within the 
transduced T cell was a critical rate limiting step for assembly and expression of the 
introduced TCR. We performed a series of experiments where CD3 molecules were 
transduced together with TCR into CD8+ T cells. We demonstrated enhanced TCR 
expression, increased in vitro Ag-specific cytokine production and improved tumour 
protection in-vivo (Ahmadi et al. 2011). Other molecules involved in proximal 
signalling were therefore investigated, such as the CD8 co-receptor. Unlike the CD3 
molecule, which is required for the expression both MHCI and MHCII restricted TCR, 
the CD8 co-receptor is only crucial for the function of the MHCI restricted TCR.  
To date, most TCR targeting cancer antigens have been isolated from CD8+ T cells. 
It was hypothesized that the co-transfer of additional CD8 co-receptor (especially 
those with ‘augmenting’ mutations) together with the MHCI restricted TCR may 
enhance Ag-specific T cell function further. Many studies have generated specific 
mutations in the CD8 co-receptor to dissect its structure and function. Most of the 
50+ different mutations examined resulted in inferior CD8 co-receptors (Wang et al. 
2009). This may suggest that the wild-type CD8 co-receptor has been optimized 
during evolution and further improvements are not possible. However some anti-CD8 
antibodies have improved the CD8 co-receptor effect on TCR activation possibly by 
optimizing the stability of the CD8 molecule for engagement with MHCI as elaborated 
in Section 1.7. Proof of principle that enhancing the binding affinity between CD8 and 
MHCI could enhance primary T cell responses has been demonstrated by Sewell et al 
(Wooldridge et al. 2007). The three CD8 mutations known to increase multimer 
staining or TCR activation in cell lines are CD8α K73A, CD8β S53L and CD8β L58R, 
the latter two were tested in this project. 
Functional assays of transduced T cells performed in this project focused on in vitro 
measures of T cell avidity and responses against tumour cells expressing the cognate 
antigen. TCR avidity is frequently defined as the responsiveness of T cells to target 
cell expressing cognate antigen (Kuball et al. 2009b; Slifka & Whitton 2001). Both 
IFN-γ and IL-2 production were measured as both Th1 cytokines are known to be 
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important for anti-tumour effects. Proliferation assays were performed but gave 
inconsistent results with the CD8 co-receptor transduced T cells due to high 
background impairing the relevant comparisons. This may have been because the T 
cells had been strongly activated during transduction and low level proliferation 
persisted for several days after activation cues were removed.   
Of the eight CD8β mutants tested in this project, four were MHC-binding site mutants 
previously described in the literature (S53L, S54V, L58R and L58R/I25A) and four 
were glycosylation site mutants, not previously described (T120A, T121A, T124A and 
TglyM). The two mutants found to be augmenting when tested in CD8β -/- T cells 
both contained the MHC-binding site L58R mutation. Expressing the CD8β chain 
containing the L58R mutation increased the maximum magnitude of IFN-γ Ag-
specific responses and peptide sensitivity. These findings were consistent with the 
increase in Ag-specific IL-2 production from transduced BW cells as demonstrated by 
Devine et al. The crystal structure of murine CD8αβ in complex with H2-Db has 
shown that the L58 residue, previously assumed to be the contact residue for MHCI, 
was found instead to be a contact residue for CD8α S108. Thus the L58R substitution 
was thought to enhance the stability of the CD8 co-receptor heterodimer (Wang et 
al. 2009). When tested in the same assays the CD8β containing the S53L mutation 
was not found to augment the Ag-specific function of CD8β-/- T cells, which may 
have been related to its lower expression. The exact reason for the lower CD8β S53L 
expression is not known. The S54V mutated CD8β although found to have increased 
MHC binding affinity, had not been shown to increase Ag-specific responses in this or 
any previous study. Therefore increasing the MHC binding of the CD8 co-receptor 
may not always translate to the augment Ag-specific responses. It is possible that 
the MHC binding mutants may also affect the ability of the CD8 co-receptor to 
associate with the TCR giving rise to this discrepancy. 
Removal of one of three CD8β glycosylation sites did not have an impact on the level 
of CD8β expression in transduced CD8β-/- T cells. However, the triple glycosylation 
site mutant (CD8β TglyM) when transduced into CD8β-/- T cells resulted in reduced 
IFN-γ T cells. This may suggest that removal of more than one O-glycan is required 
to affect the structural stability of the CD8 molecule. There is evidence that the CD8β 
stalk where these O-glycans are located interacts with the TCR connecting peptide 
motif (CPM) but whether the O-glycans directly interact with the CPM motif is 
unknown. The aim with the CD8β O-glycans was to prevent desialylation from 
occurring as the CD8β chain in the desialylated state is associated with improved TCR 
signal transduction (Section 1.4).  This hypothesis was not upheld with our 
experimental data, which may have been because CD8+ or CD4+ T cells when 
activated during the transduction process had already undergone CD8β desialylation.  
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It is possible that the augmenting effects of the CD8β glycosylation site mutants may 
only be seen in naïve T cells where the CD8β chain is typically sialylated. There is 
some evidence that less differentiated T cells may have better anti-tumour efficacy 
and persist better after transfer (Gattinoni et al. 2005; Hinrichs et al. 2009). Various 
strategies could be used to generate less differentiated naïve T cells, for example 
through the use of lentiviral vectors for gene transfer (Zhou et al. 2003; Perro et al. 
2010), through the manipulation of cellular pathways such as the Wnt-β catenin 
pathyway with the GSK kinase inhibitor (TWS119), or by using haemopoietic stem 
cells (HSC) for transduction (Gattinoni et al. 2009; Gattinoni et al. 2011). The CD8β 
glycosylation site mutants may be more useful in this setting.   
The CD8β L58R augmenting mutant when transduced into CD8+ T cells did not 
enhance Ag-specific responses. Therefore the augmenting CD8β L58R mutant did not 
confer any gain of function or dominant positive effect on T cells endogenously 
expressing the CD8 co-receptor. It would be theoretically possible to silence 
production of the endogenous protein by siRNA prior to introduction of the mutated 
co-receptor. This approach was used to study LAT mutants conferring resistance to 
ubiquitylation in Jurkat cell lines and primary CD8+ T cells (Balagopalan et al. 2011). 
The LAT mutants were transfected into CD8+ T cells treated with siRNA, which had 
reduced endogenous LAT by 30%. LAT mutant transduced CD8+ T cells upregulated 
the activation marker CD69 more rapidly than control CD8+ T cells.  
For the transduction of both F5-TCR and CD8β into CD8+ T cells a larger quad-
cistronic vector (~10kb in size) containing both TCR and CD8 genes was used as 
described in Section 3.4. Transduction of murine T cells with the large F5-TCR-CD8αβ 
vector resulted in lower TCR expression and the transduced T cells demonstrated 
reduced Ag-specific production of IL-2 (Section 3.4.5). However, human T cells 
transduced with the CMV-TCR-CD8αβ vector showed good expression of molecules 
transcribed by all the transgenes and were of high avidity (Section 5.4). The reason 
for this discrepancy is unclear but had also been noted by other researchers using 
retroviral vectors (Dr Zamoyska personal communication) and lentiviral vectors 
(Kerkar et al. 2011). Studies on the resistance of murine T cells to HIV infection have 
identified post-entry blocks due to blocking of the pre-integration complex (Baumann 
et al. 2004; Tsurutani et al. 2007). It is thought that a human specific factor is 
necessary for integration of HIV genes into murine cells (Tsurutani et al. 2007). 
Although this is unlikely to be related to the failure of the F5-TCR-CD8 vector, both 
studies highlight that cellular differences between murine and human cell can 
influence differential integration of retroviruses. 
One of the safety concerns for TCR gene transfer is the potential for off-target 
adverse effects, manifest as autoimmunity, due to mispairing of the introduced TCR 
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chains with endogenous TCR chains and formation of novel TCR heterodimers with 
unknown specificities (Thomas et al. 2011). This has been shown in mice given 
transduced T cells, which resulted in damage to the haemopoietic compartment, 
pancreatitis and colitis which was similar to graft-versus-host disease (Bendle et al. 
2010). Strategies preventing TCR mispairing include TCR chain modifications, the 
transduction of oligoclonal T cells and ex vivo Ag-specific stimulation of transduced T 
cells before transfer. Although TCR-transduced CD4+ T cells may also cause off-
target toxicity, none of the mice examined in this project were affected. This may be 
in part due to the TCR modifications previously described (Section 3.2), the lower 
numbers of CD4+ T cells used and the lack of exogenous IL-2 administration. Once 
tumour was eradicated, the surviving mice gained weight and were healthy. Co-
transfer of the CD8 co-receptor enhanced tumour eradication by transduced CD4+ T 
cells but did not seem to cause any associated graft-versus-host like disease. 
Not all adverse effects of T cell responses are caused by off-target toxicity. When 
normal tissues express the same antigens as the intended target, on-target toxicity 
may occur. This is especially relevant in the setting of cancer where tumour 
associated antigens are usually expressed at lower levels in some normal tissues. 
Examples of on-target toxicity have occurred for both TCR and CAR transduced T 
cells (Section 1.6). In addition, the CD8 co-receptor has recently been shown to 
increase the cross-reactivity of class I restricted TCR (Wooldridge et al. 2010). This 
study found that ILA1 CD8+ CTL were able to respond to a larger repertoire of 
peptides when APC contain HLA-A2 mutants with increased CD8 binding affinity. It 
might therefore be predicted that the CD8 co-receptor containing the ‘augmenting’ 
CD8β L58R mutation could increase TCR cross reactivity and potentially exaggerate 
either on- or off-target toxicities. Although no particular toxicity was seen in the mice 
given CD4+ T cells transduced with CD8 L58R, this could be because the level of 
augmentation was insufficient to induce on- or off- target toxicity or because CD8 co-
receptor was down-regulated within two weeks of transfer. Nevertheless, it will be 
interesting to study the magnitude by which the L58R mutation enhances CD8/MHCI 
binding affinity and whether it causes any cross-reactivity. 
It is widely acknowledged that CD8+ T cells and CD4+ T cells have distinct functional 
differences as described in Section 1.5. Whether transducing CD8 co-receptor would 
alter the biology of CD4+ T cells is an intriguing question but is thought to be 
unlikely as the genetic programming of peripheral CD4+ T cells is likely to be fixed. 
Formally addressing this question is complicated as the CD8 transduced CD4+ T cells 
would have to be in a resting state after activation during the transduction process 
which is likely to influence the gene profile. As murine T cells were difficult to be kept 
in culture for prolonged periods, this would mean that the transduced CD4+ T cells 
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would have to be transferred back into synergic mice to ‘rest’ for a period of time and 
then re-isolated for gene profiling by microarray. The small amounts of transferred 
CD4+ T cells persisting in the mice (<1x105 cells) after three months was unlikely to 
be sufficient for gene profiling. A less rigorous way of determining similarity or 
differences between CD4+ T cells and CD8+ T cells would be by the repertoire of 
cytokines or chemokines produced. However this was not performed in this project 
and only IFN-γ and IL-2 cytokines were measured. In murine transduced CD8+ T 
cells the ag-specific response resulted in small amounts of IL-2 but large amounts of 
IFN-γ. For murine transduced CD4+ T cells the reverse pattern is seen with large 
amounts of IL-2 but small amounts of IFN-γ. The low amount of IFN-γ produced is 
related to the small number of IFN-γ producing CD4+ T cells. This is consistent with 
the Ag-specific response of CD4+ T cells to Listeria and viral infections (Homann et 
al. 2001; Cauley et al. 2002). When CD8 is transduced into CD4+ T cells, the Ag-
specific cytokine production is heightened but the pattern of high IL-2 and low IFN-γ 
remains suggesting that there is no significant change in biology. There was Ag-
specific upregulation of CD40L, a characteristic of CD4+ T cells, with or without the 
CD8 co-receptor transduced in.    
In human CD4+ T cells transduced with MHCI restricted TCR recognising HLA-
A2/pp65, the Ag-specific response resulted in significant production of both IL-2 and 
IFN-α which is not different to transduced CD8+ T cells. These results were part of an 
extensive study of cytokine production by CD4+ and CD8+ T cells using Luminex 
multiplex technology and was performed by Dr S Xue in our laboratory which showed 
that TCR-td CD4+ T cells produce high levels of TNF-α, IL-4 and IL-5 compared to 
TCR transduced CD8+ T cells which produced very little of these cytokines. Co-
transducing the CD8 co-receptor into CD4+ T cells only resulted in enhancement of 
these cytokines and did not affect the overall pattern of cytokine production by CD4+ 
T cells. It had been observed by another group that CD4+ T cell transduced with 
MHCI restricted TCR isolated from a high avidity T cell clone are multifunctional in the 
repertoire of cytokines produced. This was similar to the study performed our 
laboratory and showed production of IL-2, TNF-α, IFN-γ and CD107a (Ray et al. 
2010). When the MHCII restricted TCR was used instead to transduce CD8+ T cells, 
it did not induce CD8+ T cells to produce large amounts of cytokines even when the 
CD4 co-receptor is co-transduced (van der Veken et al. 2005). Although co-transfer 
of CD4 co-receptor augmented the cytolytic effect of MHCII restricted TCR 
transduced CD8+ T cells. Therefore the transduction CD8 co-receptor into CD4+ T 
cells is unlikely to change the biology of the CD4+ T cells in both the murine and 
human systems. 
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The in vivo tumour protection effects of transferring CD4+ T cells were dramatic. 
Mice given tumour and mock transduced T cells deteriorated rapidly because of poor 
local control of tumour with ulceration and signs of distress indicating systemic 
tumour effects. Mice given tumour and TCR transduced CD4+ T cells remained 
healthy for prolonged periods but had to be culled because of poor local tumour 
control. Mice rescued with CD8 and TCR co-transduced CD4+ T cells had the best 
outcome in terms of both tumour regression and overall survival. Overall there was 
good correlation between in-vitro function and in-vivo tumour protection effects of 
transduced CD4+ T cells supporting the rationale of determining function first using 
in vitro tests before progressing of in-vivo experiments. 
The mechanism(s) by which transduced CD4+ T cells afford tumour protection in this 
project has not yet been delineated. The CD4+ T cells were injected into the tail vein 
and have to migrate to the tumour site. Previous experiments looking at migration of 
transduced T cells using bioluminescence showed that aggregation first occurs in the 
lungs before appearing at the tumour site from day 5 onwards (Ahmadi et al. 2011). 
The aggregation of cells at the tumour site can be difficult to study as cell numbers 
have to be above a threshold of 1 x 104 cells/cm2 before a reasonable signal is 
detected in shaved C57Bl/6 mice. High avidity CD8+ T cells were shown to have a 
greater propensity to aggregate at tumour sites compared to low avidity CD8+ T cells 
likely to contribute to greater anti-tumour efficacy (Ahmadi et al. 2011). The 
inference from this would be that F5-TCR and CD8 co-transduced CD4+ T cells may 
be superior to F5-TCR alone transduced CD4+ T cells in this aspect, but this 
phenomenon has not been studied in this project. 
In the tumour in vivo experiments described in Chapter 6, the transduced cell 
populations were depleted of CD8+ T cells before transduction. This reduces the 
number of CD8+ T cells to less than 0.5% of the total live lymphocytes pre-transfer 
and makes it seem unlikely that the tumour protection was provided by the rare 
CD8+ T cells given the rapid rate of the tumour growth. In the condition with F5-TCR 
transduced CD4+ T cells, no thy1.1 CD8+ T cells were detected in the peripheral 
blood or lymphoid organs at various time points. In the condition with CD8 co-
transduced, a population of thy1.1+ CD8+ T cells were seen that were probably 
related to the significant proportion of CD4neg and CD8neg cells that were 
incidentally transduced with CD8 co-receptor and the F5-TCR. It is unknown if these 
cells affect the tumour but as they exist at low levels at all the time points their role 
is probably limited. Despite the rigorous methodology to exclude non CD4+ T cells in 
this project, the existence of small numbers of anti-tumour CD8+ T cells that have 
escaped detection cannot be excluded. In a previously published study, minor HLA 
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specific donor CD8+ T cells had been found in patients transplanted with allogeneic 
BMT after the infusion of CD8 depleted DLI (Zorn et al. 2002).  
Both transgenic and transduced CD4+ T cells as discussed above and in Section 
1.5.2, can be ‘multi-functional’ with the ability to produce IFN-γ, TNF-α and IL-2 
cytokines plus cytotoxic effects through perforin, granzyme B and degranulation (Ray 
et al. 2010; Quezada et al. 2010; Xie et al. 2010). Therefore it is likely that the 
ability of transduced CD4+ T cells to eradicate tumour is multifactorial with some 
factors such as production of IFN-γ and IL-2 playing a larger role (Cohen et al. 2000) 
and CD40-CD40L interaction playing a lesser role (Kline et al. 2012). A recent study 
showed that MHCII restricted TRP1-TCR transduced CD4+ T cells were more effective 
than MHCI restricted Pmel1-TCR transduced CD8+ T cells to eradicate large 
melanoma tumours (Kerkar et al. 2011). This was surprising as it had generally been 
accepted that CD8+ T cells play a central role in tumour eradication with the CD4+T 
cells playing a more supportive role (Nishimura et al. 1999). The improved tumour 
protection seen with CD4+ T cells compared to CD8+ T cells was likely to be due to 
qualitative differences rather as increasing the amount of CD8+ T cells resulted in 
the same findings. The anti-tumour effects of CD4+ and CD8+ T cells may be difficult 
to compare directly because two different TCR were used. Two studies had used the 
same CD8 independent TCR for transduction into CD4+ or CD8+ T cells and 
compared their relative impact on tumour eradication. In the first study, both CD4+ 
and CD8+ T cells transduced with anti-tyrosinase TCR gave similar levels of tumour 
protection to mice with melanoma (Frankel et al. 2010). In the second study, CD4+ 
and CD8+ T cells transduced with 2C-TCR also gave similar levels of tumour 
protection against melanoma, however CD4+ T cells transduced with affinity matured 
2C-TCR (m33-TCR) had the most effective anti-tumour responses in-vivo (Soto et al. 
2012). Surprisingly the CD8+ T cells transduced with the affinity matured 2C-TCR 
(m33-TCR) gave poor tumour protection as underwent apoptosis and was deleted in 
the periphery within hours unlike CD8+ T cells transduced with 2C-TCR (Engels et al. 
2012). When CD4+ T cells were co-transduced with CD8 co-receptor and m33-TCR, 
these cells were similarly deleted in the periphery. However CD4+ T cells transduced 
just with m33-TCR was still detected 80 days after transfer.  
The potentiating effects of CD4+ T cells on cytotoxic CD8+ T cells is well documented 
(Nishimura et al. 1999; Morris et al. 2005; Kessels et al. 2006) and therefore it is 
likely that the combination of the two T cell populations is required to effect the most 
effective anti-tumour effects although the relative proportion of each cell type to 
induce the most optimum effect is unknown. The most practical way of transducing 
both the CD4+ and CD8+ T cells would be to use a TCR taken from a high avidity 
clone and transduce bulk populations containing populations. In this setting, it is 
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unknown whether the MHCI restricted TCR has any advantage over the MHCII 
restricted TCR and may be related to the role of each population. The CD8 and TCR 
co-transduced CD4+ T cells may synergise with CD8+ T cells to eradicate tumour 
better than TCR alone transduced CD4+ T cells and this area may be subjected to 
further studies in the future. However, as described above, co-transfer of CD8 co-
receptor may have a negative effect when used with a high affinity MHCI-restricted 
TCR. 
In this project the transferred CD4+ T cells persisted indefinitely and were found 120 
days after transfer even though small amounts (1x105 cells) were introduced in the 
beginning. This was similar to a study in which in vitro expanded CD4+ TIL 
transferred into synergic mice were detected at low frequencies (<1% of total 
lymphocytes) without the presence of antigen at day 90 (Wang & Plautz 2010). 
However a large proportion of CD8 transduced CD4+ T cells had down-regulated the 
CD8 co-receptor from as early as 14 days after transfer with a large proportion 
previously CD8+ CD4+ T cells no longer expressing detectable CD8 molecules above 
background. Although down-regulation of transduced molecules such as TCR and 
CD3 were observed previously, the down-regulation has not to such a great extent as 
seen with the CD8 co-receptor (Ahmadi et al. 2011). Down-regulation of CD8 
molecules were also observed during in vitro experiments when around 50% of CD8 
transduced CD4+ T cells no longer expressing CD8 molecules after one week of 
restimulation. Two possibilities could account for this; firstly the CD8 vector was in a 
less efficient pMX vector and CD8α and CD8β transgenes were separated by IRES. 
Secondly the down-regulation of CD8 could also be due to intrinsic genetic 
programming of the CD4+ T cells which suppresses endogenous CD8 expression and 
may also affect transduced CD8 expression. Nevertheless the CD4+ T cells that 
retain the CD8 molecule was found to have a greater ability to expand after 
rechallenge suggesting that the greater avidity also resulted in improved proliferative 
capacity.  
Some studies suggest that memory T cells are superior to naïve T cells at targeting 
tumour for adoptive immunotherapy (Gattinoni et al. 2005; Berger et al. 2008). 
These may be related to the classical characteristic of memory T cells of rapid 
effector cytokine responses follow activation from a previous encountered antigen 
that is greater than that of the primary response (Chandok et al. 2007; Mohrs et al. 
2005). In the situation when the tumour clearance is slow because of rapid growth, 
memory T cells that result from the early responses may have a role in the eventual 
control of tumour growth. While memory responses have been extensively studied in 
the infection setting, much less is known in the tumour setting. Moreover, it is also 
acknowledged that memory CD4+ T cells are not as well understood as the memory 
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CD8+ T cells (McKinstry et al. 2010; MacLeod et al. 2009).  This may be related to 
smaller numbers of memory CD4+ T cells and their greater functional heterogeneity 
impeding analysis. Studies showed that both murine and human memory CD4+ T 
cells decrease in numbers over time unlike CD8+ memory T cells (Homann et al. 
2001; Seder & Ahmed 2003; Jelley-Gibbs et al. 2008). Memory CD4+ T cells have 
the ability to enhance CD8+ T cell responses in both infection and tumour setting and 
can control re-infection through IFN-γ (North & Jung 2004; Brown et al. 2004). In 
Chapter 6, the CD44 and CD69 markers associated with memory T cells were 
analysed in the transferred thy1.1+ CD4+ T cells. As a result of non-Ag specific 
activation necessary for the transduction process, the pre-transferred CD4+ T cells 
already have CD44 expression which is maintained in-vivo after the cells were 
introduced into tumour bearing mice expressing cognate antigen. A recent study 
showed that the CD44 molecule is expressed after influenza virus exposure only in 
Th1 but not in Th2 or Th17 CD4+ T cells (Baaten et al. 2012). In a viral infection 
model, Th1 CD4+ T cells that go on to become memory T cells can be defined by the 
transcription pattern of high PSGL1 and low Lyt6C and Tbet but not reliably by IL7R 
expression (Marshall et al. 2011). The CD44 is an adhesion molecule enhances the 
survival of CD4+ T cells by augmenting  TCR signalling when antigen levels are low 
(Föger et al. 2000) and by inhibiting apoptotic pathways (Mielgo et al. 2006; Baaten 
et al. 2010) which may explain its association with memory T cells. High levels of 
CD44 in transferred CD4+ T cells several months after transfer without the presence 
of cognate antigen was also seen by Plautz et al (Wang & Plautz 2010) which suggest 
that once CD44 is up-regulated, expression is permanent and present even in 
progeny cells. 
Unlike the CD44 molecule, the transduced thy1.1 CD4+ T cells had variable 
expression of CD62L expression before and after transfer. Persisting transferred 
CD4+ T cells were mostly CD62Lneg (>85%) in the spleen and bone marrow with an 
enrichment of CD62L+ CD4+ T cells of 25-35% in the lymph nodes. This was similar 
to the study with Plautz et al when in-vitro expanded CD4+ T cells were transferred 
into synergic mice. CD4+ T cells that up-regulate CD62L expression after activation 
and are known as central memory T cells. CD62L is also known as L-selectin, an 
adhesion molecule involved in homing of lymphocytes into lymph nodes after 
activation. These central memory T cells were shown to arise as a result of 
asynchronous exposure to antigen from late arriving Ag-specific CD4+ T cells that 
are exposed to lower quantities of antigen (Catron et al. 2006). Down-regulation of 
CD62L on T cells can occur after activation of central memory T cells and induce 
trafficking away lymph nodes into peripheral sites. Central memory T cells are known 
to produce small amounts of effector cytokines but large amounts of IL-2 and 
associated with high proliferative potential. Effector memory T cells, in comparison, 
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produce larger amounts of effector cytokines rapidly on re-exposure to antigen. 
There are conflicting studies on the role of central and effector CD4+ T cells on 
infection and tumour immunity (Seder et al. 2008). CD62Lneg tumour specific T cells 
taken from tumour draining lymph nodes in mice were more effective against tumour 
challenge than CD62L+ T cells when transferred into synergic mice challenged with 
tumour (Peng et al. 2002; Wang et al. 2007). However transduced CD62L+ CD8+ T 
cells were more effective than transduced CD62Lneg CD8+ T cells in affording 
tumour in two different studies (Gattinoni et al. 2005; Berger et al. 2008). The 
relevance of these different cell populations are also difficult to dissect as CD62Lneg 
effector memory T cells can re-express CD62L and CD62L+ central memory T cells 
can give rise to CD62Lneg effector memory T cells. In this project, the transferred 
CD4+ T cells still expressing CD8 co-receptor proliferated and contained higher 
proportion of the central memory phenotype in tumour draining lymph nodes. The 
significance of the increased proportion of CD4+ T cells expressing CD62L is 
unknown and further experiments may be required to determine the functional 
qualities of CD62L+ versus CD62Lneg CD4+ T cells. 
This study has shown that CD8 co-receptor can augment the functional avidity of a 
MHCI restricted TCR (F5-TCR) when co-transduced into CD4+ T cells. This 
augmenting effect is further enhanced by introducing the L58R mutation in the CD8 
co-receptor. CD4+ T cells co-transduced with F5-TCR and CD8 co-receptor gave 
improved tumour protection and were able to eradicate tumour cells completely. 
These co-transduced CD4+ T cells persisted indefinitely, express the effector memory 
phenotype and respond to re-challenge. The information obtained from this project 
will have implications in the use of other MHCI restricted TCR to transduce CD4+ T 
cells. Firstly, it may avoid the need for the TCR to undergo affinity maturation if 
affinity is at the lower end of the physiological range and thus allow a greater 
number of MHCI restricted TCRs to be used to transduce the more dynamic CD4+ T 
cells for cancer immunotherapy. Secondly, it reinforces the current data that it is 
possible to use CD8 depleted CD4+ T cells to target tumour. 
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Appendices 
I. Base sequence of F5-TCR used in F5-TCR pMP71 vector 
 
Appendix I Base sequence of F5-TCR used in the F5-TCR pMP71 vector. 
Restriction sites NotI, XhoI and EcoRI are shown in red. Transgenes include Vα 
(orange), Cα (green), P2A sequence (yellow), Vβ (blue), Cβ (purple). 
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II. Base sequence of Cβ-CD8αβ construct 
 
Appendix II Base sequence of Cβ-CD8αβ construct made by Geneart. 
Restriction sites XhoI and EcoRI are shown in red. Transgenes include Cβ (purple), 
F2A peptide (cyan), CD8β (yellow) and CD8α (blue). 
  Appendices 
192 
 
III. Base sequence of revised CD8α construct 
 
Appendix III Base sequence of revised CD8α construct made by Geneart. 
Restriction sites BstZI and EcoRI are shown in red. Transgenes include 5’ portion of 
CD8β (yellow), T2A peptide (cyan) and CD8α (blue). 
 
